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� ABSTRACT 
The pharmacology of anti-tuberculous drugs； isoniazid, 
rifampicin, and pyrazinamide has been reviewed. The use of 
anti-tuberculous drugs in Uganda and Hong Kong has been 
outlined to emphasise, among other things, correlation of 
anti-tuberculous chemotherapy to economic development and 
regional variation in populations in different places. 
Previous analytical procedures for the three drugs, and 
principles of pharmacokinetics and their application, have 
also been reviewed. 
A simple procedure, based on high performance liquid 
chromatography, for simultaneous determination of isoniazid 
and hydrazine metabolite in plasma and cerebrospinal fluid 
of rabbits is described. The assay involves organic solvent 
extractions before and after derivatisation of the two 
compounds and internal standard, phenelzine with 
salicylaldehyde. The extract of derivatised compounds is 
evaporated to dryness at 40°C and residue redissolved in 
mobile phase (50 ill) . A 25 /xl aliquot is injected into the 
liquid - chromatograph and eluted with mobile phase 
consisting of acetonitrile, water and triethylamine in 
ratio of 70 : 30 : 0.4, (v/v) and 5 itiM heptane sulphonic 
acid on a 30 /xm Cg precolumn linked to a 10 /iiti C^ g /LiBondapak 
column at ambient temperature (25 土 1°C)• The eluate was 
detected by ultra—violet detector at 32 0 nm. Using the 
above procedure the pharmacokinetics of isoniazid and 
hydrazine metabolite in plasma and cerebrospinal fluid of 
ten rabbits was studied after separate intravenous and oral 
• 
1 
� administration in a cross-over study. There was no 
difference in area under plasma concentration time curves 
indicating that oral absorption was complete. There was no 
significant barrier to penetration of isoniazid into the 
CSF from the general circulation. Hydrazine metabolite 
after isoniazid dosing was eliminated at slower rate ( Ke^ 
= 0 . 1 7 h-1) than isoniazid (Ke = 0.59 h'” • There was 
prolonged exposure of the body to hydrazine (over 6 hrs 
with concentrations above 0.1 /xg/ml). 
The disposition of isoniazid, hydrazine, rifampicin, and 
pyxazinamide was compared in 18 elderly (67 to 89 years) 
and 19 young adult (19 to 63 years) patients on the day of 
their admission for treatment, and at one month (steady 
state) after treatment for tuberculosis with isoniazid, 
rifampicin and pyrazinamide. There was no difference in the 
pharmacokinetics for each of the three drugs in the two age 
groups. Plasma clearances for isoniazid and rifampicin at 
steady state were significantly lower than after first 
dose. Maximum plasma concentration for hydrazine after the 
first dose of isoniazid was significantly higher (P < 0.05) 
in the elderly (0.4 土 0.07 iig/ml) than in the young (0.24 
士 0.08 /xg/ml) . The plasma half-life of hydrazine exhibited 
an age related bimodal distribution whereby it was shorter 
in many elderly patients compared to the young. 
Pharmacokinetic parameters of isoniazid, hydrazine, 
rifampicin and pyrazinamide in a 74 year old man with 
pulmonary tuberculosis who died of submassive hepatic 
necrosis 8 days after starting anti-tuberculous 
• 鲁 11 
� chemotherapy were compared with those of other elderly 
patients who did not develop hepatotoxicity. The findings 
suggested that hydrazine may be a possible cause of 
isoniazid induced hepatic necrosis; it is produced in 
significant amounts during isoniazid metabolism and should 
not be neglected when evaluating isoniazid related 
toxicity. 
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‘ CHAPTER 1 GENERAL INTRODUCTION 
Tuberculosis is an infectious .disease caused by 
mycobacteria and is characterised by formation of tubercles 
and caseous necrosis in tissues (Dorland丨s, 1981)• The 
disease has been in existence since the earliest times/ a 
similar condition was described by ancient Chinese (Dubos 
and Dubos, 1952) , and evidence of tuberculous lesions was 
found in Egyptian skeletons dating 2,500 B.C.(Morse et al, 
1964) . Nevertheless, it was only in 1882 that the causative 
organism was discovered by Dr. Robert Kochs as Mycobacteria 
tuberculosis (Kochs, 1882). Many other species have since 
been described but Mycobacteria tuberculosis humanus 
remains the most common cause of tuberculosis in man. 
Infections due to Mycobacteria bovis and avium are rare. 
Occasionally Mycobacteria kansasii and other unclassified 
Mycobacteria are isolated in some atypical tuberculosis 
like infections. 
Tuberculosis is a world wide problem and is more 
prevalent in developing countries and Blacks‘ communities 
in South Africa where it is a major cause of morbidity and 
mortality in young adults (Hutt, 1971; Houghton, 1982)• 
Each year about 3 million new infections occur and over 
half a million die from the disease (Bulla, 1981)• 
Epidemiology of the disease has been well studied in 
developed countries. Tuberculosis was the leading cause of 
deaths among 38 communicable diseases reported in 1979 to 
Centres for Disease Control in the United States, and the 
number of deaths exceeded the combined total for the other 
1 
� 37 communicable diseases (Youmans, 1979) . The implication 
here is that such catastrophes are higher in developing 
countries where the disease is highly prevalent and many 
cases and deaths are not reported or recorded. 
Tuberculosis is controlled by case finding and treatment 
of infectious people. Treatment of the disease has improved 
during this century. It is no longer the old fashioned 
course of observation, rest, sunshine and collapse therapy. 
The past 35 years have been marked with a series of 
inventions of new anti-tuberculous chemotherapeutic agents 
with higher efficacy rates such that with right treatment 
a cure rate of 100 per cent is predictable, in the shortest 
possible time of treatment and at the cost within reach of 
most countries. In 1940 a sulphonainide promin (glucosulfone 
sodium), a derivative of dapsone, was demonstrated to have 
bacteriostatic effects on Mycobacteria tuberculosis 
(Youmans, 1979). Although this compound arrested progress 
of the disease in experimentally infected guinea pigs, it 
was abandoned because high concentrations were required for 
this action. Further investigations on anti-tuberculous 
activity of benzoic and salicylic acid related compounds 
led to the discovery of p-aminosalicylic acid (PAS) in 
1946. Anti-tuberculous activity of streptomycin was 
demonstrated in animals in 1944 (Feldman and Hinshaw, 
1944) . Streptomycin has been used in man since 1947, the 
year when thiacetazone was introduced. Later in 1952, 
workers in America and Germany, all together three 
independent laboratories, reported the anti-tuberculous 
2 
� activity of isoniazid (Bernstein et al, 1952; Fox, 1952; 
Offe et al, 1952)• Isoniazid has proven to be a wonder drug 
in the treatment of tuberculosis; it is used for 
prophylaxis and is a keystone of the most effective anti-
tuberculous regimens. Introduction of ethambutol in 19 61, 
and rifampicin in 1968 (Crossland, 1980) revolutionised 
anti-tuberculous chemotherapy not only by increasing 
efficacy but also reduced period of treatment and frequency 
of dosing. Currently, there are over ten anti-tuberculous 
4 
drugs on market. They have been classified in different 
ways like popular use, bactericidal or bacteriostatic, and 
naturally occurring or synthetic. Classification as first 
and second line drugs is easier and is more frequently 
used. Isoniazid, rifampicin, pyrazinamide, streptomycin and 
ethambutol are considered first line drugs because of their 
higher potency, relatively low toxicity and ease of 
administration. PAS, thiacetazone, ethionamide, 
cycloserine, kanainycin, capreomycin, and viomycin are 
second line drugs because they are less potent and more 
toxic. They are used to supplement actions of first line 
drugs and to guard against emergence of resistance. 
Therefore, during anti-tuberculous therapy a combination of 
three to four drugs, preferably two or three first line 
drugs and one second line drug, are used for the first two 
or three months and thereafter treatment is continued with 
two drugs for such a period depending on form of 
tuberculosis, pattern of resistance and drugs being used. 
When isoniazid, streptomycin, and thiacetazone or PAS are 
3 
� used treatment is continued for twelve to twenty four 
months, while in case of isoniazid, rifampicin, 
pyrazinamide, streptomycin and or ethambutol it is 
continued for six to twelve months. Tuberculosis of the 
central nervous system and milliary tuberculosis are 
treated for longer periods than other forms of 
tuberculosis. The long period of treatment for this disease 
is to avoid relapses due to some semidormant bacilli that 
are killed slowly with time. 
In this project the pharmacokinetics of drugs； 
isoniazid, rifampicin, and pyrazinamide has been studied 
because they form one of the most effective anti-
tuberculous regimens used in many countries (Perez-Stable 
and Hopewell, 1989; Grosset, 1989), they are potentially 
hepatotoxic (Girling, 1978), and have been associated with 
severe adverse effects in elderly patients (Woo et al, 
1987a). Hydrazine, a metabolite of isoniazid, has been 
included in the study because it is an extremely toxic 
compound that was suggested to cause isoniazid related 
hepatotoxicity (Sarma et al, 1986)• Very little is known of 
the disposition of hydrazine in the body after treatment 
with isoniazid alone or in combination with other anti-
tuberculous drugs. 
4 
^ CHAPTER 2 LITERATURE REVIEW 
In subsequent sections literature on three anti-
tuberculous drugs: isoniazid, rifampicin and pyrazinamide 
is reviewed. A review on the use of anti-tuberculous drugs 
in two centres, a developing country, Uganda, and a more 
developed country, Hong Kong, is presented to demonstrate, 
among other things, factors that may determine the choice 
of anti-tuberculous drug regimen for a nation. Thereafter, 
conclusions on which this project is based are drawn. 
2.1 SECTION 1 ISONIAZID 
2.1.1 CHEMISTRY 
Isoniazid (isonicotyl hydrazine) is one of the most 
widely used anti-tuberculous drugs. It is used for 
prophylaxis in those at risk and below 35 years of age and 
for treatment of active disease . The structure of 
isoniazid is as shown in Figure la. It is a derivative of 
isonicotinic acid with molecular weight of 137.2 and 
melting point of 1 7 2 I t is highly water soluble and has 
dissociation constants of 1.8, 3.5, and 10.8 at 20°C 
(Clarke's, 1986). 
It is a white crystalline powder that is dispensed in 
form of tablets of 100 mg or 300 mg each, syrup of 10 
mg/ml, and injection solution of 100 mg/ml. It is commonly 
given orally; 5-10 mg/kg/day in adults and 10-15 mg/kg/day 
in children less than 4 years. However, with the advent of 
short course and intermittent chemotherapy there is wide 













































































































































































� 2.1.2 ANTIMYOCBACTERIAL ACTIVITY 
Isoniazid is tuberculocidal to actively multiplying 
bacilli and tuberculostatic to slowly growing bacilli. In 
vitro minimum inhibitory concentration (MIC) for 
Mycobacteria tuberculosis is of order 0.025 to 0.05 /xg/ml 
(Mandell and Merle, 1985) • The drug is more effective 
against extracellular organisms and at neutral pH. When 
isoniazid is used alone to treat tuberculosis, resistance 
develops within few weeks. Fortunately, there is no cross 
resistance between isoniazid and other anti—tuberculous 
agents, making combined drug therapy essential to avoid 
emergence of resistant organisms. 
The mechanism of action for isoniazid is not fully 
known. Takayama et al (1975) proposed that isoniazid 
inhibits synthesis of mycolic acid in mycobacterial cell 
wall. This explains the highly selective action of 
isoniazid to mycobacteria. Later, Herman and Weber (1980) 
suggested that isoniazid also interferes with lipid or 
nucleic acid synthesis and glycolytic processes of 
mycobacteria. 
2.1.3 ABSORPTION AND DISTRIBUTION 
Isoniazid is rapidly and completely absorbed in man 
after oral and parenteral administration (Barclay et al, 
1953; Des Prez and Boone, 1961; Elmendorf et al, 1952; 
Robson and Sullivan, 1963). It is absorbed mainly in the 
small intestines (Barley et al, 1972) and peak 
concentrations are achieved in 1 to 2 hours after ingestion 
7 
� (Robson and Sullivan, 1963). Absorption is reduced by 
presence of anti-acids like aluminium hydroxide gel 
(Hurtwitz and Schlozman, 1974), simultaneous intake of food 
(Melanider et al, 1976) and some types of sugars (Rao et al, 
1971)• Plasma concentrations tend to be lower in fast 
acetylators than slow acetylators and it was proposed that 
there is appreciable first pass effect in rapid acetylators 
because acetylator polymorphism is well expressed in 
mucosal cell lining of the small intestines (Jenne, 1965; 
Hearse and Weber, 1973 ). 
Isoniazid is distributed in total body water. Apparent 
volume of distribution is approximately 61 士 11 宅 of body 
參 
weight (Jenne et al, 1961) . There is no appreciable p:rotein 
binding (Boxenbaum et al, 1975) indicating that 
distribution is both extracellular and intracellular. 
Significant amounts of isonaizid were detected in 
cerebrospinal fluid, pleural effusion, saliva and faeces of 
healthy volunteers and patients with tuberculous meningitis 
(Barclay et al, 1953; Boxenbaum and Riegelman, 1976; 
Elmendorf et al, 1952) • Nevertheless, data from these 
studies has been insufficient for proper use of isoniazid 
in treating tuberculous meningitis. Higher doses (>10 
ir^ g/kg/day) are still used for this form of tuberculosis 
(Lam et al, 1989) . As the therapeutic effectiveness and 
toxicity of isoniazid depend on extent and intensity of 
exposure of the body to the drug, kinetic studies in this 
aspect are essential to understanding how long and to what 
extent the drug stays in the central nervous system. This 
8 
� in 七urn is an essential tool to a rational approach to the 
use of this drug for treating tuberculosis of the central 
nervous system. 
2.1.4 METABOLISM AND ELIMINATION 
Isoniazid is cleared from plasma mainly by acetylation at 
a rate which is determined by type of polymorphic N-
acetyltransferase enzyme an individual carries (Evans, 
1965； Evans and White, 1964； Glowinski et al, 1978; Jenne, 
1965).工Individuals are therefore classified as either rapid 
or slow acetylators depending on the rate at which they 
eliminate isoniazid (Evans et al, 1960). Therefore, 
eliiriination half—life of isoniazid is determined by 
acetylator status. In a review of the procedures by Jenne 
(1960), Mattila and Takki (1969), Scott et al (1969) and 
Tiitinen (1969) rapid acetylators were considered as having 
isoniazid elimination half-life shorter, and slow 
acetylators longer than 110 minutes (Weber and Hein, 1979)• 
However, different antimodes have been observed by other 
workers. Paulsen and Nilsson (1985) and Kergueris et al 
(1986) used antimode 120 minutes. 
Man and rabbit species exhibit this acetylating capacity 
(Hearse and Weber, 1973) not only for isoniazid but other 
drugs as well, for example; hydrallazine, procainamide, and 
sulphonamides.工nactivation of isoniazid is optimum at pH 
6.5 to 7.0. The enzyme is resistant to sulphohydryl 
inhibition and insensitive to induction (Schulte et al, 
1974). Further, evidence from studies in rabbits suggests 
9 
� that rapid and slow N-acetyltransferases are structurally 
different enzymes (Weber et al, 1978)• 
Figure 2 shows important metabolic pathways for 
elimination of isoniazid (Boxenbaum and Reigelman, 1976; 
Ellard and Gammon, 1976)• The major metabolic step is 
acetylation of isoniazid to acetylisoniazid (Mitchell et 
al, 1976)• Acetylisoniazid is biotransformed to 
isonicotinic acid and monoacetyIhydraz ine. Isonicotinic 
acid is then conjugated with glycine and excreted in the 
urine. Most of the monoacetyIhydrazine is acetylated to 
diacetylhydrazine which together with some free 
monoacetyIhydrazine are excreted by the kidneys. Some 
isoniazid is conjugated to form pyruvic and a-ketoglutaric 
hydrazones, and a smaller proportion is hydrolysed to 
hydrazine and isonicotinic acid. Some hydrazine is lost by 
renal route while the rest is presumably biotransformed by 
yet unexplained mechanism. The Metabolic fate for hydrazine 
and monoacetyIhydraz ine is still uncertain because of the 
low recovery of these compounds in the 
urine and plasma (Weber and Hein, 1979)• However, it has 
been shown that monoacetyIhydraz ine is the only metabolite 
which exhibits polymorphic metabolism in a manner similar 
to isoniazid (Ellard and Gammon, 1976)• It was reported, in 
the same coininunication, that there is little or no 
difference between plasma concentrations of 
monoacety Ihydraz ine in the two phenotypes. This was 
contradictory to earlier proposals that rapid acetylators 







































































































































































































































� to suffer from isoniazid induced hepatotoxicity (Black et 
al, 1975) • It was demonstrated by animal experiments in 
rats that monoacetyIhydrazine can be biotransformed by the 
liver microsomal enzymes to a potent acylating agent that 
can cause hepatic necrosis, and thereby concluded, with 
clinical evidence (Mitchell et al, 1976), that it is the 
major toxic metabolite responsible for isoniazid induced 
liver toxicity. A lot of clinical evidence against this 
hypothesis has accumulated (Ellard et al, 1978; Girling, 
1978 ； Ellard, 1984; Guruinurthy et al, 1984) . It was 
suggested that since a rapid acetylator also converts 
monoacetyIhydrazine more rapidly to diacetylhydrazine the 
risk of liver toxicity should be the same in both 
phenotypes (Ellard and Gammon, 1976; Timbrell et al, 1977). 
Further studies on monoacetyIhydraz ine have shown that at 
concentrations of 1 /ig/ml this metabolite can inhibit 
antimycobacterial activity of isoniazid in vitro (Ellard, 
1976a) • The clinical significance of this is yet to be 
found. 
Renal elimination of isoniazid is approximately 11 to 27 
per cent of total body clearance for rapid and slow 
• acetylators, respectively. This is considered unimportant 
compared to the metabolic pathway. About 75 to 95 per cent 
of administered isoniazid is excreted in the urine within 
24 hours as metabolites. N-acetylisoniazid and isonicotinic 
acid are the major urinary metabolites. 
12 
‘ 2.1.4.1 HYDRAZINE 
Hydrazine is a metabolite of isoniazid that had been 
neglected on grounds that it is formed in negligible 
amounts. The structure is as shown below; 
冊 2 題 2 
Hydrazine 
Molecular weight is 32.1 (The Merck Index, 1976) 
Hydrazine is a potent toxin and carcinogen as classified 
by the American Conference of Government and Industrial 
Hygiene (Albert and Pulia, 1977)• Hydrazine group was 
incriminated for causation of lupus—like syndrome in man 
when hydrallazine and isoniazid were administered (Durant 
and Harris, 1980)• In animal studies, hydrazine caused 
convulsions, hepatic toxicity, renal damage, haematological 
abnormalities and affected many metabolic processes (Back 
and Thomas, 1970). It is associated with causation of 
choroidal carcinoma in man, and questions arise as to 
whether it may contribute to hepatic angiosarcoma a tumour 
associated with hydrazide compounds (Daneshmend and 
Bradfield, 1979; Toth, 1975 and 1976) . Hydrazine is a 
potent inhibitor of many enzyme systems in the body and can 
cause hepatic necrosis. There is species variation in 
sensitivity to hydrazine toxicity. Massive hepatic necrosis 
was observed in monkeys at doses where a less severe liver 
injury was found in rats (Back and Thomas, 1970). This 
suggests that humans may be more susceptible to hydrazine 
toxicity. As cited earlier the recovery of hydrazine 
metabolites in urine cannot account for the total amount 
13 
� presumably formed during isoniazid metabolism. Recently, it 
was reported that rifampicin increased hydrazine formation 
from isoniazid after two weeks of co-administration of the 
two drugs in healthy volunteers (Sarma et al, 1986)• 
Therefore, in wake of the unproven role of 
monoacetyIhydrazine in isoniazid related hepatotoxicity, 
hydrazine metabolite has been implicated as a possible 
culprit. Little is known of the quantity and fate of 
hydrazine in the body during anti-tuberculous chemotherapy 
with isoniazid and other drugs. Consequently, further 
studies on the kinetics of hydrazine as a metabolite of 
isoniazid are essential to explore and perhaps prevent 
isoniazid related toxicity. 
2.1.5 SIDE EFFECTS OF ISONIAZID 
The most common serious side effect of this drug is 
liver toxicity which is clinically, biochemically, and 
histologically indistinguishable from viral hepatitis. The 
risk of developing severe isoniazid induced hepatotoxicity 
increases with age; it is rare under 2 0 years of age, up to 
0.3 per cent at ages 20 to 34 years, up to 1.2 per cent at 
35 to 49 years, and up to 2.3 per cent at 50 years and over 
(Kopanoff et al, 1978). Later Stead et al (1987) and Stead 
(1981) reported that the risk of developing isoniazid 
related hepatitis is about 5 per cent in persons above 65 
years of age and over. Frequency of isoniazid induced 
hepatitis was not related to acetylator phenotype 
(Singapore Tuberculous Service, 1977) . Therefore, it was 
14 
� recommended that base line liver function tests should be 
determined in patients on isoniazid containing regimens 
before and during treatment. 
Isoniazid can cause peripheral neuropathy by interfering 
with pyridoxins metabolism. This is common in patients with 
predisposing factors like chronic alcoholism, diabetes 
mellitus and malnutrition. Pyridoxine 10 mg/day has been 
prescribed as prevention therapy while 100 mg/day has been 
used to treat the established lesion. Other side effects 
include allergy, skin rashes, gastric upsets, febrile 
reactions, and rarely, red cell aplasia (Claiborne and Dutt, 
1985),psychosis, and depression. 
2.1.6 DRUG INTERACTIONS 
There is an increased risk of hepatotoxicity when 
isoniazid and rifampicin are used together (Bistrizer et 
al, 1980), and the induced toxic hepatitis is different 
from that by either drug (Gronhage-Riska et al, 1978). P-
aminosalicylic acid led to elevation of isoniazid plasma 
concentrations and prolonged serum half—life of isoniazid 
(Bell et al, 1957; Hanngren et al, 1970; Tiitinen and 
Mattila, 1968; Jenne et al, 1961). Isoniazid inhibits 
phenytoin metabolism predisposing some patients, especially 
slow acetylators, to phenytoin toxicity (Kutt et al, 1970). 
Many interactions with other drugs have been reported but 
their clinical significance is not yet known. This includes 
drugs like, warfarin, procainamide (Schneck et al, 1979), 
carbamazepine, primidone, prednisolone, diazepam, 25 -
15 
� hydroxyvitamin D3, and enflurane to mention but a few. 
2.1.7 PATHO-PHYSIOLOGICAL FACTORS 
Table 1 compares the pharmacokinetic parameters of 
isoniazid in relation to age and acetylator status 
(Advenier et al, 1980) . For unexplained reasons the dose of 
isoniazid was higher in the elderly than in the young. 
There was no difference in the pharmacokinetics of 
isoniazid between elderly and young people (Advenier et al, 
198 0; Paulsen and Nilsson, 1985; Kergueris et al, 1986) 
and, although not proven by liver biopsy, it was concluded 
that age is an insignificant factor in the acetylator 
status of an individual (Evans et al, 1960; Advenier et al, 
1980). Nevertheless, as cited earlier, the risk of 
developing isoniazid induced hepatotoxicity increases with 
age. The reason for this phenomena is not well explained. 
Liver disease in a patient is an indicator for reassessing 
and adjusting dosage of isoniazid if deemed necessary. 
Renal disease has limited effect on isoniazid clearance 
such that dosage adjustment is not usually considered. 
Chronic diseases like diabetes mellitus (Mattila and 
Tiitinen, 1967), tuberculosis and chronic alcoholism 
(Tiitinen, 1969), and abnormalities like mongolism 
(Airaksinen et al, 1969), and obesity (Reidenberg et al, 
1973) did not effect isoniazid metabolism. However, insulin 









































































































































































































































































































































































































































































































































� 2.1.8 ACETYLATOR PHENOTYPE 
Several procedures for determination of acetylator status 
of individuals have been reviewed by Weber and Hein (1979). 
Only two procedures have been widely used in clinical work 
because they require urine samples which is convenient to 
both the patient and the clinician. One is by estimation of 
acetylisoniazid as a proportion of total hydrazides 
excreted in the urine 6 to 8 hours after oral 
administration of isoniazid (Eidus et al, 1973) . The other 
classifies individuals according to proportion of total 
sulphadimidine excreted in the acetylated form at 4 to 5 
hours after oral ingestion of sulphadimidine (Evans, 19 60; 
Weber and Brenner, 1974). In conditions where renal 
clearance is much reduced determination of acetylator 
status is best done by estimation of metabolic clearance 
rate of the drug (Fine and Sumner, 1975) . Racio-
geographical distribution of acetylator phenotype has shown 
a high prevalence of rapid acetylators in far east 
populations; Chinese (85%) (Evans, 1962), Japanese (90%) 
(Sunahara et al, 1961) , and Hong Kong Chinese (78%) 
(Ellard, 1976b), and a low prevalence in mid—eastern 
populations; East Africa (45%) (Ellard et al, 1975) and 
United States Caucasians (41%) (Eidus et al, 1979). 
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� 2.2 SECTION 2 RIFAMPICIN 
2.2.1 CHEMISTRY 
Rifampicin ( 3 — （ 4 一 m e t h y l p i p e r a z i n e — 1 一 y l i m i n o m e t h y l ) 
rifampicin S.V.) is a semisynthetic derivative of 
rifamycin—B which is produced, like other rifaitiycins, by 
Streptomyces mediterranei. The structure of rifampicin is 
as shown in Figure lb on Page 6. It is a brick red 
crystalline powder with a molecular weight of 813.0 and 
melting point of 185°C. It is slightly soluble in water and 
has dissociation constants of 1.7 and 7 .9 (Clarke‘s, 1986). 
Rifampicin is supplied either as capsules containing 150 
mg and 300 mg of rifampicin or in injectable form of 600 
itig. For treatment of tuberculosis 450 to 600 mg/day has 
been used in adults and 10-15 mg/kg/day in children. Higher 
and more frequent doses are used in other bacterial 
infections. Once daily dosing was found adequate because a 
brief exposure of the Mycobacteria tuberculosis to 
bactericidal concentrations of rifampicin (0.2 jLxg/ml) 
arrested the growth for over 24 hours (Dickinson, 1969). 
2.2.3 ANTIMYCOBACTER工AL ACTIVITY 
Rifampicin inhibits growth of most gram positive and 
gram negative bacteria. It is bactericidal to both the 
continuous and intermittently multiplying bacilli. It can 
penetrate and kill organisms in the semisolid caseous 
material (Dickinson and Mitchison, 1981)• Minimum 
inhibitory concentration for Mycobacteria tuberculosis in 
vitro is 0.005 to 0.2 ^g/ml. The drug acts by attaching to 
19 
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� the B-subunit of DNA dependent RNA polymerase of bacteria, 
leading to inhibition of initiation of chain formation in 
RNA synthesis. Human cells require much higher 
concentrations to be affected by rifampicin. When 
rifampicin is used alone to treat tuberculosis, resistance 
develops quickly (Devine et al, 1971) and is due to 
alteration in the /3-subunit. 
2.2.4 ABSORPTION AND DISTRIBUTION 
Rifampicin is rapidly and completely absorbed from the 
gastrointestinal tract (Riess et al, 1969) such that first 
pass hepatic effect is regarded as one of the factors that 
may affect the amount of drug reaching the systeinic 
circulation. Other workers, however, observed no difference 
in maximum concentration and time to reach maximum 
concentration after either oral dosage or intravenous 
infusion of rifampicin (Houin et al, 1982; Nitti et al, 
1977). When taken on an empty stomach, maximum 
concentrations are reached within 1 to 2 hours (Riess, 
1968)• A low gastric pH and empty stomach were associated 
with higher rifampicin serum levels than for high pH and 
full stomach (Velo and Vettori, 1968,• Riess, 1968). Food 
was demonstrated to delay absorption and caused a reduction 
in maximum concentration and area under plasma 
concentration time curve (AUG) of rifampicin (Kenny and 
Strates, 1981; Polasa and Krishnaswamy, 1983). 
Nevertheless, it had been observed in patients that there 
was no difference in serum concentrations when rifampicin 
20 
� was taken with or without food, and thereby concluded that 
whether the drug is given before or after meals is of minor 
importance, particulary with long term therapy (Oschkinat 
and Flemming, 1971) • Postprandial administration is 
considered more convenient because tolerance is better 
(Oschkinat and Flemming, 1971). Further, the same workers 
remarked that weight and sex could play a role with regard 
to serum levels that can be achieved. In their study, 
females showed, higher serum levels than males, and their 
weight was usually lower than that of males. 
On repeated administration, serum levels and half—life 
decreased with time presumably due to increase in clearance 
of rifampicin as a result of autoenzyme induction (Acocella 
et al, 1971) . The drug is approximately 80 per cent protein 
bound and free fraction in serum is about 15 to 20 per cent 
(Acocella, 1978). Rifampicin is bound to albumin (19 to 
45%), gammaglobulin (5 to 20%), and fibrinogen (3 to 12%) 
(Boman and Ringberger, 1974)• However, the amount bound to 
these fractions separately was lower than values observed 
when studies were carried out on whole plasma. 
The drug is well distributed into most tissues but 
poorly penetrates the blood brain barrier. Therapeutic 
concentrations were achieved in sputum and cavitary fluids 
of patients (Binda et al, 1971). Cerebrospinal fluid to 
plasma concentration ratio was 0.05 to 0.1 in normal 
rabbits after rifampicin 10 mg/kg (Chan, 1987), and 0.08 to 
0.12 in patients on 600 mg/day (Chan, 1988). 
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� 2.2.5 METABOLISM AND ELIMINATION 
Rifampicin is cleared from plasma mainly by hepatic 
metabolism with a serum half-life of 3 to 5 hours at 
beginning of treatment. Renal clearance after 12 hours 
accounted for approximately 13 per cent of a 150 mg dose, 
17 per cent for a 300 mg dose and 24 per cent for a 600 mg 
dose (Miano and Peruzzi, 1969) . The renal clearance is 12.2 
per cent of glomerular filtration rate (range, 2.2 to 
24.2%) and 2.4 per cent of paraaminohippuric acid clearance 
(range, 0.5 to 5.8%; Reubi et al, 1970). 
Figure 3 shows two metabolic derivatives of rifampicin, 
the major one of which is desacetylrifampicin• 
Desacetylrifampicin is an active metabolite with potency 
much less than the parent drug. It is formed by 
desacetylation of rifampicin most probably in the 
hepatocytes and it is the major fraction of the rifampicin 
excreted products in bile. Most of the formylrifampicin is 
formed spontaneously in the urine and a smaller proportion 
is presumably formed by metabolism. Formylrifampicin is 
responsible for about 10 per cent of antibacterial activity 
in the urine. Excretory capacity of the liver for 
rifampicin is saturable at doses of 300 to 600 mg such that 
with higher doses there was no corresponding increase in 
bile concentration of rifampicin and products (Acocella et 
al, 1967)• The drug undergoes enterohepatic circulation to 
a greater extent than its metabolites. Desacetylrifampicin 



























































































































































































































































































2.2.6 ADVERSE EFFECTS AND DRUG INTERACTION 
s 
The common side effects of rifampicin are 
gastrointestinal upsets, skin eruptions and hepatitis. More 
symptoms appear when doses over 1 g/day are used. When 
rifampicin is combined with isoniazid, especially on 
intermittent administration, the side effects are more 
severe and frequent (Perez-Stable and Hopewell, 1989). In 
clinical trials with rifampicin (15 to 20 mg/kg/day) plus 
isoniazid in the United States, the incidence of hepatitis 
was approximately 3 per cent (Snider et al, 1984). Reports 
from India indicated that this combination caused hepatitis 
in 8 per cent of patients (Parthasarathy et al, 198 6) . The 
side effects were mainly immunological reactions like 
flushing, pruritus, rash, nausea, vomiting, abdominal pain, 
a flu-like syndrome and, in a few patients, purpura with 
thrombocytopenia, haemolytic anaemia, respiratory distress 
and renal failure. Fortunately, some of these reactions are 
rare at the daily recommended doses of 10 to 15 mg/kg/day 
/ 
of rifampicin. 
Rifampicin induces metabolism of many compounds. 
Examples include warfarin (Michot et al, 1970), digitoxin 
(Peters et al, 1974), prednisolone (Edwards et al, 1974), 
and tolbutamide (Syvalahti et al, 1974). The drug competes 
with bilirubin for excretion by the liver such that 
jaundice may occur in the early days of treatment. This 
clears later probably due to increased clearance of 
bilirubin that is induced by rifampicin (Acocella, 1978; 
Remmer, 1972)• Orange discolouration of body secretions 
2 4 
� occurs in all patients on rifampicin making it imperative 
to warn all patients of this, especially those with contact 
lenses. 
2.2.7 PATHO-PHYSIOLOGICAL FACTORS 
In new borns there is a reduced clearance of the drug 
probably due to immature metabolising enzymes. Therefore, 
it is advised that doses over 10 mg/kg should not be used 
in this age group (Acocella et al, 1969) • However, in 
infants concentrations of rifampicin at doses below 10 
mg/ml are too low most likely due to larger total body 
water compartments. It was recommended that higher doses be 
used in infants and preferably be based on body surface 
area. 
Pharmacokinetic parameters of rifampicin in elderly 
people were similar to those in young ones (Table 2 ; 
Advenier et al, 1983) • It was concluded that for 
therapeutic purposes there is no need to adjust dosage of 
rifampicin in elderly patients. Liver disease, irrespective 
of cause and clinical presentation (acute or chronic), is 
an indication for a reduction in dose of rifampicin 
(Capelle et al, 1972； Jeanes et al, 1972). The drug can be 
administered at normal therapeutic doses to patients with 
severely impaired renal function because total clearance is 






























































































































































































































































� 2.3 SECTION 3 PYRAZINAMIDE 
2.3.1 CHEMISTRY 
Pyxazinamide (Pyra z inecarboxyamide) is a synthetic 
analogue of nicotinamide. The structure is as shown in 
Figure Ic on Page 6. It is a white crystalline powder with 
molecular weight of 123.1 and melting point of 188 to 
191°C. It is soluble in water, hexane and chloroform, and 
has a dissociation constant of 0.5 (Clarke's, 1986) . It is 
supplied as tablets of 500 mg and daily oral dose is 20 to 
35 mg/kg/day. 
2.3.2. ANTIMYCOBACTERIAL ACTIVITY 
Pyrazinamide has become important in short course anti-
tuberculous chemotherapy and in developing countries where 
primary resistance to other anti-tuberculous agents is high 
(Lain et al, 1989;). It is bacteriostatic and slowly 
bactericidal to mycobacteiria in acidic media of pH equal or 
less than 5.5 at minimum inhibitory concentrations of 15-20 
/xg/ml (Stottmeier et al 1966) • It has a high sterilising 
activity on slow growing bacilli which leads to a low 
incidence of relapses after treatment with pyrazinamide 
containing regimens (Girling, 1978)• Nevertheless, its 
mechanism of action is yet to be explained. 
2.3.3 ABSORPTION AND DISTRIBUTION 
Pyrazinamide is well absorbed from the gastrointestinal 
tract and is widely distributed in tissues and body fluids 
including the cerebrospinal fluid (Chan, 1988; Pauranik et 
27 
� al, 1986) . It is approximately 50 per cent protein bound 
(Clarke's, 1986). After oral administration of 20 mg/kg 
peak plasma concentrations of 65 /xg/ml were reached within 
1 to 4 hours (Stottmeier et al, 1968). This is well above 
minimum inhibitory concentrations. 
2.3.4 METABOLISM AND ELIMINATION 
The drug is cleared from plasma mainly by hepatic 
metabolism at half-life of 9 to 10 hours (Stottmeier et al, 
1968) . Only 3 per cent is excreted unchanged in urine in 
the first 24 hours (Ellard, 1969; Stottmeier et al, 1968) 
and, by glomerular filtration (Weiner and Tinker, 1972) . In 
the liver it is converted to pyxazinoic acid, by the 
hepatic microsomal enzyme deamidase, which is further 
oxidised by xanthine oxidase to 5—hydroxypyrazinoic acid 
(Ellard and Haslam, 1976; Roboz et al, 1978; Weiner and 
Tinker, 1972;) • In a healthy volunteer about 40 per cent of 
administered dose was excreted as pyrazinoic acid and 5-
hydroxypyrazinoic acid in 24 hours (Roboz et al, 1978) • 
2.3.5 SIDE EFFECTS 
Pyrazinamide causes a dose related hepatotoxicity and 
this is very high with doses of 40 to 50 mg/kg/day 
(Girling, 1978) . Severe hepatitis was observed in 6 per 
cent of patients treated with 40 mg/kg/day of pyrazinamide 
and 2 to 3 per cent in those treated with 25 mg/kg/day. 
Other adverse effects include nausea, vomiting, and 
diarrhoea. It causes increase in plasma levels of uric acid 
28 
� due to competition for excretion of uric acid and 
pyxazinoic acid. Clinical gout is uncommon. 
Photosensitivity may occur but hypersensitivity is rare. 
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� 2.4 SECTION 4 AN OVERVIEW OF THE USE OF ANTI-TUBERCULOUS 
DRUGS IN UGANDA AND HONG KONG. 
2.4.1 GEOGRAPHICAL AND HEALTH STATISTICS 
Uganda lies in East Africa covering an area of 150,4 00 
sq. km with a population of 13 million, 94.6 per cent of 
which is rural (Baitera, 1983). It has a population growth 
rate of 3 per cent per year and almost more than half the 
population is unproductive,i.e. children, the elderly, 
unemployed young adults and some housewives. Infant 
mortality rate is 110 per 1,000 live births, with a poor 
imimnisation coverage of less than 50 per cent. Only 50 to 
60 per cent of the population receive hospital services. 
Hong Kong is situated on the south east coast of China 
at the mouth of Pearl River and covers an area of 1,07 0 sq. 
km with a population of 5.6 million people 97 per cent of 
which is urban (Build, and Lands Dept., 1988). It has a low 
infant mortality rate (12 per 1,000 live births) and a 
population growth rate of 1.2 per cent. 
2.4.2 THE DISEASE PATTERN 
In spite of the vaccination programmes, health 
education, availability of economical and • effective 
chemotherapeutic drugs, tuberculosis remains the major 
paediatric problems in Africa and other tropical countries 
(Lloyd and Jones, 1972) • It is probably the commonest cause 
of death in young adults in Uganda (Hutt, 1971)• In Mulago 
hospital of Uganda, tuberculosis accounted for more than 10 
per cent of the admissions in 1980 (Baitera, 1983) • The 
30 
� National Tuberculosis Control Program has addressed the 
problem as nationwide contrary to earlier reports by Hutt 
(1971). 
Tuberculosis as a major cause of morbidity and mortality 
in Uganda is demonstrated by the high prevalence of factors 
closely associated by the disease vizi poverty, poor 
hygiene, malnutrition, poor immunisation coverage, and in 
some areas； overcrowding, alcoholism, and diseases 
associated with immunodeficiency. It is a multisystemic 
health hazard that has challenged the health personnel as 
a differential diagnosis in all ailments. Often, it has 
presented in the emergency as a cause of severe haemoptysis 
or acute abdomen. Pulmonary tuberculosis accounts for 75 
per cent of cases. Others in order of prevalence include: 
tuberculous lymphadenitis and abdominal adenitis, Pott‘s 
disease, meningeal and milliary tuberculosis, tuberculous 
osteomyelitis and arthritis, and pericarditis to mention 
but a few. 
In a one year study between 1966 and 1967 by the 
department of paediatrics Mulago hospital, it was shown 
that of the 3,734 children admitted, tuberculosis accounted 
for 154 cases (4.3%) (Lloyd and Jones, 1972). 
In a review of 1,132 paediatric necropsies at the same 
hospital in the twelve years 1953 to 1964, tuberculosis was 
the major infectious disease and the cause of death in 60 
children. 
The mortality report over the five years 1962 to 1966 
showed that 480 children with tuberculosis were admitted to 
31 
‘ Mulago hospital. The overall mortality was 15 per cent and 
the fatality as reported in Table 3. 
In Hong Kong there was an overall fall in the incidence 
of tuberculosis in the past decade. Notification rates 
decreased from 404 per 100,000 population in 1960, to 254 
in 1970 and 129 in 1987 (Chest service, 1987)• However, it 
had been noted that the incidence of this disease had risen 
in elderly people in the past decade (Chest service, 1985). 
The explanation for this was thought due to reactivation of 
quiescent tuberculous foci acquired in the past most 
probably during World War 11. 
2.4.3 THERAPEUTIC PRACTICE 
Table 4 shows the anti-tuberculous drugs commonly used 
in Uganda while Table 5 illustrates the anti-tuberculous 
drugs used in Hong Kong. The standard regimen for Uganda 
is: streptomycin, thiacetazone, and isoniazid (designated 
as STH) • The regimen was chosen because it is compatible 
with the social, financial, and medical status of Uganda 
population and earned good score in terms of efficacy, 
cost, toxicity, ease of administration and acceptability in 
this community. In a study by the East African British 
Medical Research Council (E.A./B.M.R.C.), isoniazid alone 
had an efficacy of 40 per cent. This was doubled to 80 per 
cent when combined with thiacetazone, and to 90 to 100 per 
cent when streptomycin was includeci for the first two 
months. When p-aminosalicylic acid (PAS) was substituted 











































































































































































































































































































































































































































































� associated with a high rate of defaulting because PAS is 
inconvenient to administer, expensive and causes unpleasant 
gastrointestinal upsets. Intermittent chemotherapy with STH 
was tried as twice weekly streptomycin and daily thiazina 
(thiacetazone + isoniazid, T = 150 mg, I = 300 mg)• Again 
in spite of the successes scored there was a high rate of 
defaulting. Many studies on short course chemotherapy have 
been done by the E. A. /B.M.R. C. (Aquinas, 1982) but have not 
earned wide practice here because among other reasons vast 
differences exists between the results of these controlled 
studies and those found in the routine ‘service‘ conditions 
in East Africa. Over three quarters of the patients are on 
STH regimen • PAS is used in case of intolerance to 
thiacetazone while ethambutol and pyrazinamide are used in 
cases of resistance and intolerance. A combination of 
isoniazid and ethambutol is used in pregnant mothers and 
streptomycin excluded. Usually streptomycin is included for 
the first two to three months. Pyridoxine is not routinely 
given because peripheral neuritis is not common. Thiazina 
is continued daily to the end. The course in total takes 18 
to 24 months. This contrasts to the practice in Hong Kong 
where a policy of intermittent and or short course 
chemotherapy on a 'service' basis is followed (Aquinas, 
1982)• This is possible because of the dense population in 
a small total area with good public transport and chest 
clinics which are open in the evenings to treat patients 
who work during office hours. The period of treatment is 6 
to 9 months. 
36 
� In Uganda chemoprophylaxis is rarely practised in 
adults. It is common in children who are at risk and have 
developed malnutrition, measles or are on steroid 
treatment, and infants of tuberculous mothers. Steroids as 
part of anti-tuberculous chemotherapy have been used in: 
tuberculous meningitis, overwhelming infection like 
milliary tuberculosis, serious effusion, pulmonary pressure 
symptoms and at times drug reactions. 
參 
2.4.4 ADVERSE EFFECTS 
The majority are hypersensitivity reactions. 
Thiacetazone is incriminated for more than half and 
streptomycin for a bigger part of the remainder. However, 
all the anti-tuberculous drugs were reported to have caused 
undesirable effects. Toxic effects in this setting run a 
risk of underestimation when they are associated with 
severe forms of the disease amid the inadequate laboratory 
services. 
Thiacetazone is obsolete in countries like Hong Kong 
where it is considered a weak anti—tuberculous drug and 
notorious for its side effects. Nevertheless, the drug is 
widely used in Uganda and many other countries. There was 
considerable geographical and racial differences in the 
side effects of thiacetazone (Martindale, 1982) . For 
example the Philipinos are intolerant to the drug and is 
unacceptable (Kamlae and Teoh, 1980) while it is generally 
well tolerated in the South African blacks (Houghton, 
1982). Pearson (1978) remarked that the advantages of the 
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# 
� drug outweigh its disadvantages if adequate precautions 
were taken. It is therefore advised that the toxicity and 
efficacy of any regimen which includes thiacetazone should 
be determined in a community before it is widely used 
(Martindale, 1982)• 
The incidence of hepatitis is higher when isoniazid, 
rifampicin and pyrazinamide are used together. For 
instance, there was more hepatitis in patients on daily 
isoniazid and rifampicin (4%; Brouet, 1974), or isoniazid 
and pyrazinamide (8%; Hong Kong, 1976) than those on 
isoniazid alone (0.8%; Riska, 1976). In Hong Kong severe 
adverse reactions to isoniazid, rifampicin and pyrazinamide 
regimen have been reported in elderly patients (Woo et al, 
1987a) and it was expressed that there is a need for 
further studies in aged animals and clinical surveys on 
adverse effects of isoniazid in elderly patients. 
2.4.5 FATE OF THE STREPTOMYCIN, THIACETAZONE AND ISONIAZID 
(STH) REGIMEN 
The STH regimen has been in use for over thirty years. 
The discovery of new and more powerful anti-tuberculous 
drugs has rendered this regimen a poor performer and only 
for the under privileged. The high rate of defaulting where 
patients fail to turn up for more treatment may be due to 
financial problems or interference with working hours, or 
boredom. This usually occurs at the time when they begin to 
feel better. Also there is increasing resentment to 
injections due to association with human immunodeficiency 
38 
� virus (HIV). Resistant cases are on the increase (figures 
not available now), normal secondary resistance being the 
most common. Everyday, on the TB ward in Mulago hospital, 
there is a patient on treatment for severe drug reactions 
(a personal experience)• 
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� 2.5 SECTION 5 A REVIEW OF ANALYTICAL METHODS FOR 
ISONIAZID, RIFAMPICIN AND PYRAZINAMIDE. 
2.5.1 INTRODUCTION 
Therapeutic drug monitoring and pharmacokinetic studies 
require development of clinically useful assay 
methodologies for drugs, and anti-tuberculous drugs are no 
exception. There are many methods for analysis of 
isoniazid, rifampicin and pyrazinamide in biological 
fluids. Microbiological assays are based on a relationship 
between the inhibitory effect of body fluid samples 
containing an antimicirobial on a microbial growth tested in 
vitro and concentration of the antimicrobial in the sample 
(Grove and Rindall, 1955) . These procedures require highly 
trained and skilled laboratory personnel and some of the 
assays require 10 days to completion. In instances of 
multiple antimicrobial therapy, like for tuberculosis, 
modifications in the procedures are needed to prevent 
interference by other anti-tuberculous agents or active 
metabolites in the sample. Spectrophotometric and 
fluorometric methods require tedious extractions and « 
derivatisation of samples while radioimmunoassays and 
radioenzymatic assays, though rapid and sensitive, are only 
available for a few antimicrobials and are not used 
routinely (Chan, 1988). Chromatography procedures have 
become increasingly important for quantitation and 
selectivity analysis, and high performance liquid 
chromatography (HPLC) has been preferred because is 
technically less complex. 
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2.5.2 RIFAMPICIN AND PYRAZINAMIDE 
Rifampicin and its 3 metabolites (3-formylrifampicin SV, 
25-desacetylrifampicin and 3-foritiyl-25-desacetylrifampicin 
SV) were assayed in urine and plasma by HPLC using a normal 
phase column and complicated mobile phase consisting of 5 
solvent components (Lecaillon et al, 1978)• Two procedures 
using reverse phase column have been reported (Ratti et al, 
1981; Chan, 1988). 
Pyrazinamide in plasma has been determined by reversed 
phase columns. Chan et al (1986a) reported a simple 
procedure for determination of pyrazinamide in plasma and 
cerebrospinal fluid of rabbits. Later Lacroix et al (1987) 
reported one for determination of pyrazinamide and its 
metabolites in urine and plasma. Recently a procedure for 
simultaneous determination of rifampicin and pyrazinamide 
in plasma has been described (Woo et al, 19 87b; Chan, 
1988) • It was claimed to be more convenient and economical. 
2.5.3. ISONIAZID 
There are several procedures which have been described 
for assay of isoniazid and some of its metabolites. 
However, the choice of an assay method of isoniazid in 
biological fluids varies from country to country. Developed 
countries have a wider choice than poorer countries. In 
general, the poorer countries find it difficult to use 
existing methodologies in clinical practice for routine 
therapeutic drug monitoring and pharmacokinetic studies. 
Ellard et al (1972) developed a sensitive fluorometric 
41 
� procedure for assay of isoniazid and metabolites in plasma. 
Unfortunately, the procedure is laborious and expensive. 
Like the original procedure by Scott and Wright (1967), 
fluorometric assay suffers loss of isoniazid if proteins 
are not precipitated within 1 to 2 hours of sample 
collection. Hydrazine was poorly extracted (1%) and did not 
show fluorescence. Several liquid chromatographic 
procedures for assay of isoniazid have been reported. Some 
of these procedures like that by Von Ssassen et al (1985) 
are complicated because isoniazid is highly polar thus 
difficult to extract and separate by liquid chromatography 
using reverse phase columns (Gupta and Lewis, 1988). 
Holdiness (1982 and 1985) described a high performance 
liquid chromatography assay for simultaneous determination 
of isoniazid and acetylisoniazid in plasma. A large sample 
size of 2 ml was required and the injected volume was 250 
Ml • The chromatography conditions used were drastic； mobile 
phase of 55 per cent ethanol in water (v/v) was set at pH 
2.5 with flow rate of 4 ml/min and column pressure of 138 
bars, making it difficult for local adaptation. The 
procedure described by Gupta and Lewis (1988) required 
plasma sample volume of 50 /il and 25 I J L I . Unfortunately, the 
supernatant injected contains materials that would endanger 
the chromatography system, and no internal standard was 
used thus making results questionable. 
There is apparently no well established procedure for 
direct estimation of total hydrazine formed during 
isoniazid metabolism. Beever et al (1982) used gas 
42 
� chromatography electron impact mass spectrometry to 
estimate free hydrazine in plasma of eight healthy 
volunteers. Sarma et al (1986) estimated total hydrazine 
indirectly by determining the ratio of isoniazid 
metabolised in the major pathways at 6 hours using urine 
samples. Both procedures are laborious and expensive. A 
procedure for simultaneous assay of isoniazid and hydrazine 
in biological fluids would be useful to examine the 
relationship between concentrations of the two compounds 
during anti-tuberculous chemotherapy. 
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^ 2.6 SECTION 6 CONCLUSIONS FROM THE REVIEWS 
1. From the layout above it appears the STH regimen has 
lost the efficacy and cost effectiveness it used to 
hold, and there is an increase in the use of isoniazid, 
rifampicin and pyrazinamide regimen in both countries. 
Since there are ethnic and geographical variations in 
severerity and incidence of adverse reactions to these 
drugs (Girling, 1978) , it is important, as noted 
earlier, to consider toxicity verses efficacy of any 
regimen in a population before it is widely used. 
Therefore, in the search for a better anti-tuberculous 
regimen priority should be given to a comprehensive 
exploration of factors that may influence drug response 
in a population. Pharmacokinetic studies have been 
preferred because pharmacokinetics is the basis on 
which most drug interactions have been explained thus 
is important to consider before other options are 
sought. There is a need for further studies on the 
pharmacokinetics of anti—tuberculous drugs and in 
particular, during combination chemotherapy. 
2. Tuberculosis of the central nervous system (CNS) has a 
high fatality rate and is difficult to treat. Rational 
chemotherapy of tuberculosis of the CNS is restricted 
by grossly limited data on the penetration of anti 
-tuberculous drugs in the brain (Richard et al, 1981)• 
Determination of these drugs in serum and cerebrospinal 
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fluid (CSF) during therapy is desirable to adjust the 
regimen with reference to miniinim inhibitory 
concentrations (MIC) of drugs, and is an aid to 
estimation of optimal dosages to avoid unwanted and 
toxic effects (Chan, 1988)• However, predicting 
concentration of these drugs after multiple therapy is 
difficult and it is uncertain whether the degree of 
meningeal inflammation, corticosteroids, duration of 
the disease or co-administration of anti-tuberculous 
drugs would affect drug deposition and penetration into 
the CSF. This implies that little is known of the 
concentrations of anti-tuberculous drugs that are 
achieved in the CSF during standard treatment. 
3. The incidence and nature of adverse reactions described 
in the literature may not apply to the elderly group of 
patients because the majority of patients in the 
studies, from which these conclusions were drawn, were 
middle aged (Woo et al, 1987a)• Elderly patients are at 
risk of developing or dying from adverse effects of the 
anti-tuberculous drugs. Therefore there is a need for 
further evaluation of the toxicity of these drugs in 
elderly people. 
4. There is a need of a method of drug analysis for use 
during the above mentioned studies and for routine 
therapeutic drug monitoring (TDM) or surveillance. The 
choice of a method for drug analysis in routine TDM for 
45 
� a country is like wise determined by factors similar* to 
those for anti-tuberculous regimen i.e. it requires 
consideration of the limits of financial and manpower 
resources of a country. Therefore, any system developed 
ought, to be economical and precise so that it can be 
widely used. 
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� CHAPTER 3 SOME PRINCIPLES OF PHARMACOKINETICS 
3.1 SECTION 1 INTRODUCTION 
Pharmacokinetic concepts and terminologies have been 
used to characterise course of drug absorption (A), 
distribution (D), metabolism (M), and elimination (E), and 
to relate these processes to intensity and duration of 
therapeutic and toxicological effects of drugs. In a 
clinical setting, pharmacokinetics has lead to rational use 
of drugs and to a safer and effective management of 
individual patients. Physiological models have been used to 
derive pharmacokinetic parameters of drugs (i.e. clearance, 
volume of distribution, and ADME rate constants) which have 
been used to explain intersubject variations in 
pharmacological responses to drugs, thereby: promoting a 
better understanding of the effects of disease states on 
action of drugs； enabling drug regimens to be tailored to 
needs of individual patients； and helping to explain 
treatment failures and unexpected adverse effects. This 
particularly has been of value for drugs with a narrow 
margin between toxic and therapeutic effects e.g. 
theophylline with therapeutic range of 8 to 20 mg/L 
(Gibaldi, 1984). 
Over the last few years there has been a distinct shift 
away from classical compartmenta1 models to describe and 
characterise drug pharmacokinetics (Sansom and Nation, 
1990)• With the classical approach the body was conceived 
as a one or more compartments with drug distribution and 
elimination occurring between and from the compartments, 
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� respectively- The major ciisadvantage of this approach was 
that the compartments and associated parameters, such as 
inter-compartmental rate constants, bore no obvious 
relationship to anatomical structure and physiological 
function of the animal or human body being studied and 
therefore it was difficult to interpret and apply 
pharmacokinetic data physiologically (Sansom and Nation, 
1990). Non-compartmental methods of data analysis have 
improved the ability to interpret derived pharmacokinetic 
parameters in relation to alterations in physiological 
function associated with disease states, advancing age, 
concomitant drug administration to mention but a few. 
In most cases the ADME processes associated with each 
model can be described by first order rate kinetics (i.e. 
rate of transfer of a given drug is proportional to the 
amount of drug in a compartment), therefore many 
pharmacokinetic equations have been derived using linear 
kinetics. 
For purposes of the present study, where 
noncompartmental methods have been used, only the single-
compartment data analysis has been reviewed here. 
3.1.1 NONCOMPARTMENTAL METHODS (Gibaldi, 1984) 
3.1.1.1 INTRAVENOUS ADMINISTRATION 
In one-compartment model it is assumed that the drug is 
completely and rapidly distributed to all tissues such that 
shortly after intravenous administration only elimination 
processes need be considered when describing the change in 
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� amount of drug in the body i.e: 
dA dAg 
= = kA Eq. (1). 
dt dt 
where A and A^ are the amount of drug in the body and total 
amount of drug eliminated at tine t, respectively； k is 
elimination rate constant; -dA/dt is rate of change of 
amount drug in the body and dA^/dt is rate of elimination of 
the drug. 
At distribution equilibrium plasma concentration (C) of 
the drug reflects the total amount of drug in the body (A) 
and is related by a constant termed volume of distribution 
(V). Therefore, 
A = V-C Eq. (2). 
By substitution of equation 2 into 1, and intergrating 
between limits of t = 0 and t = t, the expression becomes: 
k- t 
Log C = Log Co - Eq. (3). 
2 .303 
where Co is drug concentration immediately after injection. 
Figure 4 shows a graphical representation of plasma 
concentration C, on a semilogarithmic scale, plotted 
against time t, on a 
linear scale. Pharmacokinetic parameters like half-life 
(Tl/2), Co, k, and V can be obtained using the plot as 
indicated in figure 4. Also the elimination rate constant 


















































































k = Eq • (4). 
Tl/2 
3.1.1.2. ORAL ADMINISTRATION 
After oral administration the rate of change in amount 
of a drug in the body (dA/dt) is a function of absorption 
and elimination rates. 
dA/dt = kg-A^ - k-A Eq. (5). 
where k^ and k are absorption and elimination rate 
constants, respectively. A^ and A are the amount of drug at 
the absorption site and total amount of drug in the body, 
respectively. Maximum concentration occurs when the 
absorption and elimination rate constants are equal. After 
substitutions and intergration equation 5 becomes; 
k • F • D k- t 
3 
Log C = Log ( ) 一 Eq. (6) • 
V(kg-k) 2.303 
Figure 5 shows a graphical representation of plasma 
concentration C, on semilogarithmic scale, verses time t, 
on a linear scale. The intercept is a function of 
absorption and elimination constants, dose (D) , amount 
absorbed (F) and volume of distribution. Only when a drug 
is completely and rapidly absorbed can it be assumed that 
the intercept (Co) approximates to the ratio of amount 




































































































、 3.1.2. FURTHER A N A L Y S I S BY THE S T A T I S T I C A L M O M E N T THEORY 
Further analysis of the plots in Figures 4 and 5 can 
offer a lot m o r e information on the p h a r m a c o k i n e t i c s of a 
d r u g . T h i s is achieved by c a l c u l a t i o n s b a s e d on a 
s t a t i s t i c a l m o m e n t theory w h e r e b y zero m o m e n t of drug 
plasma c o n c e n t r a t i o n v e r s e s time curve is the t o t a l area 
u n d e r t h e curve (AUG) (Figures 4 and 5) • T h e zero m o m e n t or 
AUG h e l p s to calculate b i o a v a i l a b i l i t y , c l e a r a n c e , v o l u m e 
of d i s t r i b u t i o n , and h a l f - l i f e . 
AUG from zero to time t of sample c o l l e c t i o n can be 
obtained by p l a n i m e t r y , ‘ cut and weigh‘ m e t h o d , and m o s t 
commonly by the t r a p e z o i d a l r u l e . The area b e y o n d t h e last 
c o n c e n t r a t i o n (C*) data p o i n t (time t*) of the 
p o s t a b s o r p t i o n phase is obtained from: 
Area from t* to oo = C*/k E q . (7). 
w h e r e k is the first order elimination c o n s t a n t . W h e n this 
area is added to the AUG from zero to time t , the t o t a l AUC 
is o b t a i n e d . The ratio of total AUC o b t a i n e d a f t e r oral 
dosing (AUCp.o.) to t h a t obtained after i n t r a v e n o u s d o s i n g 
(AUCi.V.) is a m e a s u r e of the fraction of the a m o u n t drug 
t h a t r e a c h e s the systemic circulation or b i o a v i l a b i l i t y (F) 
i.e. 
A U C p . o . 
F = E q . (8). 
A U C i . V . 
T h e r e f o r e , b i o a v a l a b i l i t y is a ratio of the zero m o m e n t 
after o r a l dose to t h a t after intravenous d o s e . 
AUC from zero to time t is referred to as area u n d e r 
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« 
、 first m o m e n t curve (AUMC)• The ratio of A U M C to total AUG 
is a measure of its mean residence time (MRT)• a time by 
which over 60% of administered dose is e l i m i n a t e d from the 
b o d y . M R T , like h a l f — l i f e , is a function of v o l u m e of 
distribution and c l e a r a n c e . It may p r o v i d e i n f o r m a t i o n on 
m e a n absorption time for a d r u g . 
By statistical m o m e n t theory voluiT\e of d i s t r i b u t i o n at 
steady state (Vss), after intravenous bolus dose of a d r u g , 
can be determined independent of the drug e l i m i n a t i o n 
processes as: 
D. • AUMC 
1 • V • 
Vss = E q . (9) • 
(AUG)2 
T h e r e f o r e , volume of distribution at steady state is a 
p r o d u c t of dose and ratio of the first m o m e n t to the s q u a r e 
of the zero inoinent. 
It is known that total clearance of a drug from plasma 
equals to the ratio of overall elimination r a t e s (i.e. sum 
of elimination processes occurring in all organs) of the 
drug to drug concentration in the p l a s m a . T h i s r a t i o was 
found to be equal to the value obtained froiti e x p r e s s i o n ; 
Doseiv. 
CLp = E q . (10). 
AUCq幻 
T h e r e f o r e , clearance can be obtained by d i v i d i n g dose 
given by the zero m o m e n t . 
During c o n s t a n t or chronic frequent d o s i n g c l e a r a n c e of 
a drug at steady state can be obtained by; 
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Ro 
CLp = Eq. (11). 
Css 
w h e r e R^ is dosing rate and Css is c o n c e n t r a t i o n at steady 
s t a t e . 
Note: For drugs t h a t are completely and r a p i d l y a b s o r b e d 
after oral a d m i n i s t r a t i o n , oral dose m a y be a p p r o x i m a t e d to 
intravenous dose during the c a l c u l a t i o n s . 
3.2 SECTION 2 APPLICATION OF P H A R M A C O K I N E T I C S 
3.2.1. H A L F - L I F E 
H a l f - l i f e (Tl/2) is time taken for t o t a l a m o u n t of drug 
in the body to fall by h a l f . It is a d e t e r m i n a n t of; 
duration of action of a drug after single d o s e 
a d m i n s t r a t i o n , time to reach steady state w i t h c h r o n i c 
dosing and frequency of d o s i n g . It takes 3 to 5 h a l f - l i v e s 
of a drug to reach 75 to 97 % of the e v e n t u a l s t e a d y state 
c o n c e n t r a t i o n , and the m o r e frequent a drug is g i v e n the 
less fluctuation in steady state c o n c e n t r a t i o n . H a l f - l i f e 
is a secondary p h a r m a c o k i n e t i c p a r a m e t e r ; it is d e t e r m i n e d 
by v o l u m e of distribution (V) and c l e a r a n c e CL i.e. 
0.693-V 
Tl/2 = E q . (12). 
CL 
H a l f — l i f e can be used to d e t e r m i n e a m o u n t of drug 
r e m a i n i n g in the body after dosing: 
Q = (1/2)" E q . (13). 
W h e r e Q is fraction of the d o s e r e m a i n i n g after 
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、 administration of a drug, and n is number of h a l f — l i v e s at 
that particular time after d o s i n g . 
3.2.2. "PLASMA PROTEIN BINDING 
U n b o u n d (free) drug concentration is r e l a t e d m o r e 
closely to pharmacological and t o x i c o l o g i c a l e f f e c t s of a 
drug than total drug c o n c e n t r a t i o n . For this r e a s o n , and 
because the extent of plasma p r o t e i n b i n d i n g is a 
d e t e r m i n a n t of volume of distribution and drug c l e a r a n c e , 
it is important to appreciate the d e t e r m i n a n t s of plasma 
protein binding of a d r u g . This can be d e d u c e d from the 
expression: 
1 
fu = E q . (14)、 
1 + K (P 丁 - D P ) 
w h e r e f^ is the unbound fraction, K is e q u i l i b r i u m 
association constant or affinity (K is zero w h e n no drug is 
b o u n d , and is when all the drug is bound) , P^ is t o t a l 
molar protein concentration and DP is d r u g — p r o t e i n complex 
molar c o n c e n t r a t i o n . T h e r e f o r e , extent of plasma p r o t e i n 
binding of a drug is a function of the a f f i n i t y of p r o t e i n 
for the drug and the molar concentrations of both drug and 
protein e . g . unbound fraction (fj is low w h e n a f f i n i t y (K) 
is high and molar concentration of the drug (DP) is low 
compared to that of total protein (P^) • 
The binding protein may be albumin (for a c i d i c drugs); 
a^-acid glycoprotein (for basic drugs)； l i p o p r o t e i n s and 
other specific proteins like C o r t i s o l - b i n d i n g g l o b u l i n . The 
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affinity of a protein for a drug and the c o n c e n t r a t i o n of 
the binding protein (s) may be modified by d i s e a s e state 
such as liver or renal d i s e a s e , or other d r u g s (e.g. by 
drug d i s p l a c e m e n t from proteins)• 
3.2.3. V O L U M E OF DISTRIBUTION 
V o l u m e of distribution is a r e l a t i o n s h i p between 
• concentration of a drug in plasma to t o t a l a m o u n t of drug 
in the b o d y . It is determinant of the size of loading dose 
if steady state concentration is to be achieved q u i c k l y . A t 
equilibrium only the unbound fraction of drug c o n c e n t r a t i o n 
(fj can enter and leave the t i s s u e s , and c o n c e n t r a t i o n of 
the unbound drug in plasma and tissues is t h e s a m e . 
T h e r e f o r e , total amount of a drug in the body can be 
expressed as: 
V. C = Vp. C + Vt.Ct Eq. (15). 
where V is the total volume of d i s t r i b u t i o n , V^ is plasma 
v o l u m e , Vt is apparent volume of all t i s s u e s , C plasma 
concentration of the drug and C^ is c o n c e n t r a t i o n of the 
drug in t i s s u e s . After a series of s u b s t i t u t i o n s equation 
15 becomes； 
fu • 
V = Vp + . V^ E q . (16) • 
fut 
where f^^ is the free fraction in t i s s u e s . T h e r e f o r e , v o l u m e 
of distribution increases w i t h increases in p h y s i c a l or 
anatomical volumes or tissue binding and w i t h d e c r e a s e s in 
plasma protein binding. The volume of d i s t r i b u t i o n of a 
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drug that is unbound in the body is equal to either total 
body w a t e r (e.g. antipyrine) or e x t r a c e l l u l a r fluid v o l u m e 
e . g . (bromide ion) ,because fjf^^ = 1. A l s o , w h e n a drug is 
m o r e e x t e n s i v e l y bound to plasma p r o t e i n s than to t i s s u e 
components (i.e. f^/f^^ is very small) v o l u m e of 
d i s t r i b u t i o n for the drug w i l l be r e l a t i v e l y s m a l l . On the 
other h a n d w h e n a drug is avidly bound to t i s s u e c o m p o n e n t s 
than p l a s m a p r o t e i n s (i.e. f^/fut 土曰 v e r y large) v o l u m e of 
d i s t r i b u t i o n of the drug w i l l be l a r g e . For d r u g s w i t h 
v o l u m e of distribution over 100 l i t r e s , Vp b e c o m e s 
n e g l i g i b l e such t h a t changes in f^ and f^^ can lead to 
p r o p o r t i o n a l d i r e c t or inverse changes in V (Eq. 1 6 ) . 
3.2.4. CLEARANCE 
Clearance is a m e a s u r e of efficiency of i r r e v e r s i b l e 
elimination of a drug from the body and is a d e t e r m i n a n t of 
m a i n t e n a n c e dose rate required to a c h i e v e a d e s i r e d 
c o n c e n t r a t i o n or e f f e c t , if m e t a b o l i t e s are i n a c t i v e , at 
steady s t a t e . Clearance concepts are m o r e u s e f u l t h a n half-
life for u n d e r s t a n d i n g drug e l i m i n a t i o n b e c a u s e t h e v a l u e 
of clearance is directly c o n t r o l l e d and m o d u l a t e d by 
p h y s i o l o g i c a l f a c t o r s . Clearance can be o b t a i n e d u s i n g 
expressions: 
F (D/r) 
CL = E q . (17) • 
Cavss 




CL = E q . (18). 
Css 
w h e r e Cavss is the average steady state d r u g c o n c e n t r a t i o n 
in p l a s m a during m u l t i p l e d o s i n g , and Css is s t e a d y state 
drug c o n c e n t r a t i o n in plasma during c o n s t a n t r a t e infusion; 
F is bioavailability,* D the dose; r is d o s i n g interval; R。 
is c o n s t a n t infusion rate and CL is t o t a l s y s t e m i c 
c l e a r a n c e of the d r u g . Therefore c l e a r a n c e is m e a s u r e d in 
v o l u m e p e r u n i t t i m e . 
T o t a l systemic clearance for a drug (CL = dose/AUC) is 
a sum of r e n a l and n o n r e n a l clearance c o n t r i b u t i o n s . W h i l e 
there are a number of organs (e.g.lungs) w h i c h m i g h t 
conceivably contribute to the n o n r e n a l c l e a r a n c e of a d r u g , 
for m o s t drugs the liver appears to be t h e p r e d o m i n a n t 
site. T h e r e f o r e , substraction of renal c l e a r a n c e (C^； w h i c h 
is the only individual organ clearance t h a t can e a s i l y be 
directly m e a s u r e d ) , from total systemic c l e a r a n c e y i e l d s an 
estimate of hepatic clearance (CLJ • H e p a t i c c l e a r a n c e m a y 
be due to drug m e t a b o l i s m and/or biliary e x c r e t i o n . 
3.2.5. H E P A T I C CLEARANCE 
H e p a t i c clearance (CL„) is a function of the i n t r i n s i c 
ability of the liver to m e t a b o l i s e a d r u g (elimination 
rate) and amount of drug input (C^; the a v e r a g e e n t e r i n g 
blood drug concentration): 
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、 （elimination rate) 
CLH = E q . (19). 
•A 
E l i m i n a t i o n r a t e = Q J C ^ - E q . (20). 
•A - Cv 
T h e n , CL„ = Q" • ( ) E q . (21). 
CA 
w h e r e Q^ is the h e p a t i c blood flow r a t e and C^ is h e p a t i c 
v e n o u s b l o o d d r u g c o n c e n t r a t i o n . The t e r m in b r a c k e t s is a 
m e a s u r e of the e f f i c i e n c y of h e p a t i c d r u g e x t r a c t i o n t h u s 
is r e f e r r e d to as h e p a t i c e x t r a c t i o n r a t i o (ER). Its v a l u e 
is 0 to 1. T h e n , e q u a t i o n 21 b e c o m e s : 
CLH = QH • (ER) E q . (22). 
For a b e t t e r i n t e r p r e t a t i o n of f a c t o r s a f f e c t i n g 
c l e a r a n c e of a drug a m o r e e l a b o r a t e e x p r e s s i o n is u s e d : 
fu • CLint. 
C Lh = Qh . ( ) E q . (23). 
QH + fu . CL-nt. 
w h e r e f^ is t h e u n b o u n d f r a c t i o n of t h e d r u g p l a s m a 
c o n c e n t r a t i o n , and is h e p a t i c i n t r i n s i c c l e a r a n c e 
w h i c h is a m e a s u r e of i n t r i n s i c a b i l i t y (enzyme a c t i v i t y ) 
of t h e liver to clear a drug in a b s e n c e of b l o o d b i n d i n g 
and b l o o d flow l i m i t a t i o n s . T h a t is, i n t r i n s i c c l e a r a n c e is 
a m e a s u r e of h e p a t o c e l l u l a r m e t a b o l i c or b i l i a r y a c t i v i t y 
and it is r e l a t e d to the m a x i m u m v e l o c i t y (V^^) and the 
M i c h a e l i s — M e n t e n c o n s t a n t (KJ of e n z y m e s y s t e m s i n v o l v e d 
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、 with h e p a t i c r e m o v a l . When intrinsic c l e a r a n c e is 
independent of h e p a t i c drug c o n c e n t r a t i o n , then CL^nt. 二 
w v 
A c c o r d i n g to equation 23 h e p a t i c c l e a r a n c e for a drug is 
d e t e r m i n e d by h e p a t i c blood flow, unbound f r a c t i o n , and the 
intrinsic c l e a r a n c e . The term in b r a c k e t s is t h e e x t r a c t i o n 
ratio h e n c e the following d e d u c t i o n s are true: 
1. For drugs with low h e p a t i c e x t r a c t i o n r a t i o (ER), Q^ 
>>> f : CL^nt , t h e r e f o r e equation 23 becomes: 
CLh = fu • CL-nt. E q . (24). 
This implies t h a t clearance of such a drug is s e n s i t i v e to 
changes in the u n b o u n d fraction and i n t r i n s i c c l e a r a n c e 
(enzyme a c t i v i t y ) , and is least affected by c h a n g e s in 
liver blood f l o w , e . g . W a r f a r i n and a n t i p y r i n e (Anderson 
and V e s s e l l , 1974). This m a y be caused by i n t e r i n d i v i d u a l 
d i f f e r e n c e s , alterations by enzyme i n d u c t i o n and 
i n h i b i t i o n , or d i s e a s e s t a t e s . In a d d i t i o n , t h e r e w i l l be 
only a small first pass effect after oral a d m i n i s t r a t i o n 
and m o s t of the administered dose w i l l reach the s y s t e m i c 
c i r c u l a t i o n . T h e n , v a r i a t i o n s in the intrinsic c l e a r a n c e 
w i l l be seen largely as changes in h a l f - l i f e . In c a s e of 
changes in drug binding e l i m i n a t i o n of the d r u g is 
r e s t r i c t e d such t h a t total drug c l e a r a n c e is p r o p o r t i o n a l 
to the free drug concentration (i.e.fall in b i n d i n g leads 
to increase in c l e a r a n c e , and the v i c e v e r s a ) • E v e n t u a l l y , 
the free drug concentration is little c h a n g e d . T h i s m e a n s 
that r e d u c e d binding m a y lead to r e d u c t i o n in h a l f - l i f e of 
the d r u g . 
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、 2. For drugs with a high h e p a t i c extraction r a t i o (ER), 
fu • CLint >>> therefore equation 2 3 becomes: 
CLh = E q . (25) • 
This implies t h a t clearance of such a drug is s e n s i t i v e to 
changes in h e p a t i c blood flow and is least a f f e c t e d by 
changes in the u n b o u n d fraction or intrinsic c l e a r a n c e e . g . 
p r o p r a n o l o l (Shand and R a n g n o , 1972) and l i g n o c a i n e (Boyes 
et al, 1971)• There w i l l be a s i g n i f i c a n t p r e s y s t e m i c 
m e t a b o l i s m after oral a d m i n i s t r a t i o n w h i c h r e d u c e s 
b i o a v a i l a b i l i t y of the d r u g . A l t e r e d b i n d i n g h a s less 
effect on t o t a l drug clearance such t h a t only free drug 
levels w i l l r e f l e c t changes in b i n d i n g . F u r t h e r m o r e , 
because the v o l u m e of d i s t r i b u t i o n d e p e n d s on b i n d i n g in 
the b l o o d , reduced binding w i l l p r o l o n g the h a l f - l i f e 
because distribution is increased with little c h a n g e in 
c l e a r a n c e . 
3. For drugs having intermediate ER v a l u e s , CL, w i l l be 
p a r t i a l l y d e p e n d e n t on f^, and Q^. 
3.2.6. RENAL CLEARANCE 
R e n a l clearance (CLJ is easier to m e a s u r e . It can be 
estimated from the following expressions: 
\ fe.D dA^/dt 
CLr = = = E q . (26). 
AUG AUG C 
mp 
W h e r e A^ is amount of unchanged drug excreted into u r i n e in 
a defined p e r i o d and AUG is the area u n d e r plasma 
concentration c u r v e . fe is fraction of s y s t e m i c a l l y 
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、 administered drug that is excreted into u r i n e , dA^/dt is 
u r i n a r y excretion rate of a drug and C 叩 is plasma 
concentration at mid p o i n t of the u r i n e c o l l e c t i o n p e r i o d . 
C L d is a r e s u l t of renal filtration of a drug at the 
g l o m e r u l u s (renal filtration c l e a r a n c e ; CL^p), a c t i v e 
t u b u l a r secretion (renal secretion c l e a r a n c e ; CLj^^) , and 
p a s s i v e tubular r e a b s o r p t i o n (fraction of f i l t e r e d and 
secreted drug that is subsequently r e a b s o r b e d ; F R ) . i . e . 
CLR = (CLRF + CLRS) . (1 - FR) E q . (27). 
or 
Qr . fu . CL. 
CLR = (fu . GFR + ) . (1 一 FR) E q . (28) • 
Qr + fu . CL-
w h e r e f^ is unbound fraction, GFR g l o m e r u l a r f i l t r a t i o n 
r a t e , Q r renal blood flow r a t e , CL. is i n t r i n s i c c l e a r a n c e 
(capacity) of the tubular e n z y m a t i c c a r r i e r system to 
t r a n s p o r t a drug in absence of blood flow and b l o o d b i n d i n g 
l i m i t a t i o n s . T h e r e f o r e renal c l e a r a n c e for d r u g m a y be 
affected by changes in the f^, Q r , CL., u r i n e pH and u r i n e 
flow rate (the last two factors are involved in f i l t r a t i o n 
and r e a b s o r p t i o n i.e. in the FR t e r m ) . 
Then: 
1. For drugs with a low renal e x t r a c t i o n r a t i o (ER^) ； Q^ 
>>> f^' CL.; tubular reabsorption (FR = 0) and t u b u l a r 
secretion (CL. = 0) are n e g l i g i b l e . N o t e t h a t for any drug 
FR and CL. may be n e g l i g i b l e when r e a b s o r p t i o n and s e c r e t i o n 
are blocked by changing urine pH and g i v i n g a c o m p e t i t i v e 
i n h i b i t o r , r e s p e c t i v e l y . Then equation 28 b e c o m e s : 
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、 CLr = fu . GFR Eq. (29). 
Under such circumstances the C L r is sensitive to c h a n g e s in 
fu and G F R . 
2. For drugs with a high ER^; f^ . CL. » > Q^ >>> f^ . 
G F R . 
Equation 28 approximates to: 
CL, = Q r ( 1- FR ) Eq. (30). 
In that case the C L r is sensitive to changes in r e n a l blood 
flow r a t e , urine pH and flow r a t e . 
3.2.7. BIOAVAILABILITY 
B i o a v a i l a b i l i t y (F) is a m e a s u r e of the fraction of a 
drug that reaches the systemic c i r c u l a t i o n after 
a d m i n i s t r a t i o n . When a drug is completely a b s o r b e d after 
oral administration and there is no a p p r e c i a b l e gut 
m e t a b o l i s m then the major d e t e r m i n a n t of its 
bioavailability is p r e s y s t e m i c m e t a b o l i s m (first p a s s 
effect) by the liver. First pass elimination is d e t e r m i n e d 
by the h e p a t i c extraction ratio for a d r u g . T h u s the 
fraction of dose removed is equal to the h e p a t i c e x t r a c t i o n 
ratio (ER) such that the fraction escaping to the s y s t e m i c 
circulation is (1 一 ER) . T h e r e f o r e , s i g n i f i c a n t f i r s t pass 
effect will occur for drugs with a high h e p a t i c e x t r a c t i o n 
ratio e.g lignocaine (Boyes et al, 1971) and p r o p r a n o l o l 
(Shand and R a n g n o , 1972) but not with p o o r l y e x t r a c t e d 
drugs like a n t i p y r i n e , t o l b u t a m i d e and w a r f a r i n (Anderson 
and V e s s e , 1974). 
Bioavailability can also be estimated by d e t e r m i n a t i o n of 
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V 
fraction of drug excreted in the urine in the free form and 
m e t a b o l i t e s , if renal function is n o r m a l . 
3.2.8. CONCLUSION 
In the present p r o j e c t , it was intended to u s e the 
p h a r m a c o k i n e t i c concepts and t e r m i n o l o g i e s d e s c r i b e d to 
study the disposition of isoniazid, r i f a m p i c i n and 
p y r a z i n a m i d e in plasma of elderly p a t i e n t s on c h r o n i c 
t r e a t m e n t for.pulmonary t u b e r c u l o s i s w i t h a c o m b i n a t i o n of 
the t h r e e drugs, and to investigate the d i s p o s i t i o n of 
isoniazid and its h y d r a z i n e m e t a b o l i t e in p l a s m a , and 
penetration in the cerebrospinal fluid 
in r a b b i t s . 
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、 C H A P T E R 4. A I M S OF T H E P R E S E N T P R O J E C T 
1. To d e v e l o p a m o r e e c o n o m i c a l , c o n v e n i e n t and s e n s i t i v e 
m e t h o d , b a s e d on h i g h p e r f o r m a n c e l i q u i d c h r o m a t o g r a p h y , 
for s i m u l t a n e o u s d e t e r m i n a t i o n of i s o n i a z i d a n d 
h y d r a z i n e m e t a b o l i t e in p l a s m a and c e r e b r o s p i n a l f l u i d 
of r a b b i t s and p a t i e n t s . A r a b b i t is a g o o d a n i m a l m o d e l 
for t h e s t u d y of i s o n i a z i d b e c a u s e t h e d r u g is 
m e t a b o l i s e d by a s i m i l a r p r o c e s s to m a n (Frymoyer and 
J a c o x , 19 63; H e a r s e and W e b e r , 1 9 7 3 ) ) . 
2 . To s t u d y t h e p h a r m a c o k i n e t i c s of i s o n i a z i d and h y d r a z i n e 
m e t a b o l i t e in p l a s m a and c e r e b r o s p i n a l f l u i d of r a b b i t s . 
C e n t r a l n e r v o u s s y s t e m (CNS) k i n e t i c s t u d i e s a r e 
d i f f i c u l t to c o n d u c t in h u m a n s , t h e r e f o r e t h i s a n i m a l 
m o d e l w o u l d e n a b l e us to e l u c i d a t e on h o w long and to 
w h a t e x t e n t i s o n i a z i d stays in t h e C N S , and w i l l o f f e r 
s o m e k n o w l e d g e on t h e k i n e t i c s of h y d r a z i n e , as a 
m e t a b o l i t e , w h i c h is e s s e n t i a l for e v a l u a t i o n of its 
r o l e in i s o n i a z i d r e l a t e d t o x i c i t y . 
3 . T o d e t e r m i n e and c o r r e l a t e p l a s m a p r o f i l e s of h y d r a z i n e 
to t h o s e of i s o n i a z i d in e l d e r l y p a t i e n t s on a n t i 
一 t u b e r c u l o u s c h e m o t h e r a p y w i t h i s o n i a z i d , r i f a m p i c i n and 
p y r a z i n a m i d e , t h e r e a f t e r , to c o m p a r e a v e r a g e v a l u e s for 
a d u l t p a t i e n t s b e l o w and over 65 y e a r s of a g e . T h i s 
w o u l d g i v e a h i n t on t h e m a g n i t u d e of h y d r a z i n e t h a t is 
p r o d u c e d d u r i n g t r e a t m e n t w i t h t h i s r e g i m e n and in 
d i f f e r e n t age g r o u p s , w h i c h is e s s e n t i a l to s u b s t a n t i a t e 
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、 the recent incrimination of this m e t a b o l i t e as a cause 
of isoniazid induced liver t o x i c i t y . 
4. To compare t h e p h a r m a c o k i n e t i c s of i s o n i a z i d , r i f a m p i c i n 
and p y r a z i n a m i d e in plasma of adult p a t i e n t s , b e l o w and 
above 65 y e a r s of age, on t r e a t m e n t for p u l m o n a r y 
t u b e r c u l o s i s , with a hope to set a standard r e f e r e n c e on 
w h i c h other p a t i e n t s can be evaluated in the c l i n i c . 
There are few reports on the p h a r m a c o k i n e t i c s of anti 
- t u b e r c u l o u s drugs in elderly p e o p l e (Kergueris et a l , 
1986; A d v e n i e r et al, 198 0; P a u l s e n and N i l s s o n , 1985; 
A d v e n i e r et a l , 1983). U n f o r t u n a t e l y , only one drug w a s 
given or analyzed at a t i m e . It is m o r e a p p r o p r i a t e to 
consider all the drugs a p a t i e n t is t a k i n g w h e n 
evaluating for adverse effects of any d r u g . S i n c e the 
combination of these drugs leads to a h i g h e r r a t e of 
adverse effects and such e f f e c t s are m o r e c o m m o n and 
severe in elderly p a t i e n t s , k n o w l e d g e on w h e t h e r t h e r e 
are any age related changes in the p h a r m a c o k i n e t i c s of 
these d r u g s , w h e n used in c o m b i n a t i o n , is i m p o r t a n t for 
their safe u s e in the c l i n i c . 
5. To p r e s e n t a case report on a p a t i e n t w h o d i e d of drug 
toxicity during t r e a t m e n t w i t h i s o n i a z i d , r i f a m p i c i n and 
p y r a z i n a m i d e r e g i m e n . H y d r a z i n e m e t a b o l i t e w a s s u s p e c t e d 
to h a v e c o n t r i b u t e d to this t o x i c i t y . 
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C H A P T E R 5 . C H R O M A T O G R A P H I C M E T H O D S 
5.1 S E C T I O N 1 A S I M U L T A N E O U S A S S A Y F O R I S O N I A Z I D A N D 
H Y D R A Z I N E M E T A B O L I T E IN P L A S M A A N D 
C E R E B R O S P I N A L F L U I D IN T H E R A B B I T 
5 . 1 . 1 I N T R O D U C T I O N 
M a n y p r o c e d u r e s h a v e b e e n d e s c r i b e d for d e t e r m i n a t i o n 
of i s o n i a z i d in p l a s m a (Scott and W r i g h t , 1967； E l l a r d et 
a l , 1972; H o l d i n e s s , 1982 ； V o n S a s s e n et a l , 1985; J e n n e r 
and E l l a r d , 1987 ； G u p t a and L e w i s , 1988) . T h e 
f l u o r o m e t r i c a s s a y (Ellard et a l , 1972) , a l t h o u g h 
s e n s i t i v e , is l a b o r i o u s and e x p e n s i v e . H y d r a z i n e m e t a b o l i t e 
w a s p o o r l y e x t r a c t e d (1%) and d i d n o t show f l u o r e s c e n c e . 
S e v e r a l p r o c e d u r e s b a s e d on h i g h p e r f o r m a n c e l i q u i d 
c h r o m a t o g r a p h y for a s s a y of i s o n i a z i d w i t h or w i t h o u t 
m e t a b o l i t e s h a v e b e e n p u b l i s h e d ( H o l d i n e s s , 1982 and 1985; 
V o n S a s s e n et a l , 19 85; Gupta and l e w i s , 19 8 8;) . In s o m e 
(Von S a s s e n et a l , 1985; H o l d i n e s s , 1982 and 1 9 8 5 ) , a l a r g e 
s a m p l e v o l u m e and d r a s t i c c h r o m a t o g r a p h y c o n d i t i o n s w e r e 
u s e d , w h i l e in o t h e r s (Gupta and L e w i s , 1988) t h e 
s u p e r n a t a n t i n j e c t e d w o u l d e n d a n g e r t h e c h r o m a t o g r a p h y 
s y s t e m and did n o t include i n t e r n a l s t a n d a r d in t h e 
p r o c e d u r e t h u s m a k i n g r e s u l t s q u e s t i o n a b l e . 
H y d r a z i n e is a p o t e n t t o x i n and c a r c i n o g e n (Back and 
T h o m a s , 1 9 7 0 ) . It is formed d u r i n g t h e d i r e c t c o n v e r s i o n 
of i s o n i a z i d to i s o n i c o t i n i c a c i d . In w a k e of p r o p o s a l 
t h a t m o n o a c e t y I h y d r a z i n e p l a y s a r o l e in i s o n i a z i d r e l a t e d 
t o x i c i t y , h y d r a z i n e has been i m p l i c a t e d as a p o s s i b l e 
c u l p r i t (Sarma et a l , 1 9 8 6 ) . T h e r e is a p p a r e n t l y no w e l l 
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、 established p r o c e d u r e for direct e s t i m a t i o n of total 
h y d r a z i n e formed during isoniazid m e t a b o l i s m . Gas 
c h r o m a t o g r a p h y electron impact m a s s s p e c t r o m e t r y m e t h o d 
(Beever et a l , 1982) and indirect e s t i m a t i o n of total 
h y d r a z i n e by determining the ratio of isoniazid m e t a b o l i s e d 
in the m a j o r p a t h w a y s (Sarma et al, 1986) are l a b o r i o u s and 
e x p e n s i v e . A simultaneous assay of isoniazid and h y d r a z i n e 
w o u l d b e u s e f u l to look at the r e l a t i o n s h i p of the 
c o n c e n t r a t i o n s of the two c o m p o u n d s . A p r o c e d u r e of 
organic solvent extraction before and after d e r i v a t i s a t i o n , 
and c o n c e n t r a t i o n of d e r i v a t i v e s w a s a d o p t e d to o p t i m i s e 
sensitivity and s e l e c t i v i t y . The d e r i v a t i s a t i o n p r o c e s s 
w a s based on a m o d i f i c a t i o n of that d e s c r i b e d by S c o t t and 
W r i g h t (1967), w h i l e the c h r o m a t o g r a p h y s y s t e m w a s adopted 
from t h a t described by Abdou and M e d w i c k (1978) . T h e final 
d e r i v a t i s e d p r o d u c t s were cleaned by w a s h i n g out the 
a l d e h y d e as described by Jenner and Ellard (1987). 
5.2 M E T H O D S 
5.2.1 A P P A R A T U S 
The c h r o m a t o g r a p h y system comprises of a W a t e r s M4 5 p u m p 
(Waters 一 A s s o c i a t e s , M i l f o r d , M . A . , U . S . A . ) , a 7125 
injector (Rheodyne, C a l i f o r n i a , U.S.A.) and a v a r i a b l e 
w a v e l e n g t h H i t a c h i 220-S u l t r a — v i o l e t (UV) d e t e c t o r w i t h a 
b u i l t in chart recorder (Hitachi, T o k y o , J a p a n ) . A n a l y s e s 
w e r e p e r f o r m e d on a ^Bondapak reversed p h a s e C^g Column (10 
Min, 300 m m X 3.9 mm 工 D , W a t e r s A s s o c i a t e s ) linked to a C 
p r e c o l u m n (30 /xm, 30 mm x 4.6 mm 工 D, W a t e r s A s s o c i a t e s ) . 
Other apparatus included 10 ml capacity c e n t r i f u g e t e s t 
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、 tubes with w e l l fitting screw c a p s , and 15 m l stoppered 
evaporation tubes with finely tapered b a s e s of 100 /il 
capacity (Sovirel, Levollois - P e r r e t , F r a n c e ) • 
A l l g l a s s w a r e was soaked o v e r n i g h t in 3% s o l u t i o n of 
Extran (Merck, D a r m s t a d t , F.R.G.) in w a t e r , t h e n r i n s e d 
t h o r o u g h l y w i t h m e t h a n o l and h o t tap w a t e r f o l l o w e d by 
distilled w a t e r . The tubes w e r e s u b s e q u e n t l y s i l a n i s e d by 
r i n s i n g w i t h a 3 per cent solution of h e x a m e t h y l d i s i l a z a n e 
(HDMS) in distilled chloroform (Chan, 1988) . T h i s w a s to 
ininimise loss of drugs due to adsorption on to t h e g l a s s 
w a l l s . A H a m i l t o n syringe (25 fil) w a s u s e d . 
5.2.2 M A T E R I A L S 
The following m a t e r i a l s w e r e used : d i e t h y l e t h e r , n-
h e x a n e , ethanol and e t h y l a c e t a t e , all of a n a l y t i c - r e a g e n t 
(AR) grade (Merck, D a r m s t a d t , F . R . G . ) , w e r e freshly 
d i s t i l l e d before u s e . Water was d o u b l e d i s t i l l e d in a 
glass a p p a r a t u s . Salicylaldehyde (Molecular w e i g h t , 122.2; 
The M e r c k I n d e x , 1976), t r i e t h y l a m i n e , h y d r a z i n e h y d r a t e 
24% in w a t e r (Merck, D a r m s t a d t , F.R.G.) w e r e of A R g r a d e . 
Isoniazid (B.P.) and p h e n e l z i n e sulphate (B.P.) (Molecular 
w e i g h t , 13 6.2; The merck I n d e x , 1976) w e r e p u r c h a s e d from 
U n i v e r s a l P h a r m a c e u t i c a l s L a b o r a t o r i e s , H o n g K o n g . o t h e r 
reagents used include h e p t a n e s u l p h o n i c acid (Sigma St. 
L o u i s , M . O . , U . S . A . ) , acetic acid and a c e t o n i t r i l e (AR) 
grade (Merck, D a r m s t a d t , F . R . G . ) . 
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、 5.2.3 SYNTHESIS OF REFERENCE COMPOUNDS 
S a l i c y l h y d r a z o n e s of isoniazid (INH—HDZ) and p h e n e l z i n e 
(PHEN-HDZ) and salicylazine of h y d r a z i n e w e r e s y n t h e s i s e d 
by a m o d i f i c a t i o n of a procedure used by J e n n e r and E l l a r d 
(1987) • 100 m g of INH or p h e n e l z i n e s u l p h a t e or 50 m g of 
h y d r a z i n e h y d r a t e w a s shaken with 120 mg of s a l i c y l a l d e h y d e 
in 2 m l of e t h a n o l in a tightly screw c a p p e d 10 m l 
centrifuge t u b e . The m i x t u r e was incubated in a w a t e r bath 
at 60 °C for 30 m i n u t e s . P r o d u c t s w e r e p u r i f i e d by 
c r y s t a l l i s a t i o n in ethylacetate and the d e r i v a t i v e s w e r e 
distinguished from parent c o m p o u n d s by u l t r a v i o l e t 
absorption spectra and thin layer c h r o m a t o g r a p h y (TLC) 
system T1 (Curry, 1975). B r i e f l y , the c o m p o u n d s , in 
m e t h a n o l i c solutions of 1 m g / m l , w e r e s p o t t e d on a silica 
p l a t e (coated w i t h silica G 60, 0.2 mm t h i c k . ； S i g m a , 
L o u i s , U.S.A.) 1.5 cm from the bottom l i n e . The p l a t e w a s 
placed in a tank containing a solvent m i x t u r e c o n s i s t i n g of 
strong ammonia solution : m e t h a n o l (1.5 : 100) to a depth . 
of 0.5 to 1 c m , and the tank was closed air t i g h t w i t h a 
lid. A f t e r 30 m i n . of solvent run the p l a t e w a s d r i e d in 
air and the compounds w e r e located by p o t a s s i u m 
iodoplatinate spray (Sigma, L o u i s , USA)• 
M a s s r e a c t i o n ratio for d e r i v a t i s a t i o n is 1:1 (Cram and 
H a m m o n d , 1964)• T h e general equation being: 
H y d r a z i d e + Excess Salicylaldehyde ——Acid c a t a l y s i s — 
-> H y d r a z o n e + W a t e r . 
T h e r e f o r e , m o l e c u l a r weights for I N H - H D Z , P H E N - H D Z and 
A z i n e w e r e taken as 241.4, 240.4 and 2 4 0 . 5 , r e s p e c t i v e l y . 
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、 5.2.4 STANDARD SOLUTIONS 
Stock solutions were p r e p a r e d for i s o n i a z i d and 
p h e n e l z i n e sulphate at 1 m g / m l and h y d r a z i n e h y d r a t e at 6 
/xg/inl in d o u b l e distilled w a t e r . They w e r e s t o r e d at -20°C 
and w e r e stable for two m o n t h s . Daily w o r k i n g s t a n d a r d 
solutions w e r e prepared by d i l u t i o n of the stock s o l u t i o n s 
with double d i s t i l l e d w a t e r . 
5.2.5 C H R O M A T O G R A P H I C CONDITIONS 
The m o b i l e p h a s e consisted of a c e t o n i t r i l e , w a t e r and 
t r i e t h y l a m i n e in a ratio of 70 : 30 : 0.4 (v/v) w i t h 5 m M 
h e p t a n e sulphonic a c i d . Using c o n c e n t r a t e d g l a c i a l a c e t i c 
acid pH w a s adjusted to 6.0. The m o b i l e p h a s e w a s then 
filtered b e f o r e u s e using a M i l l i p o r e v a c u u m f i l t e r system 
equipped with 0.22 fim filter (Waters A s s o c i a t e s , M i l f o r d , 
M . A . , U.S.A.) . Degassing w a s not n e c e s s a r y iimnediately 
after the f i l t r a t i o n . 
O p e r a t i n g conditions were: flow rate at 1 m l / m i n ; 
p r e s s u r e , 35 bars; UV detector w a v e l e n g t h at 320 nm; and 
ambient t e m p e r a t u r e (25 土 1°C) • The c o n c e n t r a t i o n s of 
isoniazid and h y d r a z i n e w e r e c a l c u l a t e d u s i n g 
internalstandard and peak h e i g h t ratios• 
5.2.6 SAMPLE PREPARATION 
Plasma and c e r e b r o s p i n a l fluid w e r e o b t a i n e d from the 
r a b b i t as d e s c r i b e d by Chan et al (1986b) (See c h a p t e r 6). 
Plasma (0.5 ml) or CSF (0.2 ml) was p i p p e t t e d into 10 ml 
t e s t t u b e and 50 /xl of p h e n e l z i n e sulphate (50 fiq/ml) was 
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、 added as internal standard. A f t e r adding 0.1 m l of a q u e o u s 
acetic acid (v/v) to adjust pH to 4, i m p u r i t i e s w e r e 
extracted by shaking w i t h 5 m l of n - h e x a n e for 30 m i n u t e s , 
and then centrifuged for 10 m i n at 3,000 r . p . m . The o r g a n i c 
layer w a s d i s c a r d e d . The sample w a s d e r i v a t i s e d by a d d i n g 
0.3 m l of ethanolic solution of 0.1% (v/v) s a l i c y l a l d e h y d e , 
0.4 m l of 10% aqueous acetic acid and incubated in a w a t e r 
bath for 30 min at 60°C. After cooling to room t e m p e r a t u r e 
(25 士 1°C) the sample w a s shaken for 10s w i t h 1 m l of IM 
K2HPO4 buffer (pH 6.5) for optimum e x t r a c t i o n and r e m o v a l of 
the excess s a l i c y l a l d e h y d e . The s a l i c y l h y d r a z o n e s and azine 
w e r e extracted by shaking with 5 m l of d i e t h y l e t h e r for 10 
min and centrifuging for 10 m i n , at 3,000 r . p . m . T h e ether 
extract was t r a n s f e r r e d into a t a p e r e d test t u b e and 
evaporated dry under a stream of n i t r o g e n at 40°C. Th e 
r e s i d u e was dissolved in 50 /xl of m o b i l e p h a s e and 
d u p l i c a t e 25 (il w e r e injected into H P L C for a n a l y s i s . 
E x t r a c t i o n and d e r i v a t i s a t i o n p r o c e d u r e t a k e s a p p r o x i m a t e l y 
two h o u r s for a batch of 10 samples and the d e r i v a t i v e s 
w e r e stable at 4 f o r over 48 h o u r s . 
5.2.7 QUANTITATION AND RECOVERY 
B l a n k plasma and CSF w e r e spiked w i t h d r u g s to g i v e 
concentration ranges of 0.5, 1, 2, 4, 6 and 10 ^ q / m l for 
isoniazid and 76.8, 153.6, 307.2, 6 1 4 . 4 , a n d , 768.0 n g / m l 
for h y d r a z i n e . The samples w e r e then t r e a t e d , e x t r a c t e d and 
run in HPLC as described a b o v e . C a l i b r a t i o n g r a p h s w e r e 
constructed by plotting m e a n peak h e i g h t r a t i o s of 
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i s o n i a z i d and h y d r a z i n e to that of i n t e r n a l s t a n d a r d 
a g a i n s t the r e s p e c t i v e c o n c e n t r a t i o n s . 
To a s s e s s r e c o v e r y peak h e i g h t s of d i r e c t l y i n j e c t e d 
INH-HDZ or azine w e r e compared w i t h t h o s e o b t a i n e d after 
a p p l y i n g the e x t r a c t i o n p r o c e d u r e to I N H — H D Z or a z i n e , and 
w i t h isoniazid or h y d r a z i n e w h e n taken t h r o u g h t h e w h o l e 
p r o c e d u r e of d e r i v a t i s a t i o n and e x t r a c t i o n at 
c o n c e n t r a t i o n s : 0.5 /ig/ml and 5 fiq/ml for i s o n i a z i d and 
153.6 n g / m l for h y d r a z i n e (n = 5) . T h e a m o u n t of a c e t i c 
a c i d , s a l i c y l a l d e h y d e as w e l l as c o n d i t i o n s for i n c u b a t i o n 
and e x t r a c t i o n w e r e e x p e r i m e n t a l l y d e t e r m i n e d and found to 
be optiiTum for the a n a l y s i s . 
5.3 R E S U L T S AND D I S C U S S I O N 
5.3.1 C H A R A C T E R I S A T I O N OF THE R E F E R E N C E C O M P O U N D S 
F i g . 6 shows the UV a b s o r p t i o n s p e c t r a for the 
d e r i v a t i v e s of i s o n i a z i d , p h e n e l z i n e , and h y d r a z i n e 
c o m p a r e d w i t h those of the p a r e n t c o m p o u n d s and F i g . 7 
i l l u s t r a t e s their s e p a r a t i o n on T L C . For UV a b s o r p t i o n 
spectra the c o n c e n t r a t i o n s of p a r e n t c o m p o u n d s w e r e over 5 
t i m e s for d e r i v a t i v e s (i.e. 0.00024 m o l / 1 for i s o n i a z i d and 
p h e n e l z i n e v e r s e s 0.000027 m o l / l for I N H - H D Z and P H E - H D Z ; 
0.0023 m o l / 1 for h y d r a z i n e v e r s e s 0 . 0 0 0 1 8 5 mol/1 for 
A z i n e ) . D e r i v a t i v e s absorbed u l t r a v i o l e t m u c h g r e a t e r than 
the p a r e n t c o m p o u n d s m a k i n g the c h o i c e of d e t e c t o r 
a p p r o p r i a t e w h i l e on TLC they e x h i b i t e d b i g g e r r e t e n t i o n 
f a c t o r s b e c a u s e they are less p o l a r . By d i s s o l v i n g 


























































































































































































































































Figure 7 Thin layer chromatogram for the reference and parent 
compounds with retention factors inprinted. 
1) INH (isoniazid) 2) INH-HDZ (INH-hydrazone) 
3) PHEN (phenelzine) 4) PHEN-HDZ (PHEN-hydrazone) 
5) HYD (hydrazine) 6)Azine 7) Salicylaldehyde. 
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c h r o m a t o g r a p h i c separation systena was d e v e l o p e d . 
5.3.2 C O N D I T I O N S OF D E R I V A T I S A T I O N 
D e r i v a t i s a t i o n w a s n e c e s s a r y to a t t a i n a clean 
c h r o m a t o g r a m w i t h o u t interfering p e a k s , optixnum s e n s i t i v i t y 
and s e l e c t i v i t y u s i n g optimal a m o u n t s of r e a g e n t s . The 
a m o u n t of 10% a c e t i c a c i d , 0.1% s a l i c y l a l d e h y d e , the 
e x t r a c t i o n pH at both steps of o r g a n i c e x t r a c t i o n , 
t e m p e r a t u r e s and time for incubation w e r e d e t e r m i n e d 
e x p e r i m e n t a l l y . 
A c e t i c acid w a s used during the a c i d i c w a s h i n g of s a m p l e 
b e c a u s e a mineiral acid would form u n r e a c t i v e l i g a n d s of the 
p a r e n t c o m p o u n d s and would r e q u i r e n e u t r a l i s a t i o n . W e need 
n o t n e u t r a l i s e the weak acid b e c a u s e it is t h e m a j o r 
c a t a l y s t of the d e r i v a t i s a t i o n r e a c t i o n . A good d e t e c t o r 
r e s p o n s e w a s o b t a i n e d using 0.5 ml of 10% a c e t i c a c i d (Fig. 
8 a ) . 
S a l i c y l a l d e h y d e w a s best for the c o n d i t i o n s d e s c r i b e d . 
C i n n a m a l d e h y d e w a s n o t used b e c a u s e it h a s a l i m i t e d shelf 
life (Gupta and L e w i s , 1988). P - h y d r o x y b e n z a l d e h y d e and P-
m e t h o x y b e n z a l d h y d e could not be w a s h e d w i t h the p o t a s s i u m 
s a l t , and r e a c t i o n w i t h h y d r a z i n e and i n t e r n a l s t a n d a r d w a s 
poor. T h e r e w a s no a d v a n t a g e in u s i n g h i g h e r 
c o n c e n t r a t i o n s of s a l i c y l a l d e h y d e and no g u a r a n t e e t h a t 
K2HPO4 w o u l d w a s h out all the e x c e s s s a l i c y l a l d e h y d e even 
w h e n t r e a t e d t w i c e . An optimal q u a n t i t y of 0.3 m l of 0.1% 
s a l i c y l a l d e h y d e w a s found a d e q u a t e for the p r o c e d u r e (Fig. 






































































































































































































































































































































I n c u b a t i o n of the reaction m i x t u r e for 3 0 minuter, .ir 
60°, 80° and 90 °C showed that the d e r i v a t i v e s riro 
t h e r m o l a b i l e (Fig. 8c) • The yield was poor at lov/er 
t e m p e r a t u r e s and v a r i a b l e when incubated for a s h o r t e r 
t i m e . T h u s , o p t i m a l reaction c o n d i t i o n w a s 60 °C for 3 0 
m i n . P h e n e l z i n e e x h i b i t e d many i n t e r m e d i a t e p r o d u c t s v;hen 
i n c u b a t e d for a s h o r t e r t i m e . 
E x t r a c t i o n of the d e r i v a t i v e s was o p t i m u m at pH 6.5 -
7.5 (Fig. 8d). T h e r e f o r e , pH 6.5 was chosen for s u b s e q u e n t 
p r o c e d u r e s . 
H y d r a z i n e r e s p o n s e was similar to i s o n i a z i d in all the 
above o b s e r v a t i o n s . P h e n e l z i n e was u s e d as interna 1 
s t a n d a r d b e c a u s e of similar s t r u c t u r a l and s o l u b i l i t y 
p r o p e r t i e s to i s o n i a z i d . The s t r u c t u r e of p h e n e l z i n e is 
shown in figure Id on Page 6. Isoniazid and p h e n e l z i n e are 
h y d r a z i d e s and react with s a l i c y l a l d e h y d e by the h y d r a z i n e 
g r o u p . P h e n e l z i n e is unlikely to be an e n d o g e n o u s 
i n t e r f e r e n c e b e c a u s e both d r u g s are r e l a t i v e l y 
c o n t r a i n d i c a t e d for c o n c u r r e n t a d m i n i s t r a t i o n . I s o n i a z i d 
and p h e n e l z i n e are d i a m i n e oxidase (histaminase) i n h i b i t o r s 
(Uragoda, 1978). 
5.3.3 P E R F O R M A N C E OF THE HPLC SYSTEM 
T h e r e p r e s e n t a t i v e c h r o m a t o g r a m s of the h y d r a z o n e s and 
a z i n e in s t a n d a r d s o l u t i o n and sample e x t r a c t s are shown in 
Fig. 9 for plasma and Fig. 10 for C S F . No e n d o g e n o u s 
i n t e r f e r e n c e was o b s e r v e d in the blank plasma or C S F . T h e 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































for isoniazid h y d r a z o n e , 180s for p h e n e l z i n e hydr'、zom', arvi 
240s for the a z i n e . The excess s a l i c y l a l d e h y d e reso I Vfjd ,it 
1 2 6 s . T h e r e is no h y d r a z i n e peak in figure 10c b e c a u s e 
h y d r a z i n e was not d e t e c t e d in CSF (discussed in c h a p t e r 6). 
Peak h e i g h t ratio was found s a t i s f a c t o r y for q u a n t i t a t i o n . 
Run time for assay was 9 m i n u t e s for plasma and 7 m i n u t e s 
for C S F . 
5.3.4 L I N E A R I T Y , S E N S I T I V I T Y , P R E C I S I O N , R E C O V E R Y AND 
S E L E C T I V I T Y 
Daily s t a n d a r d i s a t i o n curves for i s o n i a z i d and h y d r a z i n e 
in p l a s m a and CSF' resulted in a linear c o n c e n t r a t i o n -
r e s p o n s e r e l a t i o n s h i p . C o n c e n t r a t i o n r a n g e 0. 5 to 10 /xg/ml 
for i s o n i a z i d , and 76.8 to 768.0 n g / m l for h y d r a z i n e w e r e 
u s e d for s t a n d a r d i s a t i o n and r e g r e s s i o n a n a l y s i s . T h e mean 
c o r r e l a t i o n c o e f f i c i e n t for the six s t a n d a r d i s a t i o n c u r v e s 
w e r e 0.993 for isoniazid and 0.9997 for h y d r a z i n e (Table 6 
and A p p e n d i c e s 5.1a and b) . The p r e c i s i o n d a t a w e r e 
o b t a i n e d by the r e p e a t e d analysis of s p i k e d p l a s m a and CSF 
s a m p l e s . The s t a n d a r d curves for p l a s m a and CSF w e r e 
i d e n t i c a l . I n t r a b a t c h variation was 6.7% for i s o n i a z i d at 
5 /xg/ml and 7.2% for h y d r a z i n e at 153.6 n g / m l . T h e limit of 
d e t e c t i o n was 0.2 pLg/ml for i s o n i a z i d and 10 n g / m l for 
h y d r a z i n e ; n = 12) . The e f f i c i e n c y of d e r i v a t i s a t i o n w a s 
88% at 0.5 jjLg/ml and 83.6% at 5 fig/ml for i s o n i a z i d and 
"73.7% at 153.6 n g / m l for h y d r a z i n e . E x t r a c t i o n of the 
h y d r a z o n e s was 59.5% at 0. 5 /jg/ml and 60.2% at 5 ^ g / m l for 



















































































































































































































































































































































































































































































































































































































overall recovery of 52.4% at 0.5 /ig/ml and 50.3% at 5 fig/ml 
for i s o n iazid, and 4 9.7% at 153.6 ng/ml for h y d r a z i n e . 
A n t i - t u b e r c u l o u s drugs such as r i f a m p i c i n , p y r a z i n a m i d e and 
PAS were t e s t e d , and did not interfere with the a s s a y . 
M o s t of these are extracted in h e x a n e and they do not r e a c t 
with the s a l i c y l a l d e h y d e . 
5.3.5 COMMENT 
The p r o c e d u r e is e c o n o m i c a l and c o n v e n i e n t w i t h r e s p e c t 
to m a t e r i a l s and sample volume u s e d . In the m o b i l e p h a s e , 
h e p t a n e s u l p h o n i c acid improved peak s h a p e s w h i l e 
t r i e t h y l a m i n e , in a d d i t i o n , reduced v i s c o s i t y such t h a t 
operating p r e s s u r e was low (35 b a r s ) . The m o b i l e p h a s e w a s 
recycled three times w i t h o u t causing i n t e r f e r e n c e . The 
c o e f f i c i e n t of v a r i a t i o n is a d e q u a t e . T h i s is b e c a u s e of 
increase in r e f r a c t o r y h y d r a z i d e and or h y d r a z i n e with 
increasing c o n c e n t r a t i o n (Ellard et a l , 1 9 7 2 ) . The 
recovery rate for isoniazid is c o m p a r a b l e to t h a t o b t a i n e d 
by Jenner and Ellard (1987) using urine s a m p l e s a n d , like 
wise the p r o c e d u r e can only d e t e c t acid labile i s o n i a z i d 
and m e t a b o l i t e . M o n o a c e t y I h y d r a z i n e was not d e t e r m i n e d 
under the c o n d i t i o n s d e s c r i b e d . 
The m a j o r a d v a n t a g e of the assay is the s i m u l t a n e o u s 
estimation of isoniazid and h y d r a z i n e in p l a s m a . It a l l o w s 
d i r e c t d e t e r m i n a t i o n of total h y d r a z i n e formed d u r i n g 
isoniazid m e t a b o l i s m . The p r o c e d u r e has been used to study 
the d i s p o s i t i o n and kinetics of isoniazid and h y d r a z i n e in 
rabbits (chapter 6) , and in elderly t u b e r c u l o u s p a t i e n t s 
8 7 
(chapter 7) . The results and c o n c l u s i o n s on isoniazid 
d i s p o s i t i o n w e r e similar to those obtained by o t h e r m e t h o d s 
for r a b b i t s (Welles et al, 1953) and human (Kergueris et 
a l , 1986). In c o n c l u s i o n , this assay is a u s e f u l r e s e a r c h 
and c l i n i c a l t o o l in the study of h y d r a z i n e as a m e t a b o l i t e 
of i s o n i a z i d . 
88 
、 5.4 SECTION 2 A S I M U L T A N E O U S ASSAY FOR R I F A M P I C I N A N D 
P Y R A Z I N A M I D E IN HUMAN PLASMA 
T h e p r o c e d u r e w a s adopted from t h a t d e s c r i b e d by W o o et 
al (1987b) and Chan (1988) • It involves e x t r a c t i o n of the 
d r u g s and internal s t a n d a r d , b u t y l a r y l a m i n o p h e n o l (1 fig), 
from 0.5 m l of an acidified sample c o n t a i n i n g 2% a s c o r b i c 
acid at pH 4.2 into d i c h l o r o m e t h a n e — d i e t h y l e t h e r (2:3). 
T h e s o l v e n t was e v a p o r a t e d to d r y n e s s w i t h aid of n i t r o g e n 
and the r e s i d u e r e d i s s o l v e d in m e t h a n o l (75 /il) . T h e 
c o n c e n t r a t e w a s a n a l y z e d by a liquid c h r o m a t o g r a p h u s i n g a 
r e v e r s e d p h a s e 30-/m Cg p r e c o l u m n linked to a 10 /xm C^g 
/iBondapak a n a l y t i c a l column w i t h a g r a d i e n t s o l v e n t 
p r o g r a m m e , w h i c h d e l i v e r e d 6% to 48% (v/v) a c e t o n i t r i l e in 
p h o s p h a t e buffer (10 mM p o t a s s i u m d i h y d r o g e n p h o s p h a t e , pH 
3.5) in 10 min. at 1 m l / m i n . The e l u a t e w a s d e t e c t e d by 
u l t r a - v i o l e t d e t e c t o r set at 215 n m . A l l a p p a r a t u s w e r e 
from W a t e r s A s s o c i a t e s , M i l f o r d , M A , U . S . A . 
Six c a l i b r a t i o n g r a p h s w e r e p l o t t e d for c o n c e n t r a t i o n s 
of 0.5, 1, 2, 4, 6, and 10 /ig/ml for r i f a m p i c i n ; and 2.5, 
5, 10, 20, 30, and 50 fiq/ml for p y r a z i n a m i d e in 0.5 m l of 
h u m a n p l a s m a . A v e r a g e e q u a t i o n s and c o e f f i c i e n t of 
c o r r e l a t i o n after r e g r e s s i o n a n a l y s i s are shown in T a b l e 7 
(Appendices 5.2a and b) . Figure on 19 P a g e 129 s h o w s 
t y p i c a l c h r o m a t o g r a m s of sample e x t r a c t from a p a t i e n t 5 
h o u r s after oral ingestion of the d r u g s . Peak h e i g h t s w e r e 
found s a t i s f a c t o r y for q u a t i t a t i o n . T h e p r o c e d u r e w a s used 
to assay for r i f a m p i c i n and p y r a z i n a m i d e in p l a s m a of 














































































































































































































































































































































C H A P T E R 6 THE P H A R M A C O K I N E T I C S OF I S O N I A Z I D AND H Y D R A Z I N E 
M E T A B O L I T E IN THE PLASMA A N D C E R E B R O S P I N A L FLUID 
OF R A B B I T S . 
6.1 I N T R O D U C T I O N 
I s o n i a z i d is one of the m o s t i m p o r t a n t and w i d e l y used 
a n t i - t u b e r c u l o u s d r u g s . Its t h e r a p e u t i c e f f e c t i v e n e s s and 
t o x i c i t y depend on the intensity and e x t e n t of e x p o s u r e to 
t h e b o d y (Weber and H e i n , 1979) • H i g h e r a m o u n t s (>10 
m g / k g ) h a v e been used to t r e a t t u b e r c u l o u s m e n i n g i t i s . The 
t r e a t m e n t of t u b e r c u l o u s m e n i n g i t i s h a s been i n a d e q u a t e l y 
i n v e s t i g a t e d such that the c h o i c e of d r u g s and d u r a t i o n of 
t h e r a p y are largely e m p i r i c a l (Lam et a l , 1 9 8 9 ) . R a t i o n a l 
u s e of a n t i - t u b e r c u l o u s d r u g s in t u b e r c u l o u s m e n i n g i t i s is 
r e s t r i c t e d by limited data on p e n e t r a t i o n of t h e s e d r u g s 
into t h e central nervous system (Richard et a l , 1 9 8 1 ) . 
P h a r m a c o k i n e t i c studies for d r u g s in the c e n t r a l n e r v o u s 
s y s t e m are d i f f i c u l t to c o n d u c t in h u m a n s . H u m a n s t u d i e s 
i n v e s t i g a t e d by Barclay et al (1953), B o x e n b a i m et al 
(1975), and Elmendorf et al (1952) w e n t no f u r t h e r than 
c e r t i f y i n g that s i g n i f i c a n t a m o u n t s of i s o n i a z i d w e r e 
d e t e c t a b l e in c e r e b r o s p i n a l fluid in p a t i e n t s w i t h 
t u b e r c u l o u s m e n i n g i t i s and h e a l t h v o l u n t e e r s . W e l l e s et al 
(1953) r e p o r t e d on the d i s t r i b u t i o n and e x c r e t i o n of 
i s o n i a z i d in five p r e g n a n t r a b b i t s at 2 h o u r s . In t h a t 
study d o s e s h i g h e r than t h o s e in c l i n i c a l p r a c t i c e w e r e 
g i v e n and the a n i m a l s w e r e s a c r i f i c e d at two h o u r s to 
o b t a i n s a m p l e s . K i n e t i c s t u d i e s are n e e d e d to e s t a b l i s h 
how long and to w h a t extent the drug s t a y s in the c e n t r a l 
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n e r v o u s s y s t e m . R e s u l t s of these s t u d i e s m a y throw some 
light on the r a t i o n a l use of these d r u g s in t u b e r c u l o u s 
m e n i n g i t i s . 
H y d r a z i n e is a p o t e n t toxin the assay of w h i c h had been 
n e g l e c t e d on g r o u n d s that it w a s formed in n e g l i g i b l e 
a m o u n t s . In w a k e of the d i s p u t e on t h e r o l e of 
m o n o a c e t y I h y d r a z ine in isoniazid r e l a t e d side e f f e c t s , 
h y d r a z i n e m e t a b o l i t e has been i m p l i c a t e d as a p o s s i b l e 
c u l p r i t (Sarma et al, 1986) . U r i n a r y r e c o v e r y of h y d r a z i n e 
m e t a b o l i t e s cannot a c c o u n t for the t o t a l a m o u n t p r e s u m a b l y 
formed d u r i n g isoniazid m e t a b o l i s m (Weber and H e i n , 1 9 7 9 ) . 
F u r t h e r , it w a s r e p o r t e d t h a t r i f a m p i c i n i n c r e a s e d 
h y d r a z i n e formaition from isoniazid a f t e r two w e e k s of 
a d m i n i s t r a t i o n (Sarma et a l , 1 9 8 6 ) . T h e r e f o r e , a s t u d y on 
the k i n e t i c s of h y d r a z i n e as m e t a b o l i t e is e s s e n t i a l to 
e x p l o r e its role in isoniazid r e l a t e d t o x i c i t y . P r e s e n t e d 
h e r e are findings on plasma and c e r e b r o s p i n a l fluid 
p r o f i l e s of isoniazid and h y d r a z i n e a f t e r s e p a r a t e 
i n t r a v e n o u s (I.V.) and oral (P.O.) a d m i n i s t r a t i o n of 
i s o n i a z i d to 10 r a b b i t s using a c r o s s - o v e r d e s i g n d e s c r i b e d 
by Chan et al (1986b) (Section 6 . 2 . 1 ) . 
6.2 M E T H O D S 
6.2.1 T H E R A B B I T M O D E L 
The r a b b i t m o d e l and the p r o c e d u r e for o b t a i n i n g 
c e r e b r o s p i n a l fluid (CSF) and blood s a m p l e s w a s a d o p t e d 
from t h a t d e s c r i b e d by Chan et al (1986b) . New Z e a l a n d 
w h i t e r a b b i t s of either sex (2 m a l e , 8 female) w e i g h i n g 4.6 
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- 5 . 1 kg w e r e fasted o v e r n i g h t b e f o r e t h e s t u d y . T h e i r 
d o r s a l c e r v i c a l area and o c c i p i t a l area of t h e s k u l l w e r e 
s h a v e d . T h e c e n t r a l ear a r t e r y and l a t e r a l e a r v e i n w e r e 
c a n n u l a t e d for b l o o d s a m p l i n g and d r u g a d m i n i s t r a t i o n 
r e s p e c t i v e l y . C e r e b r o s p i n a l fluid (CSF) s a m p l e s (0.2 ml) 
w e r e o b t a i n e d from the c i s t e r n a m a g n a u n d e r l i g h t 
a n a e s t h e s i a w i t h i n t r a v e n o u s (I.V.) t h i o p e n t o n e (40 m g / k g ) 
at 0, 0 . 5 , 1, 4, 6 and 24 h r . Blood s a m p l e s (1.0 ml) w e r e 
o b t a i n e d at 0, 2 . 5 , 5, 10, 15 and 30 m i n , and 1, 2, 4 , 5, 
6, 8, 10 and 24 hr a f t e r 工 d o s e , and at 0, 0 . 2 5 , 0 . 5 , 1, 
2, 4, 5, 6, 8, 10 and 2 4 hr a f t e r o r a l (P.O.) d o s e . U s i n g 
t h e c r o s s - o v e r d e s i g n i s o n i a z i d 5 m g / k g w a s a d m i n i s t e r e d at 
r a n d o m P . O . (via a p o l y t h e n e tube) and I . V . on t w o 
o c c a s i o n s s e p a r a t e d by seven d a y s . 
6.2.2 K I N E T I C A N D S T A T I S T I C A L C A L C U L A T I O N S 
P h a r m a c o k i n e t i c p a r a m e t e r s w e r e o b t a i n e d from p l a s m a • 
c o n c e n t r a t i o n - t i m e p o i n t s a c c o r d i n g to s t a n d a r d f o r m u l a e 
(Gibaldi and P e r r i e r , 1982) • A r e a s u n d e r p l a s m a 
c o n c e n t r a t i o n s p l o t t e d a g a i n s t t i m e c u r v e s (AUC) w e r e 
c a l c u l a t e d u s i n g t h e t r a p e z o i d a l r u l e . T h e a b s o l u t e 
b i o a v a i l a b i l i t y , F, of i s o n i a z i d w a s d e t e r m i n e d a c c o r d i n g 
to e q u a t i o n 3 1 . 
A U C P . O . 
F = E q . (31). 
A U C 丨 乂 
A p p a r e n t f i r s t o r d e r r a t e c o n s t a n t s for d e c l i n e of 
p l a s m a c o n c e n t r a t i o n s a f t e r a d m i n i s t r a t i o n w e r e o b t a i n e d by 
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linear least square regression on log plasma c o n c e n t r a t i o n 
a g a i n s t t i m e . On the assumption that the drug was 
c o m p l e t e l y absorbed with i n s i g n i f i c a n t first p a s s e f f e c t , 
a p p a r e n t v o l u m e of d i s t r i b u t i o n V^g^^^j of i s o n i a z i d w a s 
c a l c u l a t e d according to equation 32; 
DOSE 
V(area) = Eq • (32). 
AUC 
W h e r e 3 is the p r o d u c t of terminal slope and 2.303 of the 
log p l a s m a c o n c e n t r a t i o n curve v e r s e s t i m e . S i g n i f i c a n c e 
d i f f e r e n c e s of p h a r m a c o k i n e t i c p a r a m e t e r s of i s o n i a z i d and 
h y d r a z i n e after P . O . and I. V . a d m i n i s t r a t i o n s w e r e 
e v a l u a t e d using the Student‘s t一test, w i t h P < 0 . 0 5 
c o n s i d e r e d to be the limit of s i g n i f i c a n c e . 
6.3 R E S U L T S 
During the study two r a b b i t s died b e f o r e c r o s s - o v e r to 
oral study such that the r e s u l t s p r e s e n t e d h e r e are for 
eight r a b b i t s after oral and ten r a b b i t s a f t e r i n t r a v e n o u s 
route of a d m i n i s t r a t i o n of i s o n i a z i d . Death w a s due to 
brain injury during c i s t e r n a l p u n c t u r e . I s o n i a z i d w a s 
c o m p l e t e l y absorbed after P . O . a d m i n i s t r a t i o n . Peak p l a s m a 
c o n c e n t r a t i o n (Cmax) of 4.28 (± 1.49) fig/ml w e r e r e a c h e d at 
(Tmax) 1.03 (± 0. 6 6 ) h . T h e r e a f t e r the drug d e c l i n e d from 
pl a s m a m o n o e x p o n e n t i a l l y . A f t e r I. V . a d m i n i s t r a t i o n p l a s m a 
isoniazid c o n c e n t r a t i o n s declined r a p i d l y w i t h i n 10 - 15 
min and s u b s e q u e n t l y s l o w l y , following a b i e x p o n e n t i a 1 




































































































































































































































































































c o n c e n t r a t i o n s after oral and i n t r a v e n o u s r o u t e s w e r e 
s i m i l a r . 
T a b l e s 8 and 9 summarise i n d i v i d u a l p l a s m a 
c o n c e n t r a t i o n - t i m e p o i n t s of isoniazid in the 10 r a b b i t s 
for both routes of a d m i n i s t r a t i o n . T a b l e 10 c o m p a r e s 
k i n e t i c p a r a m e t e r s of the drug in plasma (Appendices 6.1a 
and b ) . The AUG curves were similar i n d i c a t i n g t h a t o r a l 
a b s o r p t i o n was c o m p l e t e . A p p a r e n t v o l u m e s of d i s t r i b u t i o n 
w e r e d i f f e r e n t p r o b a b l y due to c o n t i n u o u s input of the drug 
after P . O . r o u t e . Plasma elimination h a l f - l i f e , e l i m i n a t i o n 
rate c o n s t a n t , c l e a r a n c e and mean r e s i d e n c e t i m e w e r e 
s i m i l a r . 
H i g h e r C . S . F . c o n c e n t r a t i o n s of isoniazid w e r e a c h i e v e d 
initially after I. V . a d m i n i s t r a t i o n . T h e y d e c l i n e d m o r e 
rapidly than after oral dose such that by 4 hrs the 
c o n c e n t r a t i o n s w e r e similar after either r o u t e (Fig. 1 2 ) . 
CSF c o n c e n t r a t i o n s w e r e over 50% of c o r r e s p o n d i n g p l a s m a 
c o n c e n t r a t i o n s after one hour (Table 11 and a p p e n d i c e s 6.2a 
to d)• E l i m i n a t i o n h a l f - l i f e for isoniazid in CSF seem to 
be longer than in plasma (Table 12). 
H y d r a z i n e m e t a b o l i t e was rapidly d i s t r i b u t e d and w a s 
s u b s e q u e n t l y .eliminated slowly from plasma (Fig. 13 and 
a p p e n d i c e s 6.3a and b) • Plasma c o n c e n t r a t i o n s a f t e r e i t h e r 
route w e r e above 0.1 ^g/ml. H y d r a z i n e is c l e a r e d from the 
c i r c u l a t i o n m o r e slowly than isoniazid (Table 13) . only 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.4 D I S C U S S I O N 
The p r e s e n t study has d e m o n s t r a t e d that the I.V. rout^-
has no a d v a n t a g e over P.O. route for isonicizici 
a d m i n i s t r a t i o n in r a b b i t s . Isoniazid is not s i g n i f i c a n t l y 
p r o t e i n bound (f ^ ~ 1; equation 14) • It has a low h e p a t i c 
e x t r a c t i o n ratio (ER ~ 0) and c l e a r a n c e is d e t e r m i n e d 
m a i n l y by h e p a t i c enzyme activity (CL-^^.). 
I s o n i a z i d crossed the blood brain b a r r i e r (BBB) into CSF 
in s i g n i f i c a n t a m o u n t s . The rate of e l i m i n a t i o n of 
i s o n i a z i d from CSF seem to be slower than that of p l a s m a as 
shown by the longer e l i m i n a t i o n h a l f - l i f e or s m a l l e r 
e l i m i n a t i o n rate c o n s t a n t s (Tables 10 and 12), s u g g e s t i n g 
a s p e c i a l b e h a v i o u r of the BBB to m o v e m e n t of i s o n i a z i d 
m o l e c u l e s across it into the g e n e r a l c i r c u l a t i o n . T h i s 
o b s e r v a t i o n c a n n o t be c o n c l u s i v e b e c a u s e e r r o r s c o u l d have 
a r i s e n the short sampling period and the c o n t i n u a l input of 
i s o n i a z i d into the C S F . There seems to be a b a r r i e r a g a i n s t 
i s o n i a z i d t r a n s f e r from CSF to the g e n e r a l c i r c u l a t i o n 
(Table 11)• N e v e r t h e l e s s , a d e q u a t e CSF c o n c e n t r a t i o n s of 
the d r u g were s u s t a i n e d for a long p e r i o d (>6hrs) . T h e 
c o n c e n t r a t i o n s were over ten fold the m i n i m u m i n h i b i t o r y 
c o n c e n t r a t i o n (MIC) for the M y c o b a c t e r i a (25 - 50 n g / m l ; 
Fig. 12) . It is likely that the drug is not m e t a b o l i s e d in 
the C N S . We could p o s s i b l y use the MIC as a g u i d e l i n e to 
t r e a t t u b e r c u l o u s m e n i n g i t i s in o r d e r to avoid a d v e r s e 
e f f e c t s a s s o c i a t e d with high d o s e s . H o w e v e r , t h i s . a p p r o a c h 
only w o r k s if s e n s i t i v i t y of m y c o b a c t e r i a to isoniazid is 
k n o w n . 
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H y d r a z i n e m e t a b o l i t e , is formed during d i r e c t c o n v e r s i o n 
of isoniazid to isonicotinic a c i d . It is a p o t e n t toxin 
and a c a r c i n o g e n as classified by the A m e r i c a n C o n f e r e n c e 
of G o v e r n m e n t and I n d u s t r i a l H y g i e n e (Albert and P u l i a , 
1977) • H y d r a z i n e group has been i n c r i m i n a t e d for 
c a u s a t i o n of lupus—like syndrome in man w h e n h y d r a l l a z i n e 
and isoniazid w e r e a d m i n i s t e r e d . In a n i m a l s t u d i e s , 
h y d r a z i n e caused c o n v u l s i o n s , h e p a t i c t o x i c i t y , r e n a l 
d a m a g e , and blood injury, and affected m a n y m e t a b o l i c 
p r o c e s s e s (Back and T h o m a s , 1970). It is a s s o c i a t e d w i t h 
c a u s a t i o n of c h o r o i d a l carcinoma in m a n , and q u e s t i o n s 
arise as to w h e t h e r it may c o n t r i b u t e to h e p a t i c 
a n g i o s a r c o m a w h i c h is a tumour a s s o c i a t e d w i t h all 
h y d r a z i d e c o m p o u n d s (Daneshmend and B r a d f i e l d , 1979; T o t h , 
1975 and 1976) . H y d r a z i n e is a p o t e n t i n h i b i t o r of m a n y 
enzyme systems (Back and T h o m a s , 1970) and can be 
a c e t y l a t e d to m o n o a c e t y I h y d r a z i n e (Ellard and G a m m o n , 
1976) • This may be part of the e x p l a n a t i o n for 
o b s e r v a t i o n s by L a u t e r b u r g et al (1985) t h a t A U C of 
m o n o a c e t y I h y d r a z i n e was inversely p r o p o r t i o n a l to rate of 
d i s a p p e a r a n c e of i s o n i a z i d . F u r t h e r m o r e , it w a s s u g g e s t e d 
that isoniazid h y d r o x y l a s e (Sarma et a l , 1986) and the 
m o n o x y g e n a s e (Lauterburg et al, 1985) p a t h w a y s are 
i n d u c i b l e . L e t h a l dose (LD^^) of h y d r a z i n e in r a b b i t s is 25 
m g / k g (The Merck I n d e x , 1976). 
It was noted that plasma c o n c e n t r a t i o n of h y d r a z i n e w a s 
above 0.1 Mg/ml for over 6 h r s , and the rate of e l i m i n a t i o n 
is s l o w . This indicates that there is a p r o l o n g e d e x p o s u r e 
1 0 6 
of the body to this toxin • A p p a r e n t l y t h e r e is no 
literature on the effects of such an e x p o s u r e , or 
c o r r e l a t i o n of isoniazid e l i m i n a t i o n to t h a t of h y d r a z i n e . 
M o r e studies are required to e v a l u a t e and a s s e s s the fate 
of h y d r a z i n e in the body and to c o r r e l a t e t h i s w i t h some 
isoniazid related adverse e f f e c t s . 
In c o n c l u s i o n , for p r a c t i c a l p u r p o s e s t h e r e is no 
s i g n i f i c a n t barrier to the p e n e t r a t i o n of i s o n i a z i d into 
the CSF of normal r a b b i t s . The c o n c e n t r a t i o n and fate of 
h y d r a z i n e m e t a b o l i t e is w o r t h y a m o m e n t of our a t t e n t i o n . 
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C H A P T E R 7 THE DISPOSITION OF SOME A N T I T U B E R C U L O U S D R U G S Hi 
THE PLASMA OF ELDERLY P A T I E N T S . 
7.1 I N T R O D U C T I O N 
I s o n i a z i d , r i f a m p i c i n , and p y r a z i n a m i d e are p o t e n t i a l l y 
h e p a t o t o x i c and form one of the m o s t e f f e c t i v e anti-
t u b e r c u l o u s r e g i m e n s used in many c o u n t r i e s ( P e r e z - S t a b l e 
and H o p e w e l l , 1989; G r o s s e t , 1989). The r i s k of d e v e l o p i n g 
i s o n i a z i d induced h e p a t i t i s increases w i t h age from a l m o s t 
n o n e in p a t i e n t s below 20 years of age to a b o u t 3 per c e n t 
in p a t i e n t s over 55 y e a r s of age (Riska, 1976)• T h e liver 
d a m a g e is e x a c e r b a t e d by factors like c o - e x i s t i n g liver 
d i s e a s e or c o — a d m i n i s t r a t i o n with other h e p a t o t o x i c a g e n t s , 
and has little or no r e l a t i o n s h i p to a c e t y l a t o r s t a t u s , 
d o s e of isoniazid or h y p e r s e n s i t i v i t y r e a c t i o n s (Black et 
a l , 1975; K e r g u e r i s et a l , 1 9 8 6 ) . T h e i n c i d e n c e of 
h e p a t i t i s is h i g h e r when i s o n i a z i d , r i f a m p i c i n and 
p y r a z i n a m i d e are used t o g e t h e r . For i n s t a n c e , t h e r e w a s 
m o r e h e p a t i t i s in p a t i e n t s on d a i l y i s o n i a z i d and 
r i f a m p i c i n (4%)(Brouet, 1974), or i s o n i a z i d and 
p y r a z i n a m i d e (8%) (Hong K o n g , 1976) than t h o s e on i s o n i a z i d 
alone (0•8%) (Riska, 1976) . Severe a d v e r s e r e a c t i o n s to 
a n t i - t u b e r c u l o u s d r u g s h a v e been r e p o r t e d in e l d e r l y 
p a t i e n t s w h e n on t r e a t m e n t w i t h i s o n i a z i d , r i f a m p i c i n and 
p y r a z i n a m i d e r e g i m e n (Woo et al, 1987a) t h e r e b y c a u s i n g a 
need for further studies on the d i s p o s i t i o n of a n t i -
t u b e r c u l o u s d r u g s in elderly p e o p l e . T h e r e are a few 
r e p o r t s on the p h a r m a c o k i n e t i c s of a n t i - t u b e r c u l o u s d r u g s 
in e l d e r l y p e o p l e (Advenier et al, 1980; A d v e n i e r et a l , 
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1983 ; K e r g u e r i s et al, 1986; Paulsen and Ni Isson, I'j 叫 . 
U n f o r t u n a t e l y , only one drug isoniazid or r i f a m p i c i n 
g i v e n or a n a l y z e d at a time. C o m b i n a t i o n t h e r a p y v/j th 
a n t i - t u b e r c u l o u s d r u g s leads to a h i g h e r rate of a d v e r s e 
e f f e c t s and such effects are m o r e c o m m o n and s e v e r e in 
e l d e r l y p a t i e n t s . K n o w l e d g e on w h e t h e r t h e r e are any age 
r e l a t e d changes in the p h a r m a c o k i n e t i c s of t h e s e d r u g s , 
w h e n used in c o m b i n a t i o n , is i m p o r t a n t for their safe use 
in the c l i n i c . 
T h i s study was u n d e r t a k e n to d e t e r m i n e the 
p h a r m a c o k i n e t i c s of isoniazid, h y d r a z i n e m e t a b o l i t e , 
r i f a m p i c i n and p y r a z i n a m i d e in p l a s m a of e l d e r l y p a t i e n t s 
on t r e a t m e n t with isoniazid, r i f a m p i c i n and p y r a z i n a m i d e 
for p u l m o n a r y t u b e r c u l o s i s with a h o p e to set a s t a n d a r d 
r e f e r e n c e on which other p a t i e n t s c o u l d be e v a l u a t e d in the 
c l i n i c . A group of young p a t i e n t s was i n c l u d e d for 
c o m p a r i s o n . F i n a l l y , a short r e p o r t on a p a t i e n t who died 
of h e p a t i c n e c r o s i s due to a n t i - t u b e r c u l o u s d r u g s is 
J 
p r e s e n t e d . 
7.2 SECTION 1 M E T H O D S 
7 . 2 . 1 E X P E R I M E N T A L 
N i n e t e e n young p a t i e n t s (12M,7F; age 19 to 63 years) and 
18 e l d e r l y p a t i e n t s (14M,4F; age 67 to 89 years) w e r e 
s e l e c t e d for the study as soon as d i a g n o s i s for 
t u b e r c u l o s i s was c o n f i r m e d by a p o s i t i v e Ziehl. N i e l s e n 
s t a i n of sputum for acid fast b a c i l l i . Full informed 
c o n s e n t was o b t a i n e d and the study was a p p r o v e d by the 
1 0 9 
• 
U n i v e r s i t y E t h i c a l C o m m i t t e e (UEC) . P a t i e n t s w i t h chrori ic 
i l l n e s s e s or on t r e a t m e n t for o t h e r a i l m e n t s w e r e exc丄udf 一 
Ijiver, r e n a l and h a e m a t o l o g y f u n c t i o n t e s t s w e r e d e t e r m i n e d 
b e f o r e the s t u d y (Appendix 7 . 1 ) . T h e p a t i e n t s r e c e i v e d 
d a i l y d o s e s of i s o n i a z i d , r i f a m p i c i n , and p y r a z i n a m i d e for 
t r e a t m e n t of t u b e r c u l o s i s . On the f i r s t d a y of t r e a t m e n t 
b l o o d s a m p l e s (5 ml) w e r e t a k e n at t i m e s 0, 0 . 5 , 1, 2, 4, 
6, 8, 12, and 2 4 h o u r s t h r o u g h a n t e c u b i t a l v e n e p u n c t u r e ; 
o n e m o n t h after i n i t i a l t r e a t m e n t a b l o o d s a m p l e w a s 
o b t a i n e d in a s i m i l a r m a n n e r for s t e a d y s t a t e c o n c e n t r a t i o n 
a s s e s s m e n t . A light m e a l (fluids only) w a s a l l o w e d 0.5 to 
2 h o u r s a f t e r i n g e s t i o n of d r u g s . T h e s a m p l e s w e r e 
c o l l e c t e d in h e p a r i n i s e d p l a s t i c t u b e s , i m m e d i a t e l y 
c e n t r i f u g e d and p l a s m a was s t o r e d at 一 2 〇 ° C u n t i l a s s a y . 
O n l y s i x t e e n p a t i e n t s (9 e l d e r l y , 7 y o u n g ) w e r e a s s e s s e d at 
s t e a d y s t a t e . N e v e r t h e l e s s , all p a t i e n t s w e r e u n d e r 
c o n s t a n t c l i n i c a l o b s e r v a t i o n . 
T h e d r u g s w e r e p u r c h a s e d p u r e and in t a b l e t ( i s o n i a z i d 
/ 
and p y r a z i n a m i d e ) or c a p s u l e ( r i f a m p i c i n ) form: i s o n i a z i d 
(100 mg) w a s from S h a n g h a i P h a r m a c e u t i c a l I n d u s t r y 
C o r p o r a t i o n (Shanghai, China)； r i f a m p i c i n (3-（4)methy1-1-
p i p e r a z i n y l - i m i n o m e t h y l - r i f a m p i c i n s . v . , i 5 0 mg) w a s from 
C i b a - G e i g y L i m i t e d (Basle, S w i t z e r l a n d )； and p y r a z i n a m i d e 
(500 mg) w a s from B r a c c o I n d u s t r i a C h e m i c a s • p • a • ( M i l a n , 
I t a l y ) . C o n c e n t r a t i o n s of i s o n i a z i d and h y d r a z i n e w e r e 
d e t e r m i n e d by high p e r f o r m a n c e liquid c h r o m a t o g r a p h y (HPLC) 
as d e s c r i b e d in c h a p t e r 5. 
1 1 0 
7 . 2 . 2 . K I N E T I C AND S T A T I S T I C A L C A L C U L A T I O N S 
P h a r m a c o k i n e t i c p a r a m e t e r s were o b t a i n e d from plasma 
c o n c e n t r a t i o n — t i m e p o i n t s according to s t a n d a r d f o r m u l a e 
(Gibaldi and P e r r i e r , 1982)• A r e a s u n d e r plasma 
c o n c e n t r a t i o n p l o t t e d a g a i n s t time c u r v e s (AUG) w e r e 
c a l c u l a t e d using the t r a p e z o i d a l r u l e . A p p a r e n t f i r s t o r d e r 
rate c o n s t a n t s for d e c l i n e of plasma c o n c e n t r a t i o n s a f t e r 
a d m i n i s t r a t i o n were obtained by linear least s q u a r e s 
r e g r e s s i o n on log plasma c o n c e n t r a t i o n a g a i n s t t i m e . On the 
a s s u m p t i o n that the drugs were c o m p l e t e l y a b s o r b e d with 
i n s i g n i f i c a n t first pass e f f e c t , a p p a r e n t v o l u m e s of 
d i s t r i b u t i o n V(a「ea) for each drug were c a l c u l a t e d a c c o r d i n g 
to e q u a t i o n 33; 
DOSE 
V ( a r e a ) = E q • ( 3 3 ) . 
B. AUG 
W h e r e 5 is the p r o d u c t of t e r m i n a l slope and 2.303 of the 
log p l a s ma c o n c e n t r a t i o n curve v e r s e s t i m e . C l e a r a n c e at 
steady state (CLpss) was c a l c u l a t e d a c c o r d i n g to e q u a t i o n 
34 . 
Dosing rate 
CLpss = E q . (34). 
C o n e . a t steady state 
P h e n o t y p i c s e p a r a t i o n for a c e t y l a t i o n of i s o n i a z i d was 
attained by frequency h i s t o g r a m of p l a s m a h a l f - l i f e . 
S i g n i f i c a n c e of d i f f e r e n c e s in p h a r m a c o k i n e t i c p a r a m e t e r s 
and a c e t y l a t o r status w e r e evaluated using the S t u d e n t ' s t_ 
test and Chi s q u a r e , r e s p e c t i v e l y with P < 0.05 c o n s i d e r e d 
1 1 1 
to be the limit of s i g n i f i c a n c e . 
7.3 SECTION 2 C L I N I C A L A S S E S S M E N T 
T a b l e 14 and a p p e n d i x 7. 1 show l a b o r a t o r y r e s u l t s for 
p a t i e n t s b e f o r e t r e a t m e n t (n 二 37) and at o n e m o n t h a f t e r 
initial t r e a t m e n t (n = 16)• F i g u r e s 14 and 15 i l l u s t r a t e 
types of side effects (by codes) e x p e r i e n c e d by the 
p a t i e n t s b e t w e e n 2 w e e k s and 2 m o n t h s of t r e a t m e n t , in the 
w h o l e g r o u p and in the sixteen p a t i e n t s , r e p e c t i v e l y . A f t e r 
2 w e e k s the effects of r i f a m p i c i n on b i l i r u b i n w e r e a s s u m e d 
to be c o m p l e t e . Before t r e a t m e n t h a e m o g l o b i n was below 
n o r m a l (< 11.5 g/1) in 5 young and 10 e l d e r l y p a t i e n t s . One 
y o u n g and 6 elderly p a t i e n t s had a l b u m i n c o n c e n t r a t i o n s 
less than 3 2 g / L . This was m o s t p r o b a b l y due to loss of 
a p p e t i t e and w e i g h t caused by the d i s e a s e a n d , r e l a t i v e to 
c o r r e s p o n d i n g b i l i r u b i n and a l a n i n e t r a n s a m i n a s e , a l b u m i n 
c o n c e n t r a t i o n s w e r e not s u g g e s t i v e of liver f a i l u r e , o t h e r 
a b n o r m a l tests before t r e a t m e n t were: urea > 8.9 m m o l / L , 1 
y o u n g and 3 elderly; c r e a t i n i n e > 107 ^ m o l / L , 1 y o u n g and 
3 e l d e r l y ; b i l i r u b i n >15 /imol/L 2 young and 2 e l d e r l y ; 
A l k a l i n e p h o s p h a t a s e >136 i . u . / L , 2 e l d e r l y ; a l a n i n e 
t r a n s a m i n a s e > 58 i.u./L, 1 e l d e r l y . T h e s e p a t i e n t s w e r e 
included in the study b e c a u s e the liver and r e n a l 
d y s f u n c t i o n their laboratory r e s u l t s e l u d e d w e r e 
s u b c l i n i c a l . 
A f t e r 1 month of t r e a t m e n t the r e n a l and l i v e r . f u n c t i o n 
tests indicated in Table 14 w e r e in n o r m a l r a n g e for the 
young but those for elderly p a t i e n t s o v e r - s h o t the u p p e r 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































KEY TO FIGURES 14 A N D 15 
Codes: 1 = Alive and w e l l . 
F 
2 = N o n - s p e c i f i c side effects e . g . n a u s e a . 
3 = Haematological abnormalities (e.g. 
reduced Hb.) 
4 = Skin and H a e m a t o l o g i c a l a b n o r m a l i t i e s . 
5 = Skin side e f f e c t . 
6 = H e p a t o t o x i c i t y . 
7 = Death. 






























































































































limits (especially bilirubin) . E x c l u s i o n of P a n g y c , in thie 
e l d e r l y , gives steady state b i l i r u b i n as 4.99 土 4.9 i . u . / L . 
N e v e r t h e l e s s steady s t a t e results (16 p a t i e n t s , T a b l e 14) 
could not be used to a s s e s s the o c c u r r e n c e of side e f f e c t s 
in p a t i e n t s b e c a u s e t h e s e samples w e r e not o b t a i n e d at the 
t i m e p a t i e n t s e x h i b i t e d the side e f f e c t s . T h e r e f o r e , for 
e v a l u a t i o n of the d i s t r i b u t i o n of side e f f e c t s , p a t i e n t s 
w e r e o b s e r v e d from 2 w e e k s to 2 m o n t h s of t r e a t m e n t for 
a d v e r s e e f f e c t s . R e c o r d s for p a t i e n t s w h o w i t h d r e w from the 
s t u d y w e r e r e v i e w e d to c o m p a r e the s t u d y g r o u p (restricted 
g r o u p ; Figure 15) with that when the u n r e s t r i c t e d p a t i e n t s 
are included (Figure 14). The side e f f e c t s w e r e c o d e d 
a c c o r d i n g to type (not severity) and w e r e used to s t u d y the 
d i s t r i b u t i o n of side effects in the p a t i e n t s . T h e 
d i s t r i b u t i o n in both g r o u p s was s i m i l a r implying t h a t the 
o b s e r v a t i o n s i m u l a t e s the r o u t i n e s e r v i c e c o n d i t i o n s . 
T h e h i g h p r e v a l e n c e of side e f f e c t s in e l d e r l y p a t i e n t s 
than the young is w e l l d o c u m e n t e d (Riska, 1976) • T h e 
/ 
e s s e n c e of this c l i n i c a l e v a l u a t i o n w a s to try and s h o w , 
a m i d s t the s h o r t c o m i n g s a s s o c i a t e d w i t h use of p a t i e n t s for 
s t u d y (e.g. a b n o r m a l l a b o r a t o r y r e s u l t s due to the d i s e a s e 
it self) , that a s i m i l a r trend (more side effects) w a s 
o b s e r v e d in this s m a l l study g r o u p . 
It w a s c o n c l u d e d t h a t e l d e r l y p a t i e n t s w e r e at a g r e a t e r 
r i s k of d e v e l o p i n g a d v e r s e e f f e c t s from a n t i - t u b e r c u l o u s 
r e g i m e n of i s o n i a z i d , r i f a m p i c i n and pyraz.inamide. 
L a b o r a t o r y results r e q u i r e c l i n i c a l e v i d e n c e to d i a g n o s e 
o n s e t of o v e r t renal or liver m a l f u n c t i o n . 
1 1 6 X 
7.4 SECTION 3 G E N E R A L FINDINGS 
7.4.1 THE D I S P O S I T I O N OF ISONIAZID AND H Y D R A Z I N E 
M E T A B O L I T E IN THE PLASMA OF ELDERLY P A T I E N T S . 
7.4.1.1 R E S U L T S 
Figure 16 shows typical c h r o m a t o g r a m s of p l a s m a e x t r a c t 
from one of the elderly p a t i e n t s . Peaks w e r e s y m m e t r i c a l 
thus peak h e i g h t ratios w e r e used for q u a n t i t a t i o n . Six 
c a l i b r a t i o n g r a p h s were p l o t t e d for c o n c e n t r a t i o n s of 1, 2, 
5, 8, and 10 fig/ml for isoniazid; 76.8, 1 5 3 . 6 , 3 0 7 . 2 , 
4 6 0 . 8 , 6 1 4 . 4 , and 768.0 ng/ml for h y d r a z i n e in 0.5 ml of 
human p l a s m a . The average e q u a t i o n s and c o e f f i c i e n t of 
c o r r e l a t i o n after r e g r e s s i o n a n a l y s i s were: y = o.681x 一 
0.721, r = 0 . 9 9 8 , CV% = 4 .7 to 9.0 for isoniazid/ y = 
0.003X - 0.161, r = 0.998, CV% = 7.0 to 9.5 for h y d r a z i n e 
(Appendix 7.2a and b). 
Figure 17 i l l u s t r a t e s the frequency d i s t r i b u t i o n of 
plasma h a l f - l i f e of isoniazid in all the s u b j e c t s and age 
g r o u p s . S u b j e c t s were c o n s i d e r e d rapid a c e t y l a t o r s w h e n 
h a l f — l i f e was below 4 h o u r s . Eight p a t i e n t s (21.6%) w e r e 
slow a c e t y l a t o r s . 
Table 15 shows the p h a r m a c o k i n e t i c p a r a m e t e r s of 
isoniazid in the two age groups and p h e n o t y p e s (see 
a p p e n d i c e s 7.3a to d )• Isoniazid was r a p i d l y a b s o r b e d 
(Tmax = 1 to 2.5 hours) and it was assumed t h a t o r a l dose 
was c o m p l e t e l y a b s o r b e d t h e r e was no a p p r e c i a b l e p r o t e i n 
b i n d i n g . T h e r e w e r e 6 slow a c e t y l a t o r s in the e l d e r l y g r o u p 
and 2 in the young g r o u p . H o w e v e r , the i n c i d e n c e of slow 
a c e t y l a t o r s in both g r o u p s was found not s i g n i f i c a n t l y 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































d i f f e r e n t (P < 0.05) using Chi square t e s t . T h e r e v;as no 
significant d i f f e r e n c e between the k i n e t i c p a r a m e t e r s of 
isoniazid for elderly and young p a t i e n t s of the same 
acetylator s t a t u s . At steady state c o n c e n t r a t i o n s and 
clearance of isoniazid were the same i r r e s p e c t i v e of age or 
p h e n o t y p e . The average c l e a r a n c e at steady state for the 16 
patients (1.41 ± 0.82 m l / m i n / k g ) was s i g n i f i c a n t l y lower 
than after first dose (4.68 土 1.63 ml/inin/kg) . The 
reduction in c l e a r a n c e bore no r e l a t i o n s h i p to a c e t y l a t o r 
s t a t u s . 
Figure 18 shows the frequency d i s t r i b u t i o n of plasma 
h a l f - l i f e of h y d r a z i n e in all p a t i e n t s and age g r o u p s . It 
is a b i m o d a l d i s t r i b u t i o n w h e r e b y more e l d e r l y p a t i e n t s 
eliminated h y d r a z i n e faster than the y o u n g . H o w e v e r , t h e r e 
was no s i g n i f i c a n t d i f f e r e n c e between the a v e r a g e h y d r a z i n e 
half — lives of the two g r o u p s (Table 16) • As h y d r a z i n e is 
generated frorr\ isoniazid it is d i f f i c u l t to m a k e valid 
c o n c l u s i o n s h e r e . Plasma h a l f - l i f e of h y d r a z i n e w a s not 
related to that of isoniazid such t h a t a t t e m p t s to 
correlate its level with isoniazid p h e n o t y p e w e r e 
f r u i t l e s s . M a x i m u m plasma c o n c e n t r a t i o n (Cmax) of h y d r a z i n e 
in the elderly (0.40 ± 0.07 ^g/ml) was s i g n i f i c a n t l y h i g h e r 
than in the young (0.24 土 0.08 /ig/ml) (Appendices 7.4a to 
d) . This may be due to a h i g h e r first pass e f f e c t which 
d e v e l o p s as a c o n s e q u e n c e of age (Sarma et a l , 1 9 8 6 ) . 
C o n c e n t r a t i o n s of h y d r a z i n e at steady state w e r e s i m i l a r in 
both groups (0.2 ± 0.04 Mg/ml) . H o w e v e r , no c l e a r cut 
interpretation of these r e s u l t s can be made w i t h o u t 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































information on volume of d i s t r i b u t i o n and c l e a r a n c e oi 
h y d r a z i n e . 
7.4.1.2 DISCUSSION 
Age limit was set at 65 years for the s a k e of easy 
comparison of results w i t h p r e v i o u s s t u d i e s (Advenier et 
al,1980/ K e r g u e r i s et a l , 1986; Paulsen and N i l s s o n , 1985) 
w h e r e a s i m i l a r c r i t e r i o n w a s u s e d . 
The study is a t y p i c a l d e s c r i p t i o n of the d i s p o s i t i o n of 
a n t i - t u b e r c u l o u s drugs in the way they are p r e s c r i b e d in a 
clinical s e t t i n g . The c o n d i t i o n s under w h i c h the study w a s 
done s i m u l a t e routine s e r v i c e c o n d i t i o n s in Hong Kong such 
that the r e s u l t s can be used to e v a l u a t e o t h e r p a t i e n t s in 
the c l i n i c . T h e r e w e r e no s i g n i f i c a n t age r e l a t e d c h a n g e s 
in the p h a r m a c o k i n e t i c s of isoniazid d u r i n g c o m b i n e d 
c h e m o t h e r a p y with rifanipicin and p y r a z i n a m i d e for 
t u b e r c u l o s i s . Despite the p o s s i b l e ethnic d i f f e r e n c e s , the 
k i n e t i c p a r a m e t e r s for isoniazid after f i r s t d o s e w e r e 
similar to v a l u e s o b s e r v e d in other s t u d i e s (Advenier et 
al, 1980; K e r g u e r i s et a l , 1 9 8 6 ; Paulsen and N i l s s o n , 1985) 
where the drug was a d m i n i s t e r e d a l o n e . C l a s s i f i c a t i o n into 
fast and slow a c e t y l a t o r s was attained by a f r e q u e n c y 
d i s t r i b u t i o n h i s t o g r a m of isoniazid plasma h a l f - l i f e (Fig. 
17). A s i m i l a r m e t h o d had been s u c c e s f u l l y used by 
K e r g u e r i s et al (1986) and P a u l s e n and N i l s s o n (1985). In 
both s t u d i e s oral isoniazid w a s given to the s u b j e c t s and 
antimode of 2 hours was used to d e t e r m i n e fast and slow 
a c e t y l a t o r s . A d v e n i e r et al (1980) used a n t i m o d e of iio 
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m i n . to classify a c e t y l a t o r status after a d m i n i s t r a t i o n ot 
isoniazid i n t r a v e n o u s l y . V a r i a t i o n s between t h e s e s t u d i e s 
could have arisen from d i f f e r e n c e s in p o p u l a t i o n s 
c o n c e r n i n g e t h n i c o r i g i n , sample s i z e , a g e , and g e n d e r . In 
small p o p u l a t i o n s , like for the p r e s e n t s t u d y , l i m i t s for 
a n t i m o d e are m o r e d i f f i c u l t to d e t e r m i n e b e c a u s e of the 
t e n d e n c y to t r i m o d a l d i s t r i b u t i o n into h o m o z y g o u s (RR) and 
h e t e r o z y g o u s (Rr) rapid and r e c e s s i v e (rr) slow 
a c e t y l a t o r s . A p r o l o n g e d plasma h a l f - l i f e of i s o n i a z i d w a s 
strongly associated with a n t i - t u b e r c u l o u s c h e m o t h e r a p y , old 
age and c o n c u r r e n t a d m i n i s t r a t i o n of other m e d i c a t i o n s 
(Paulsen and N i l s s o n , 1985). It w a s o b s e r v e d t h a t v a l u e s of 
plasma h a l f - l i f e for isoniazid (Walubo et a l , 1991; see 
chapter 6) and p y r a z i n a m i d e (Chan and W o n g , 1988) w e r e 
longer after oral a d m i n i s t r a t i o n than after i n t r a v e n o u s 
route in r a b b i t s . P r o b a b l y this is due to c o n t i n u o u s input 
of the drug from a b s o r p t i o n s i t e . The a p p a r e n t p r o l o n g a t i o n 
of isoniazid plasma h a l f - l i f e in this case was p r e s u m a b l y 
as a r e s u l t of oral r o u t e of a d m i n i s t r a t i o n , i n t e r a c t i o n of 
isoniazid with r i f a m p i c i n and or p y r a z i n a m i d e , and 
d i f f i c u l t i e s a s s o c i a t e d with p h e n o t y p i n g small p o p u l a t i o n 
s a m p l e s . N e v e r t h e l e s s , isoniazid e x h i b i t e d p o l y m o r p h i c 
m e t a b o l i s m implying t h a t all p a t i e n t s were e q u a l l y a f f e c t e d 
by any of the above f a c t o r s . Using a n t i m o d e of 4 h o u r s the 
f r e q u e n c y of slow a c e t y l a t o r s w a s 21.6% which is c l o s e to 
the 22% v a l u e o b t a i n e d in p r e v i o u s s t u d i e s in the H o n g Kong 
C h i n e s e (Ellard et a l ' 1 9 7 6 b ) . The i n c i d e n c e of slow 
a c e t y l a t o r s in the e l d e r l y g r o u p was similar to that in the 
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young g r o u p . The c l e a r a n c e for isoniazid at s t e a d y state 
was the same i r r e s p e c t i v e of age or a c e t y l a t o r s t a t u s . T h i s 
o b s e r v a t i o n c o n f i r m s prior r e m a r k s t h a t a c e t y l a t o r 
p h e n o t y p e per se c a n n o t explain the v a r i a t i o n in o c c u r r e n c e 
of isoniazid r e l a t e d t o x i c i t y and is not an i n d i c a t i o n for 
a d j u s t m e n t of d o s e s in i n d i v i d u a l s if s t a n d a r d t h e r a p y is 
adhered to (Ellard, 1984). Isoniazid is e l i m i n a t e d m a i n l y 
by liver m e t a b o l i s m . The r e d u c t i o n in c l e a r a n c e for 
isoniazid at steady state may be due to e n z y m e s a t u r a t i o n , 
c o m p e t i t i o n for m e t a b o l i s m with or i n h i b i t i o n by its 
m e t a b o l i t e s , or drug interaction with r i f a m p i c i n and or 
p y r a z i n a m i d e . in that way a s i m u l t a n e o u s s t u d y of the 
p h a r m a c o k i n e t i c of the three drugs may g i v e a clue to 
u n d e r s t a n d i n g of which m e c h a n i s m is m o r e i m p o r t a n t . 
H y d r a z i n e is p r o d u c e d in s i g n i f i c a n t a m o u n t s as 
indicated by the c o n c e n t r a t i o n at steady state (0.2 ± 0.04 
^9/ml) and t o t a l AUG ratio (Hydrazine : i s o n i a z i d ) of 
••06 ± O.OS in young and 0.07 土 O.OI in e l d e r l y p a t i e n t s . 
It was r e p o r t e d that c o n c e n t r a t i o n s of i s o n i a z i d in slow 
a c e t y l a t o r s are h i g h e r than in fast a c e t y l a t o r s (Weber and 
H e i n , 1979), and that slow a c e t y l a t o r s p r o d u c e m o r e 
h y d r a z i n e than fast a c e t y l a t o r s (Beever et a l , 1982; 
M i t c h e l l et a l , 1976) . In this s t u d y , lack of d i f f e r e n c e in 
h y d r a z i n e c o n c e n t r a t i o n s of the two p h e n o t y p e s and age 
g r o u p s may s u g g e s t that the enzyme system r e s p o n s i b l e for 
h y d r a z i n e formation from isoniazid has a limited c a p a c i t y 
such that beyond some c o n c e n t r a t i o n of isoniazid the m a j o r 
d e t e r m i n a n t of h y d r a z i n e c o n c e n t r a t i o n is its c l e a r a n c e 
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(not rate of p r o d u c t i o n ) . Slight d i f f e r e n c e s in isoniazid 
c o n c e n t r a t i o n s in the two p h e n o t y p e s may not a f f e c t 
h y d r a z i n e c o n c e n t r a t i o n in p a t i e n t s with a good h y d r a z i n e 
clearing c a p a c i t y . This implies that v a r i a t i o n in 
h y d r a z i n e metabolisin may be a better e x p l a n a t i o n for 
h y d r a z i n e t o x i c i t y d u r i n g t r e a t m e n t with i s o n i a z i d than the 
slow isoniazid a c e t y l a t o r s t a t u s . The assay m e t h o d used in 
this study can d e t e c t h y d r a z i n e either in the free form or 
as h y d r a z i n e h y d r a t e . Both forms are p o t e n t t o x i n s (Back 
and T h o m a s , 1970; The Merck Index, 1976). 
Enzyme a c t i v i t y , in g e n e r a l , r e d u c e s w i t h a g e . 
T h e r e f o r e , the fast e l i m i n a t i o n of h y d r a z i n e in m a n y 
elderly p a t i e n t s may be m i s l e a d i n g . Elderly p e o p l e are m o r e 
sensitive to d r u g s . Initial h y d r a z i n e c o n c e n t r a t i o n s (Cmax) 
were higher in the elderly g r o u p . It is p o s s i b l e that the 
fast e l i m i n a t i o n of h y d r a z i n e in some elderly p a t i e n t s m a y 
be due to increased h y d r a z i n e tissue binding in old age by 
unknown m e c h a n i s m . Such a m e c h a n i s m may not be far from 
that d e s c r i b e d by M i t c h e l l et al (1976) for soniG h y d r a z i n e 
c o m p o u n d s . W h e r e a s fast e l i m i n a t i o n of h y d r a z i n e by m a n y 
elderly p a t i e n t s could be of c l i n i c a l s i g n i f i c a n c e , p r o p e r 
c o n c l u s i o n s can only be made from studies on h y d r a z i n e w h e n 
a d m i n i s t e r e d a l o n e . Further s t u d i e s on h y d r a z i n e in t h i s 
r e s p e c t are n e e d e d . 
In c o n c l u s i o n , there is little or no s i g n i f i c a n t age 
related c h a n g e in the p h a r m a c o k i n e t i c s of i s o n i a z i d d u r i n g 
c o m b i n a t i o n c h e m o t h e r a p y with r i f a m p i c i n and p y r a z i n a m i d e . 
H o w e v e r , on c o n t i n u e d t r e a t m e n t there is a s i g n i f i c a n t 
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r e d u c t i o n in c l e a r a n c e of i s o n i a z i d . The c l e a r a n c e i or 
isoniazid at steady state was the same in the two 
a c e t y l a t o r p h e n o t y p e s . H y d r a z i n e m e t a b o l i t e e x h i b i t e d age 
related v a r i a t i o n in the e l i m i n a t i o n h a l f - l i f e w h e r e b y m o r e 
elderly p a t i e n t s seem to e l i m i n a t e h y d r a z i n e at a f a s t e r 
r a t e . M o r e s t u d i e s are needed to confirm t h e s e f i n d i n g s . 
N e v e r t h e l e s s , h y d r a z i n e is p r o d u c e d in s i g n i f i c a n t a m o u n t s 
and this should not be n e g l e c t e d when e v a l u a t i n g i s o n i a z i d 
r e l a t e d t o x i c i t y . 
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7.4.2 THE D I S P O S I T I O N OF I S O N I A Z I D , P Y R A Z I N A M I D E A N D 
RIFAMPICIN IN THE PLASMA OF ELDERLY P A T I E N T S . 
7.4.2.1 RESULTS 
Figure 19 shows t y p i c a l c h r o m a t o g r a m s of p l a s m a e x t r a c t s 
from one of the elderly p a t i e n t s . Peak h e i g h t r a t i o w a s 
used for q u a n t i t a t i o n . The study was b a s e d on the 
a s s u m p t i o n that the drugs were c o m p l e t e l y a b s o r b e d and 
p r o t e i n binding for r i f a m p i c i n (80%； Boman and R i n g b e r g e r , 
1974) and p y r a z i n a m i d e (50%; C u r r y , 1975) r e m a i n e d 
u n c h a n g e d in both age g r o u p s , and i s o n i a z i d w a s not 
a p p r e c i a b l y p r o t e i n bound (Boxenbaum et a l , 1975) . T a b l e 17 
s u m m a r i s e s the p h a r m a c o k i n e t i c p a r a m e t e r s of i s o n i a z i d , 
r i f a m p i c in and pyirazindmide (also see append ices 7 5a t〇 d 
for r i f a m p i c i n and 7.6a to d for p y r a z i n a m i d e ) . The t h r e e 
drugs w e r e rapidly absorbed (Tmax in hours: l to 2.5 for 
isoniazid; 2 to 4 for r i f a m p i c i n ; 1 to 3 for p y r a z i n a m i d e ) . 
There was no d i f f e r e n c e in the p h a r m a c o k i n e t i c s of 
i s o n i a z i d , r i f a m p i c i n and p y r a z i n a m i d e in the y o u n g and 
eldeiTly p a t i e n t s both after first dose and at s t e a d y s t a t e . 
R i f a m p i c i n a v e r a g e c l e a r a n c e at steady state in the 16 
p a t i e n t s (1.4 ± 0.82 m l / m i n / k g ) was s i g n i f i c a n t l y lower 
than after first dose (2.82 土 l.06; F i g . 2 0 ) . It was also 
observed that the c l e a r a n c e for isoniazid at steady s t a t e 
(1.41 ± 0.82) was s i g n i f i c a n t l y lower than after first d o s e 
(4.68 ± 1.63 m l / m i n / k g ; Fig.21) w h i l e that of p y r a z i n a m i d e 
rei^ained u n c h a n g e d after first dose (0.79 ± 0.24 inl/min/kg) 
and at steady state (0.65 ± 0.25 ml/niin/kg; f i g . 2 2 ) . 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The s t u d y , once a g a i n , is a t y p i c a l d e s c r i p t i o n of the 
d i s p o s i t i o n of a n t i - t u b e r c u l o u s d r u g s d u r i n g r o u t i n e 
service c o n d i t i o n s . Several r e p o r t s on the p h a r m a c o k i n e t i c s 
of isoniazid (Advenier et al, 19 8 0; K e r g u e r i s et a l , 1986; 
Paulsen and N i l s s o n , 1985) and r i f a m p i c i n (Advenier et a l , 
1983) in elderly p e o p l e have been p u b l i s h e d • In t h e s e 
reported studies an age limit of 65 y e a r s w a s used to 
separate s u b j e c t s into elderly and y o u n g , g r o u p s . 
T h e r e f o r e , for the sake of easy c o m p a r i s o n of r e s u l t s , a 
similar c r i t e r i o n was adopted in the p r e s e n t s t u d y . 
W h e r e a s v a r i a t i o n s in drug m e t a b o l i s m are m o r e d i f f i c u l t to 
d e t e c t than for r e n a l e x c r e t i o n (Gibaldi, 1984) it w a s 
concluded that there is no change in the p h a r m a c o k i n e t i c s 
of isoniazid and r i f a m p i c i n in old age (Advenier et a l , 
1980; A d v e n i e r et a l , 1 9 8 3 ; K e r g u e r i s et a l , 1986; P a u l s e n 
and N i l s s o n , 1985) • C o n f l i c t i n g r e p o r t s h a v e been p u b l i s h e d 
on the i n t e r a c t i o n b e t w e e n isoniazid and rif ainpicin • It had 
been observed t h a t c o m b i n a t i o n of i s o n i a z i d and r i f a m p i c i n 
caused a b n o r m a l liver function t e s t s and h e p a t i c n e c r o s i s 
(Satinder et al, 1972), and the h e p a t o t o x i c i t y w a s 
d i f f e r e n t from t h a t induced by either drug s e p a r a t e l y 
(Grohagen-Riska et a l , 1978) . A l s o , a p r o l o n g e d i s o n i a z i d 
h a l f — l i f e was s t r o n g l y a s s o c i a t e d with a n t i - t u b e r c u l o u s 
c h e m o t h e r a p y and one of the d r u g s w a s rifanipicin (Kergueris 
et al, 1986; P a u l s e n and N i l s s o n , 1985) . On the c o n t r a r y 
M o d a i et al (1978) failed to show any i n t e r a c t i o n b e t w e e n 
isoniazid and r i f a m p i c i n . W h e r e a s some t h o u g h t s have 
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expressed the incidence of h e p a t o t o x i c i t y with isoniazid 
and r i f a m p i c i n reginiens as e n c o u r a g i n g l y low (Girling, 
1978), it was observed that such c o n c l u s i o n s only refer to 
cases that had apparently no p r e d i s p o s i n g factors to drug 
toxicity b e f o r e institution of a n t i - t u b e r c u l o u s t h e r a p y . 
Many p a t i e n t s on a n t i — t u b e r c u l o u s c h e m o t h e r a p y h a v e one or 
more u n f a v o u r a b l e factors like； severe form of the d i s e a s e , 
liver d i s e a s e , concurrent t r e a t m e n t w i t h other d r u g s , 
advancing age, recent anaesthesia and female g e n d e r (Weber 
and H e i n , 1979) . T h e r e f o r e a n t i - t u b e r c u l o u s drug a s s o c i a t e d 
moirbidity and m o r t a l i t y is high and s p e c i a l p r e c a u t i o n s 
should be taken where p o s s i b l e . 
In the p r e s e n t study it has been o b s e r v e d t h a t d u r i n g 
a n t i - t u b e r c u l o u s t r e a t m e n t with a c o m b i n a t i o n of i s o n i a z i d , 
r i f a m p i c i n and p y r a z i n a m i d e the p h a r m a c o k i n e t i c s of each of 
the drugs is not altered in old a g e . T h e r e d u c t i o n in 
c l e a r a n c e at steady state for isoniazid and r i f a m p i c i n is 
s u g g e s t i v e of an interaction between the two or t h r e e 
d r u g s . It was cited earlier that plasma h a l f - l i f e of 
isoniazid was prolonged by other a n t i - t u b e r c u l o u s d r u g s 
(Kergueris et al, 1986; Paulsen and N i l s s o n , 1 9 8 5 ) . 
Interaction of i s o n i a z i d , rifampicin and or p y r a z i n a m i d e 
seems to be a slow or indirect p r o c e s s such t h a t the 
observed low c l e a r a n c e at steady state may be an e x p r e s s i o n 
of the c o m p l e t e p r o c e s s . Enzyme saturation per se could not 
explain this phenomena because c l e a r a n c e s for isoniazid and 
rifampicin at steady state were not c h a r a c t e r i s t i c of 
p o l y m o r p h i c m e t a b o l i s m and a u t o - e n z y m e i n d u c t i o n , 
1 3 6 X 
r e s p e c t i v e l y . This s u p p o r t s e a r l i e r s u g g e s t i o n s that dur i nq 
c h r o n i c a n t i - t u b e r c u l o u s c h e m o t h e r a p y a u t o - e n z y m e induct ion 
by r i f a m p i c i n could be brief and p o s t - p r a n d i a l or pre-
p r a n d i a l a d m i n i s t r a t i o n is not i m p o r t a n t (Oschkinat and 
F l e m m i n g , 1971)• 
D e s p i t e the e l e v a t e d renal and liver f u n c t i o n t e s t s at 
s t e a d y state in e l d e r l y p a t i e n t s (Table 14) the d r u g 
c o n c e n t r a t i o n s at steady state in the two g r o u p s of 
p a t i e n t s w e r e similar (Table 17). T h i s implies t h a t e l d e r l y 
p a t i e n t s w e r e h a n d l i n g (metabolising) the d r u g s at f a i r l y 
n o r m a l r a t e . N e v e r t h e l e s s , more side e f f e c t s o c c u r r e d in 
e l d e r l y p a t i e n t s b e t w e e n 2 w e e k s and 2 m o n t h s of t r e a t m e n t . 
T h e r e f o r e , elderly p a t i e n t s are m o r e s u s c e p t i b l e to a n t i -
t u b e r c u l o u s drug t o x i c i t y . C o n s i d e r a t i o n of s e v e r a l f a c t o r s 
is n e e d e d to m a k e a good p r e d i c t i o n of the o u t c o m e or to 
p r e v e n t o c c u r r e n c e of u n w a n t e d side e f f e c t s . A t this 
j u n c t u r e m o d i f i c a t i o n in d o s a g e for e l d e r l y p a t i e n t s n e e d 
be c o n s i d e r e d . Using m i n i m u m i n h i b i t o r y c o n c e n t r a t i o n s 
/ 
(MIC) as a g u i d e l i n e , d o s a g e s of i s o n i a z i d and r i f a m p i c i n 
can be r e d u c e d to the least p o s s i b l e level for the e l d e r l y 
p e r s o n w i t h o u t loss of e f f i c a c y . C a u t i o n is t h a t it 
r e q u i r e s k n o w l e d g e of the s e n s i t i v i t y p a t t e r n of the 
b a c i l l i and c o n f i r m a t i o n by c l i n i c a l t r i a l s . A l t e r n a t i v e l y , 
the c o n c e p t of MIC may be used to r e d u c e s u b s e q u e n t d a i l y 
d o s e s a f t e r r e a c h i n g s t e a d y state in e l d e r l y p a t i e n t s . 
In c o n c l u s i o n , it has been shown that t h e r e is no age 
r e l a t e d c h a n g e in the p h a r m a c o k i n e t i c s of each of t h e d r u g s 
i s o n i a z i d , r i f a m p i c i n and p y r a z i n a m i d e w h e n used in 
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、 c o m b i n a t i o n for treating t u b e r c u l o s i s . The p o s s i b i l i t y of 
an interaction between the three d r u g s was indicated by the 
reduced c l e a r a n c e at steady state for i s o n i a z i d and 
r i f a m p i c i n , and a c o n c o m i t a n t failure for both d r u g s to 
e x h i b i t the c h a r a c t e r i s t i c p r o p e r t i e s of p o l y m o r p h i c 
m e t a b o l i s m and a u t o e n z y m e i n d u c t i o n , r e s p e c t i v e l y . E l d e r l y 
p a t i e n t s are m o r e prone to d e v e l o p side e f f e c t s to anti-
t u b e r c u l o u s drugs and is h e r e b y s u g g e s t e d t h a t a 
m o d i f i c a t i o n in the d o s a g e of a n t i - t u b e r c u l o u s d r u g s in 
this group of p a t i e n t s be r e c o n s i d e r e d . 
1 3 8 X 
7.5 SECTION 4 CASE REPORT ON A PATIENT WHO D I E D OF 
A N T I - T U B E R C U L O U S DRUG A S S O C I A T E D 
H E P A T O T O X I C I T Y 
7 . 5 . 1 . H I S T O R Y 
A 7 4 year old man was admitted to h o s p i t a l for 
p r o d u c t i v e cough and loss of a p p e t i t e for two w e e k s . He had 
h i s t o r y of p u l m o n a r y t u b e r c u l o s i s 15 years p r e v i o u s l y w h i c h 
w a s t r e a t e d for half a y e a r . There was no h i s t o r y of 
e x p o s u r e to a n a e s t h e t i c agents or h e p a t o t o x i c c h e m i c a l s 
p r i o r to a d m i s s i o n . On e x a m i n a t i o n , signs of c o n s o l i d a t i o n 
w e r e d e t e c t e d over the right upper chest and w a s c o n f i r m e d 
by chest r a d i o g r a p h . His h a e m o g l o b i n was 9.1 g / d l and w h i t e 
cell c o u n t was 5.5 x /L. E r y t h r o c y t e s e d i m e n t a t i o n r a t e 
w a s 97 mm in the first h o u r . Plasma sodium w a s 130 m m o l / L , 
p o t a s s i u m 2.7 m m o l / L , urea 2.7 minol/L and c r e a t i n e 62 
m o l / h . Liver function tests showed total p r o t e i n 65 g / L 
(normal range 66 to 81 g / L ) , albumin 30 g / L (36 to 4 8 ) , 
total b i l i r u b i n 30 mhioI/L (0 to 15), a l k a l i n e p h o s p h a t a s e 
85 i.u./L (40 to 136) and a l a n i n e t r a n s a m i n a s e 12 i . u . / L (0 
to 58) . Spot sugar was 11.6 m m o l / L and f r u c t o s a m i n e was 1.9 
m m o l / L (1.5 to 2.2). H e p a t i t i s B s u r f a c e a n t i g e n and IgM 
a n t i b o d y to H e p a t i t i s A v i r u s were n e g a t i v e . P r o t h r o m b i n 
time was 14.4 seconds (control 12.50 s) and a c t i v a t e d 
p a r t i a l t h r o m b o p l a s t i n time 49.9 seconds (control 25 to 40 
s)• Ziehl N i e l s e n stain of sputum showed large n u m b e r s of 
acid fast b a c i l l i (this was later r e a f f i r m e d by p l e u r a l 
biopsy r e s u l t s ) . His body w e i g h t was 35 Kg and anti-
t u b e r c u l o u s treatinent was started with i s o n i a z i d 200 m g , 
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r i f a m p i c i n 300 m g , p y r a z i n a m i d e 750 mg and e t h a m b u t o l 8 00 
mg d a i l y . Five days later, the liver function t e s t s were: 
total protein 53 g / L , albumin 25 g / L , t o t a l b i l i r u b i n 33 
fimol/L, a l k a l i n e p h o s p h a t a s e 325 i.u./L and a l a n i n e 
t r a n s a m i n a s e 19 i . u . / L . P r o t h r o m b i n time w a s p r o l o n g e d to 
34.5 seconds and activated p a r t i a l t h r o m b o p l a s t i n t i m e w a s 
66.8 s e c o n d s . I s o n i a z i d , r i f a m p i c i n , and p y r a z i n a m i d e w e r e 
s t o p p e d . R e p e a t liver function tests on the f o l l o w i n g day 
showed an increase in bilirubin to 4 9 /iimol/L, a l k a l i n e 
p h o s p h a t a s e 334 i.u./L and alanine t r a n s a m i n a s e 52 i . u . / L . 
His a p p e t i t e r e m a i n e d s a t i s f a c t o r y . On the m o r n i n g of the 
eighth day after initiation of t r e a t m e n t , he w e n t into 
sudden c a r d i a c a r r e s t and failed to be r e s u s c i t a t e d . 
P o s t m o r t e m e x a m i n a t i o n revealed s u b m a s s i v e h e p a t i c 
n e c r o s i s . No space occupying lesion was s e e n . E x a m i n a t i o n 
of the lungs showed caseous n e c r o s i s , c a v i t a t i o n and 
c a l c i f i c a t i o n in the right upper lobe. A d r e n a l g l a n d s w e r e 
n o r m a l . 
The p a t i e n t had been recruited for p h a r m a c o k i n e t i c study 
of a n t i - t u b e r c u l o u s drugs in the e l d e r l y . T h e r e f o r e all the 
p r o c e d u r e s for o b t a i n i n g and p r o c e s s i n g of t h e blood 
samples w e r e as d e s c r i b e d in section 7.2, e x c e p t for the 
steady state c o n c e n t r a t i o n for this p a t i e n t w h i c h was 
obtained on the day of t r e a t m e n t . T h e r e s u l t s are 
compared w i t h t h o s e for other elderly p a t i e n t s w h o did not 
d e v e l o p h e p a t o t o x i c i t y (Table 18, and a p p e n d i c e s 7.7a and 
b, and 7.8a to d ) . 
The age and d o s a g e s of a n t i - t u b e r c u l o u s d r u g s of this 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































p a t i e n t were similar to the mean v a l u e s for the other 
elderly p a t i e n t s . The initial p h a r m a c o k i n e t i c p a r a m e t e r s 
w e r e within 1 to 2 standard d e v i a t i o n s of the m e a n v a l u e s 
of the group of elderly p a t i e n t s , with the e x c e p t i o n of a 
p r o l o n g e d h a l f - l i f e for rifampicin and p y r a z i n a m i d e 
(greater than 2 s.d. from the mean v a l u e s for t h e e l d e r l y 
group)• H o w e v e r , at steady s t a t e , the c o n c e n t r a t i o n s of 
h y d r a z i n e and r i f a m p i c i n exceeded t w i c e t h e v a l u e 
r e p r e s e n t i n g mean + 1 s.d. for the e l d e r l y g r o u p . 
C o n c e n t r a t i o n s of isoniazid and p y r a z i n a m i d e w e r e s i m i l a r 
to those for the elderly group as a w h o l e . 
7.5.2 D I S C U S S I O N 
A l t h o u g h a s y m p t o m a t i c elevation of t r a n s a m i n a s e s d u r i n g 
isoniazid and r i f a m p i c i n therapy is w e l l d o c u m e n t e d 
(Editorial, 1980), m a s s i v e h e p a t i c n e c r o s i s is usually-
a t t r i b u t e d to isoniazid therapy (Mitchell et a l , 1976) . The 
theory of m o n o a c e t y I h y d r a z i n e , where rapid a c e t y l a t o r s are 
more at risk of d e v e l o p i n g h e p a t i c t o x i c i t y , w o u l d not 
explain the h i g h e r incidence of h e p a t o t o x i c i t y a m o n g slow 
a c e t y l a t o r s as r e p o r t e d in some studies ( G r o h a g e n - R i s k a et 
al, 1978; D i c k i n s o n et al, 1977). Sarma et al (1986) 
p r o p o s e d that in slow a c e t y l a t o r s a g r e a t e r p r o p o r t i o n of 
isoniazid is m e t a b o l i s e d to h y d r a z i n e w h i c h p r e d i s p o s e s 
them to h i g h e r risk of isoniazid induced liver t o x i c i t y . 
H o w e v e r there had been no reports on m e a s u r e m e n t of plasma 
h y d r a z i n e c o n c e n t r a t i o n in p a t i e n t s t a k i n g i s o n i a z i d w h o 
d e v e l o p m a s s i v e h e p a t i c n e c r o s i s . Plasma h y d r a z i n e 
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c o n c e n t r a t i o n for this p a t i e n t 2 days before d e a t h was two 
times h i g h e r than the mean + s. d . value for t h e g r o u p oi 
elderly s u b j e c t s who did not d e v e l o p h e p a t o t o x i c i t y . T h i s 
finding s u g g e s t s that h y d r a z i n e may be a p o s s i b l e c a u s e of 
isoniazid induced h e p a t i c n e c r o s i s . 
A t the same t i m e , steady state r i f a m p i c i n c o n c e n t r a t i o n 
was also very h i g h . This is probably a r e f l e c t i o n of 
d e r a n g e d liver* function a f f e c t i n g the h e p a t i c m e t a b o l i s m of 
r i f a m p i c i n , r a t h e r than a d i r e c t toxic e f f e c t of the drug 
itself. P a t i e n t s with similar serum c o n c e n t r a t i o n s of 
r i f a m p i c i n did not exhibit any a b n o r m a l liver f u n c t i o n test 
(Oschkinat and F l e m m i n g , 1971). 
P y r a z i n a m i d e , which is partly excreted by t h e k i d n e y , 
was not e l e v a t e d in this p a t i e n t compared to t h e e l d e r l y 
g r o u p . The high r i f a m p i c i n level may h a v e an added 
d e l e t e r i o u s e f f e c t in that it could lead to i n c r e a s e d 
formation of h y d r a z i n e by inducing the e n z y m e i s o n i a z i d 
h y d r o l a s e , w h i c h c o n v e r t s isoniazid to h y d r a z i n e and 
i s o n i c o t i n i c a c i d . 
Isoniazid h e p a t o t o x i c i t y increases w i t h a g e . A n o t h e r 
p a t i e n t who d e v e l o p e d m a s s i v e liver n e c r o s i s in the same 
h o s p i t a l was also aged (age 85 years; Woo et a l , 1 9 8 7 a ) , 
and death o c c u r r e d within one week of s t a r t i n g anti-
t u b e r c u l o u s c h e m o t h e r a p y . A l t e r e d h e p a t o c y t e s u s c e p t i b i l i t y 
to h y d r a z i n e with age may be a p o s s i b l e e x p l a n a t i o n . 
A l t e r n a t i v e l y , the p h a r m a c o k i n e t i c s of h y d r a z i n e may be 
d i f f e r e n t in e l d e r l y p a t i e n t s , resulting in h i g h e r l e v e l s . 
Little is known r e g a r d i n g the m e t a b o l i s m of h y d r a z i n e , 
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t h e r e f o r e m o r e s t u d i e s are needed e s p e c i a l l y in r e l a t i o n to 
a g e . L a s t l y , the p r e s e n c e of other p o t e n t i a l h e p a t o t o x i c 
d r u g s and t h e i r m e t a b o l i t e s m a d e it d i f f i c u l t to 
i n c r i m i n a t e h y d r a z i n e as the sole c a u s e of the 
h e p a t o t o x i c i t y in this p a t i e n t . N e v e r t h e l e s s , the high 
serum levels of h y d r a z i n e and rapidity of s y m p t o m a t o l o g y 
m a d e it w o r t h y an e f f o r t to r e p o r t and c a u t i o n all t h o s e 
involved in r e s e a r c h and or t r e a t m e n t of t u b e r c u l o s i s t h a t 
h y d r a z i n e should be c o n s i d e t e d when e v a l u a t i n g for 
isoniazid r e l a t e d t o x i c i t y . 
1 4 4 X 
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8.1 SECTION 1 G E N E R A L C O N C L U S I O N S 
1. A m o r e e c o n o m i c a l , c o n v e n i e n t and s e n s i t i v e p r o c e d u r e , 
based on high p e r f o r m a n c e liquid c h r o m a t o g r a p h y , for 
s i m u l t a n e o u s d e t e r m i n a t i o n of isoniazid and h y d r a z i n e 
m e t a b o l i t e in plasma and c e r e b r o s p i n a l fluid h a s been 
d e v e l o p e d . 
2. The p h a r m a c o k i n e t i c s of isoniazid and h y d r a z i n e 
m e t a b o l i t e in plasma and c e r e b r o s p i n a l fluid of r a b b i t s 
has been d e t e r m i n e d . This has improved the p r o s p e c t s of 
further studies on both c o m p o u n d s e s p e c i a l l y for 
h y d r a z i n e w h i c h is very t o x i c and e x p e r i m e n t a t i o n in m a n 
has not been p o s s i b l e . 
3. It has been d e m o n s t r a t e d that there is no s i g n i f i c a n t 
b a r r i e r to the p e n e t r a t i o n of -isoniazid into t h e 
c e r e b r o s p i n a l fluid (CSF) in normal r a b b i t s , and 
isoniazid is e l i m i n a t e d from the CSF at a s l o w e r rate 
than for p l a s m a . A s s u m i n g that a s i m i l a r p r o c e s s is 
h a p p e n i n g in p a t i e n t s the p r a c t i c a l a p p l i c a t i o n of this 
r e s u l t can lead to a safer p r e s c r i b i n g of the drug in 
the c l i n i c . 
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4. The plasma p r o f i l e s of h y d r a z i n e d u r i n g t r e a t m e n t with 
isoniazid in c o n j u n c t i o n with other a n t i — t u b e r c u l o u s 
d r u g s (rifampicin and p y r a z i n a m i d e ) h a v e been 
d e t e r m i n e d . H y d r a z i n e is p r o d u c e d in s i g n i f i c a n t a m o u n t s 
(steady state c o n c e n t r a t i o n ^ 0.2 /ig/ml) and t h i s 
s h o u l d not be n e g l e c t e d when e v a l u a t i n g i s o n i a z i d 
r e l a t e d t o x i c i t y . 
5. D u r i n g c h r o n i c a n t i — t u b e r c u l o u s t r e a t m e n t w i t h the 
r e g i m e n of i s o n i a z i d , r i f a m p i c i n and p y r a z i n a m i d e , t h e 
p h a r m a c o k i n e t i c s of each of the d r u g s is n o t a l t e r e d in 
old a g e . On c o n t i n u a l t r e a t m e n t the c l e a r a n c e s for 
isoniazid and r i f a m p i c i n are r e d u c e d w h i l e t h a t of 
p y r a z i n a m i d e r e m a i n s u n c h a n g e d . 
6. E l d e r l y p e o p l e are m o r e s u s c e p t i b l e to the t o x i c i t y of 
a n t i - t u b e r c u l o u s d r u g s than young p e o p l e such t h a t 
m o d i f i c a t i o n in d o s a g e for elderly p a t i e n t s should be 
c o n s i d e r e d . 
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8.2 SECTION 2 FUTURE STUDIES 
1. Further s t u d i e s , both in vitro and in v i v o , are r e q u i r e d 
to e s t a b l i s h the role of h y d r a z i n e in i s o n i a z i d r e l a t e d 
h e p a t o t o x i c i t y and how it can be p r e v e n t e d . 
2. Since t h e r e are no c h a n g e s in the p h a r m a c o k i n e t i c s of 
i s o n i a z i d , rifampicin and p y r a z i n a m i d e in old age 
further s t u d i e s , p r o b a b l y on p h a r m a c o d y n a m i c s , are 
needed to establish factors r e s p o n s i b l e for the h i g h e r 
i n c i d e n c e of side e f f e c t s in elderly p e o p l e . 
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A 
SUMMARY 
Anti-tuberculous (Anti-TB) chemotherapy in Uganda is outlined. Its pattern 
of use and the subsequent shortcomings have prompted the need for the 
present review. A collateral comparison to that of Hong Kong was run to 
emphasize the correlation of anti -TB chemotherapy with economic develop-
ment and regional variation in the population of the two areas. Tuberculosis 
of the central nervous system (CNS) has a high fatality rate. In the search for 
a more comprehensive ant i -TB dosage regimen, the difficulty in treating 
tuberculosis of the CNS has attracted special attention with emphasis on the 
fate of anti -TB drugs across the meninges. The choice of a method for drug 
analysis in routine therapeutic drug monitoring for a country is likewise 
determined by factors similar to those for the ant i -TB regimen. Uganda needs 
an inexpensive, precise and selective method for T B treatment tailored to its 
financial and manpower resources. 
G E O G R A P H I C A L A N D H E A L T H S T A T I S T I C S (1980 C E N S U S ) (1) 
Uganda lies in East Africa and covers an area of 150,400 km' with a population of 13 
million，94-6% of which is rural. It has a population growth rate of 3 % per year 
and almost more than half the population is unproductive, i.e. children, the elderly， 
unemployed young adults and some housewives. The infant mortality rate is 110/1,000 
live births, with a poor immunization coverage of less than 5 0 � ) . O n l y 5 0 - 6 0 % of the 
population receives hospital services. � 
T H E D I S E A S E P A T T E R N 
In spite of vaccination programmes, health education, the availability of economic and 
effective chemotherapeutic drugs, tuberculosis remains one of the major paediatric 
problems in Africa and other tropical countries (2). It is probably the most common 
cause of death in young adults in Uganda (3). In Mulago hospital, tuberculosis 
accounted for more than 10% of the admissions in 1980. The National Tuberculosis 
Control Program (NTCP) has addressed the problem nationwide，contrary to earlier 
reports by Hutts (3). ‘ 
Tuberculosis is a major causc of morbidity and mortality in Uganda and there is 
high prcvalcncc of factors closcly associated with the disease, namely: poverty, poor 
()3 
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hygiene, malnutrition, poor immunization coverage, and, in some areas, ovcrcrowding’ 
alcoholism and diseases associated with immunodcficicncy. It is a health hazard that 
has challenged the diagnostic skills of health personnel. Often, it has presented in 
the emergency room as a cause of severe haemoptysis or acute abdomen. Pulmonary 
tuberculosis accounts for 75% of cases. Others in order of prcvalcncc inciudc: 
tuberculous lymphadenitis and abdominal adenitis. Pott's disease, meningeal and 
milliary TB, TB osteomyelitis and arthritis, and pericarditis. 
In a 1-year study between 1966 and 1967, by the Department of Paediatrics in 
Mulago hospital (2)’ it was shown that of the 3,734 children admitted, tuberculosis 
accounted for 154 cases (4-3%). 
In a review of 1,132 paediatric necropsies at the same hospital in the 12 years between 
1953 and 1964, tuberculosis was the major infectious disease and causcd the death of 60 
children. 
The mortality report over the 5 years between 1962 and 1966 showed that 480 
children with tuberculosis were admitted to Mulago hospital. The overall mortality was 
15% and the fatality is reported in Table 1. Tuberculosis meningitis has claimed most of 
its victims or left them with severe disabilities. 
Table 1. The case fatality report for TB between 1962 
and 1966 
Type of TB Fatality 
TB Meningitis 47 
TB of abdomen 37 
Milliary TB 20 
TB bronchopneumonia 17 
Table 2. The seven anti-TB drugs commonly in use in Uganda with efficacy rates 
and the drug cost per patient dose per day (1989) 
Daily Cost inSU.S. 
Drug adult dose per dose Efficacy rates 
Isoniazid 300 mg 001 + + + + 
Thiacctazonc 150mg 001 十 
/>-Aminosalicylic acid 12 g (>25 + + 
Streptomycin 1 g 0 80 + + 十 
Ethambutol 800 mg 0.51 十 + + 
Pyrazinamide 2g 0 75 + + + 
Rifampicin 600 mg 1 80 + + + + 
Afiti-tubcrculom dru^s 05 
Tabic 3. The live major am卜TI3 drugs in use in Hong Kong 
Drug Comment 
Rifampicin 
Isoniazid ( Given intermittently three times 
Streptomycin j a week for 6, 9 or 12 months 
Pyrazinamide ^ 
Ethambutol and others, 
e.g. ethionamide Used in case of resistance 
T H E R A P E U T I C P R A C T I C E 
Table 2 shows the anti -TB drugs commonly used in Uganda while Table 3 illustrates 
the anti -TB drugs used in Hong Kong. The standard regimen for Uganda is: strepto-
mydn’ thiacetazone, and isoniazid (designated as STH). The regimen was chosen 
because it is compatible with the social, financial，and medical status of the Uganda 
population (4)，and has earned a good score in terms of efficacy, cost, toxicity, ease of 
administration and acceptability in this community. In a study by the East African 
British Medical Research Council (EA/BMRC), isoniazid alone had an efficacy of 40% 
This was doubled to 80% when combined with thiacetazone, and to 9 0 - 1 0 0 % when 
streptomycin was included for the first 2 months. When para-aminosalicylic acid (PAS) 
was substituted for thiacetazone, better results were obtained but it was associated with 
a high rate of defaulting because PAS is inconvenient to administer, expensive and 
causes unpleasant gastrointestinal upsets. Intermittent chemotherapy with S T H was 
tried as twice weekly streptomycin and daily thiazina (thiacetazone + isoniazid, T = 
丄 5 0 m g ’ I = 300mg). Again, in spite of the successes scored there was high rate of 
f a u l t i n g Many studies on short course anti -TB chemotherapy have been carried out 
by the EA/BMRC (4) but have not earned wide practice here because vast differences 
exist between the results of these controlled studies and those found under routine 
service conditions in East Africa. 
Over three-quarters of the patients are on S T H regimen. PAS is used in case of 
intolerance to thiacetazone while ethambutol and pyrazinamide are used in cases of 
resistance and intolerance. A combination of isoniazid and ethambutol is used in preg-
n - m mothers and streptomycin is excluded. The rest are reserved for those who 丄 
f o r d them individually. Usually streptomycin is included for the first 2 - 3 months 
Pyridoxine IS not routinely given because peripheral neuritis is uncommon. Thiazina is 
continued daily for the whole course of treatment. The course in total takes 18-^4 
n^^onths. This contrasts with the practice in Hong Kong where a policy of intermittent 
二 ? r t - 二 o u r s e chemotherapy on a ‘service’ basis is followed (4). This is possible because 
of the dense population m a small total area with good public transport and chest clinics 
which^ are open m the evenings to treat patients who work during office hours The 
period of treatment is 6 - 9 months. 以 
In Uganda Che二prophylaxis is rarely practised in adults. It is common in children 
who are at risk and have developed malnutrition, measles or arc on steroid treatment 
a n d ^ f a m s of T B mothers. Steroids as part of anti -TB chemotherapy have b c c n ^ d 
in: T B meningitis, overwhelming infection such as milliary TB, serious effusion 
pulmonary pressure symptoms and, at times, drug reactions. 
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A D V E R S E E F F E C T S 
The majority are hypersensitivity reactions. Thiacetazone is incriminated in more than 
half of the cases and streptomycin for the majority of the remainder. However, all ihc 
anti -TB drugs were reported to have caused undesirable cffccts. Toxic cffccis in this 
setting may be underestimated due to their association with the severe forms oi' ihc 
disease and inadequate laboratory services. 
Thiacetazone is obsolete in countries like Hong Kong where it is considered to be a 
weak anti -TB drug and notorious for its side-effects. Nevertheless, the drug is widely 
used in Uganda and many other countries. Fox et al. (5), in 1966, noted that there were 
considerable geographical and racial differences in the side-effects of thiacetazonc. For 
example，the Filipinos are intolerant to the drug (6) while it is generally well tolerated in 
South African blacks (7). Pearson, in 1978, remarked that the advantages of the drug 
outweigh its disadvantages if adequate precautions are taken (8). It is therefore advised 
that the toxicity and the efficacy of any regimen which includes thiacetazone should be 
determined in a community before it is widely used (9). 
F A T E OF S T H R E G I M E N 
The S T H regimen has been in use for over 30 years. The discovery of new and more 
powerful anti -TB drugs has rendered this regimen a poor performer and only for the 
underprivileged. The high rate of defaulting where patients fail to turn up for more 
treatment may be due to financial problems or interference with working hours, or 
boredom. This usually occurs when they begin to feel better. There is also an increasing 
resentment to injections due to the association with the human immunodeficiency virus 
(HIV). Resistant cases appear to be on the increase with normal secondary resistance 
being the most common. Everyday, in the T B ward in Mulago hospital, there is a patient 
on treatment for severe drug reactions (personal experience). 
C O N C L U S I O N 
From the layout above it appears that S T H regimen has lost the efficacy and the cost 
effectiveness it used to hold. The hopes for a change were shunned by the country's 
ailing economy. Thus priority has been given to a comprehensive exploration of factors 
that influence drug response in this population. Our concern today is T B of the CNS. It 
has a high fatality rate and is difficult to treat. Rational chemotherapy of T B of the CNS 
is restricted by grossly limited data on the penetration of ant i -TB drugs in the brain 
(10). The determination of these drugs in serum and cerebrospinal fluid (CSF) during; 
therapy is desirable to adjust the regimen with reference to minimum inhibitory con-
centration (MIC) of drugs, and is an aid to the estimation of optimal dosages to'avoid 
unwanted and toxic effects (11). However, prediction of the concentration of these 
drugs after multiple chemotherapy is difficult and it is uncertain whether the degree 
of meningeal inflammation, corticosteroids, the duration of the disease or co-
administration of anti -TB drugs would affcct drug deposition and penetration into the 
CSF. Consequently there is a need tor a method of drug analysis during such studies 
and for routine T D M or survcillancc. 
Such a method requires consideration of the limits of linancial and manpower 
rcsourccs of a country. Therefore, any system developed ought to be economical and 
Anti-tubcrculous drugs 67 
precise so that it can be widely used. The success of such a projcct will be a blessing not 
only to Uganda but to many other regions of the world. 
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The Pharmacokinetics of Isoniazid and Hydrazine Metabolite in 
Plasma and Cerebrospinal Fluid of Rabbits 
A. Wahibo, K. Chan and C,L. Wong 
Department of Pharmacology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong 
SUMMARY 
The pharmacokinetics of isoniazid (INH) and hydrazine metuboliie (U YD) in plasma and cerebrospinal fluid (CSF) often rabbits was studied 
ofter separate intravenous {i.v. J and oral (p.o.) adrninisl ration in a crossover study. The concenlruiiuns of IN// unci HYD in the biological fluids 
we/ie determined by high performance liquid chromatography (HPLC). There was no difference in the area under plasma conceniralion-time 
cwrves, indicating that oral absorption was complete. The mean apparent volume of distribution after i.v. (3.02 土 0.55 L) was smaller (p < 
0 0” than that after p.o. (4.29 土 ！.25 L) dosing. The elimination t,/】 of INH in CSF was longer (p < 0.005) than that in plasma after either 
of administration. There was no significant barrier to the penetration of INH into the CSF from the general circulation. The HYD plasma 
concentrations were similar after either route. HYD was eliminated at a slower rate (Ke = 0.17 h than INH (Ke = 0.59 h]). There was prolonged 
exposure of the body to HYD (> 6 h - above 0.1 fig/ml). 
Key words: Isoniazid - Hydrazine - Pharmacokinetics - Cerebrospinal fluid - Plasma - Rabbit 
INTRODUCTION higher than【hose in clinical practice were given and the 
Isoniazid ( INH) is one of the most important and animals were sacrificed at 2 h to obtain the samples 
widely used antituberculous (anti-T.B.) drugs. Its thera- Kinetic studies are needed to establish how long and 
peutic effectiveness and toxicity depend on the inten- to what extent the drug slays in the CNS Results of 
sity and extent of exposure to the body (1). Higher these studies may shed some light on the rational use 
amounts ( > 10 mg/kg) have been used to treat tuber- of these drugs in TBM 
二 o u s meningitis (TBM). The treatment of TBM has Hydrazine (HYD) is'a potent toxin, the assay of 
^ n inadequately investigated so that the choice of which has been neglected on grounds that it was formed 
f ^ f 如 d duration of therapy are largely empirical ⑵ . i n negligible amounts (8). In the wake of the unproven 
In fact the rational use of anti-T.B. drugs in TBM is role of monoacetylhydrazine in INH-related side effects 
^ n c t e d bythe b ^ t ^ data on the penetration of these the hydrazine metabolite has been implicated as a possi-
t X I ⑶.CNuS kinetic studies are dif- ble culprit (9). The urinary recovery of hydrazine Z -
二 t to conduct m h u m a n s . 广 腿 studies investigated bolites cannot account for the total an J m presumably 
by Barclay 二. (4), Boxenham et al. (5) and Elmen- formed during INH metabolism (1). Further it wa 
dorf e/ al. (6) went no further than certifying that reported that rifampicin increased hydrazine fo mation 
= 『 t c o u n t s of INH were detectable in the CSF from INH after 2 weeks of administration (8). T 
l l Z patients arjd healthy volunteers. Welle et al. fore’ a study on the kinetics of hydrazine a the n.cta-
eported on the distribution and excretion of INH in bolitc is essential to explore its role .n INH-rcIatcd 
nve pregnant rabbus at 2 h (7). In that study doses aty. Wc now report our findings on p l a s m a t d 
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— profiles of INH and H Y D after separate i.v. and p.o. plotted against time (AUC) were calculaicd using the 
adminisiraiion of INH to 10 rabbits using a crossover irapczoidaJ rule. The absolute bioavailability, I . of INI 1 
• design previously described tor pyrazinamide (10). was determined according to equation 1. 
i R 
( M A T E R I A L S A N D METHODS F = 
» … J . ~ A U C ( 1 ) 
Rabbit model 、 
！ New Zealand white rabbits of either sex (2 male, 8 八 , . . , . ‘， 』， . , 、 . . . , . ^ , , ,, / ’ Apparent first order rate constants for dcclinc of 
temale) weighing 4.6-5.1 kg were astcd ovcrnmht , . . . 
, • 、 ： , . . , • , , ^ plasma concentrations after adminisiraiion were ob-
betore the study. The dorsal ccrvical area and occipita . . , . , 。…Af 11 . . ^ ^ , P tamed by linear least square regression on log plasma 
area of the skull were shaved. The centra car artery • .. 
I , ， … • ， J r L , 」 concentration against time. The apparent volume of and lateral ear vein were cannulated for blood sam - H i c f r ; K , . f i ^ r . v ^ r i m u , , . 薩 ^ . . . , . , 广pp distribution of INH was calculated according lo 
2 Pling and drug administration, respectively. CSF equation 2 
• samples (0.2 ml) were obtained from cisterna magna “• 
“ under light anesthesia with i.v. thiopentone (40 mg/kg) DOSF 
I at 0，0.5，1，4，6 and 24 h. Blood samples (1.0 ml) were V (一 = -
j obtained at 0，2.5, 5, 10’ 15 and 30 min, and 1’ 2’ 4’ AUC (2) 
I 5, 6, 8, 10 and 24 h after i.v. dose, and at 0,0.25, 0.5’ t-
« 1，2’ 4, 5, 6，8，10 and 24 h after p.o. dose. Using the Significance difterences of pharmacokinetic 
S crossover design INH 5 mg/kg was administered at ran- Parameters of INH and H Y D after p.o. and i.v. ad-
『 d o m P.O. (via a polythene tube) and i.v. on two occa- mmistrau^s were evaluated using the Student's / test, 
三 sions separated by 7 days. Details of the procedure for ^ h p < 0.05 considered to be the limit of significance. 
I" obtaining CSF and blood samples from ihe rabbits were 
卜 described previously (10). RESULTS 
f INH was completely absorbed after p.o. administra-
[ Analysis of isoniazid and hydrazine in the biological tion. Peak plasma concentrations ( C _ ) of 4.28 
r. nu丄?s (土 1.49) /xg/ml were reached at 1.03 (土 0.66) h. 
Plasma or CSF sample (0.2-0.5 ml) was washed with The drug declined from ihc plasma monoexponential-
. h e x a n e under acidic conditions. INH, H Y D and inter- ly after complete absorption. After i.v. administration 
； n a l standard phenelzine (PHEN) in CSF or plasma were the plasma INH concentrations declined rapidly within 
denvatized with salicylaldehyde to form the respective 10-15 min and subsequently slowly, following a biex-
hydrazones and an azine. These were extracted into poneniial manner (Fig. 1). By two hours post-admin-
ether (5 ml) which was evaporated to dryness and the istration the plasma concentrations after p o and i v 
residue dissolved in mobile phase 50 /xL Aliquots (25 routes were similar. Tables 1 and 2 summarize the in-
/J) were injected into the HPLC. The mobile phase con- dividual plasma concentration-lime points of INH in 
sisted of acetonitrile, water and triethylamine in the the 10 rabbits for both routes of administration Table 
二ti。、。/ 0.4 (V/V) with heptane sulphonic acid 3 compares the kinetic parameters of the drug in 
(5 m M ) ， d was adjusted to final pH 6 by the addi- plasma. The A U C curves were similar, indicating that 
？ o n of glacial acetic acid. The eluent was delivered at oral absorption was complete. The apparent volumes 
i m l / j ^ n through a RP8 precolumn linked to a ^Bon- of distribution were different, probably due to the con-
f 叩 ^ h " 如 c o ^ m n and a UV-variable wave tinuous input of the drug after p.o. route. The plasma 
length detector set at 320 nm. The calibration graphs elimination haJf-life. elimination rate constant clear-
f height ratios to concentrations were linear over ance and mean residence time were similar 
/ / ^ f i e ' ' v n l ' I^NH and 0.0768-0.768 Higher CSF concentrations of isoniazid were achieved 
0 07 r 二 -.战,r、=隱3; y = initially after i.v. administration. They declined more 
1.64X - 0.07, r = 0.9997, respectively). rapidly than after oral dose so that by 4 h the concen-
- r r — 二 二 ： 
Pharmacokinetic parameters were obtained from ing plasma concentrations after 1 h (Tabic 4) The 
S Z I 二 " T ? ， 他 e f d i n g to standard elimination haJf-Iife for INH in CSF was longer than 
formulae (11). The areas under plasma concentrations that in plasma (Tabic 5). 
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FIG. 1. Average plasma concentrations of isoniazid after separate intravenous (n = 10) and oraJ (n = 8) doses in rabbits. 
The hydrazine metabolite was rapidly distributed and ministration in rabbits. The drug crossed the blood-
was subsequently eliminated slowly from the plasma brain barrier (BBB) into the CSF in significant amounts. 
(Fig. 3). The concentrations after either route were The rate of elimination of INH from the CSF was 
above 0.1 /xg/ml. Hydrazine was cleared from the cir- slower than that of plasma as shown by the longer 
dilation more slowly than INH (Table 6). Trace elimination t./, or smaller elimination constants (Tables 
amounts of H Y D were detected in the CSF. 3 and 5), suggesting a special behavior of the BBB to 
the movement of INH molecules across it into the 
DI!>CUSSION general circulation. There seems to be a barrier against 
The present study has demonstrated that the i.v. INH transfer from CSF into general circulation Ade-
route has no advantage over p.o. route for INH ad- quate CSF concentrations of the drug were sustained 
TABLE 1. Plasma concentraUons of isonia/jd (/zg/ml) in 10 rabbits after i.v. dose (5 mg/kR) 
丁 — ） 1 2 3 4 5 6 7 8 9 10 Mean 土 S.D. 
！ I •奶 11.12 11-07 14.00 14.03 13.80 11.76 11.15 13.19 10.51 12 26 ± 1 17 
丨 1.13 9.80 8.52 14.00 12.87 11.72 9.98 9.55 11.67 9.88 10.91 土 168 I'll 1-1' 7.48 13.29 11.37 8.11 7.99 8.48 9.43 8.86 9.36 士 1:76 I II I'll l-ll 6.19 8.95 8.96 6.28 5.97 7.97 6.20 6.73 7.37 士 1.30 
0- 0 I f 6.73 5.14 7.64 7.88 5.07 4.34 7.20 5.40 6.56 6.15 士！ 21 
f 4.99 3.05 6.33 5.65 4.39 3.05 3.36 3.10 4.07 4.11 土 1 21 I 3.63 1.95 2.87 3.25 2.16 2.14 2.44 2.00 2.21 2 ⑷士 0 
• f：! 1.53 1.62 1.26 ,.88 1.58 1.35 ,.,6 ,.6： ： 0：43 
I I II 1.67 — 1-67 1.36 1.19 1.07 1.20 1.23 0.89 1 士 0 
«6 = 丨 . 4 9 丨.04 1.53 1.07 0.78 0.84 0.95 0.74 O'l 二 ^ 
’ 门 0 0.70 1.10 0.80 0.51 0.61 0.94 0.63 0.62 0 76 ^ ^ ^ 
丨0 丨 丨 0.50 0 . ^ 0.55 0.43 0.50 0.68 0.49 0.53 0：55 “ 0：；； 
24 0 0 + + 0 0 + + 0 + 
applicable 
+ Trace detected; 0 Not dcicctcd; — Not done. ‘ — 
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TAB!上 2, Plasma concenlniCions of isonia/id O'U/nil) in M ruhbiis utii.r p.o. tlost. (5 mji/ky) 
T i � 1 2 3 4 5 6 7 « 10 Mean . S I； 
0.25 0.60 3.24 0.72 — 7.26 2.44 0.48 1.42 — “ — " ^ 30 ~ 
1-31 3.79 2.03 — 5.67 3.10 2.6H 4.77 一 4.K0 3 52 1 51 
\ 2.21 3.48 2.24 - 3.95 2.35 3.20 5.30 — 4.33 3.3K ± 丨 12 
： 4.27 3.34 2.82 — 2.32 1.67 3.16 2.52 一 3.48 2.95 ± O.HO 
, 1-67 1-67 — 1.53 1.15 l.4() 1.51 - 1.59 l.5« ^ 0 22 
5 1-35 1.09 — 1.42 0.92 1.21 1.39 — i 27 1 27 ± U 19 
‘ lil ； 謹 一 1.二 0.76 1.15 1.26 — 1.10 1：13 . 0：20 
’ ，二， . . 0.74 - 0.86 0.44 0.95 1.00 一 0.67 0.84 0.22 
10 0.74 0.82 0.50 — 0.76 0.36 0.85 0.75 一 0.65 0.6« 土 0.17 
24 0 0 0 一 0 0 0 0 一 0 '、⑴ 
• applicable 
+ Trace delected; 0 Not detected; — Not done. “ — ‘ 
TABLE 3. Plasma pharmacokinetic paramctcni of isoniazid in ten rabbitj» after p.o. and i.v. dosinj： (5 me/ke) Mean 土 SD ‘* 
Parameters After p.o. route After i.v. route p 
Number of rabbits 8 (7F. IM) 10 (SV, 2M) _ 
Weight (kg) 4.78 (0.21) 4.75 (0.2) — 
23.88 (1.06) 23.75 (0.98) _ 
AUG (,g ml > h) 12.3 (3.65) 13.96 (3.31) >0 . 35 
Dmnbution t./, (h) — 0.28 (0.06) _ 
fhmm^don l./, (h) 1.48 (0.46) 1.20 (0.23) > 0 05 
App Vo, D.st. V .„ (L) 4.29 (1.28) 3.02 (0.55) < 0.01 
8.丨3 (2.38) 8.05 (1.78) >0.40 
二（）， 0.5丨（0.18) 0.59 (0.09) > 0 10 
Plasma clearance (ml min > kg-) 7.57 (2.81) 6.25 (1.33) > 0 40 
Mean residence time (h) 2.68 (0.81) 1.6^(0.31) 0:30 
10 — 
j 
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P i a 2. Average CSF conccn.a.ons of . o n . . . , a.er .cp .a tc ..ravenous (n = 10) and oral (n = S) ⑴ 
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TABLE 4. CSF/plasma ratios of isoniazid al various time intervals. Mean 士 SI) 
After P.O. route After i.v. route 
Time (h) (n = 8) (n = 10) p 
0.05 0.39 (0.24) 0.68 (0.16) < 0.01 
1 0.46 (0.14) 1.13 (0.28) < 0.005 
4 丨.02 (0.32) 1.16 (0.30) > 0.15 
6 0.95 (0.37) 1.40 (0.39) > 0.35 
TABLE 5. Some pharmacokinetic parameters of isoniazid in CSF of rabbits. Mean 士 SD 
After P.O. route After i.v. route 
Parameters (n = 8) (n = 10) p 
Elimination ti/^ (h) 3.72 (1.58) 2.45 (0.54) < 0.05 
e^csf (h.,) 0.22 (0.12) 0.30 (0.08) >0.05 
Plasma K^ V5. p < 0.0025 p < 0.005 — 
TABLE 6. Hydrazine elimination rale after p.o. and I.v. isoniazid (5 mg/kR). Mean ± SD 
After P.O. route After i.v. route 
Parameters (n = 8) (n = 10) p 
Elimination【丨力(h) 3.64 (2.48) 3.16 (2.32) > 0.30 
Ke«(h.i) 0.28 (0.18) 0.17 (0.12) < 0 . 1 0 
i 
i 
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ABSTRACT 
A simple procedure for the simullancous dclcrm,nation of ison.a/.d and hydrazine metabolite in p l u s - . 
i^a and cerebrospinal Ouid in the rabb.i is dcscr.bcd. The assay involves organic extraction before and after 
derivalization of the two compounds and the .nlcrnal standard, phenelzine. The cxtract of the denvatizcd 
二 i 『 o u n d s was evaporated to dryness al 40。C and the residue rcd.ssolvcd in ihc mobile phase (50 / … A 
丨quot 簡 injected into the liquid chromalograph and cluicd w.ih accton.inle-waler-lneihvlammc 
(70:_>0:0.4，v/v) containing 5 mA/ hcptanesulphon.c ac.d on a C , precolumn linked to a 10-"m C 
^ o n d a p a k column at ambient temperature (25 土 1°C). The clualc was dclcctcd by ultraviolet detection i i 
3zU nm. 
“ — -.. 
I N T R O D U C T I O N 
n l a ^ n ^ P r e d u r e s have been described for the assay of isoniazid ( I N H ) in 
plasma [1-6] The fluorometric assay [1], although sensitive, is laborious and 
e x ^ s i v e . The hydrazine ( H Y D ) metabolite was poorly extracted ( l % ) ^ d d 
not show fluorescence. Several procedures based on hmh-per lbrmanL liquid 
chromatography (HPLC ) for assay of I N H with or whhout metabo t L ^ ^ 
been ubhshed [3-6]. In some [3,4]’ a large sample volume and drastic 
wou d e T used, and in the others [5,6] the supernatant in ,ec^d 
v^ou^d endanger the chromatographic system and did not include an in c n n l 
standard, thus making the results questionable. 
H Y D is a potent toxin and carcinogen [7]. It is formed durino the direct 
o f l N H into isonicotinic a ad . In the wake of the proposafth ^ ^ 
二 麵 - r e l i e d toxicity, H V D has b L -丨丨二: 
a poss blc culprit 8]. There is apparently no well established procedure for direct 
二 ? a t i o n of total H Y D formed dunng I N H metabolism. Gas d m 二 ; . 二 
electron-impact mass spectrometry [91 and the nuin-ect estimation of total I m ) 
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by determin ing the ratio o f IN I I metabol ized in llic ma jor pa thways |8| arc lah。-
rious and expensive. 
This paper describes the development of a simultaneous assay「or IN I i and 
H Y D , to examine the relationship of the concentrations of the Ivvo compounds. 
The procedure of organic solvent extraction before and after dcrivatization and 
concentration of the solvent extract was adopted to optimize sensitivity and selec-
tivity. The chromatographic system used was a modification of that used by other 
workers [10,11 . 
E X P E R I M E N T A L 
Reagents 
Salicylaldehyde, triethylamine and hydrazine hydrate (24% in water) (Merck, 
Darmstadt, Germany) were of analytical grade (AR) . I N H and phenelzine 
(PHEN) sulphate were purchased from Universal Pharmaceuticals Labs. (Hong 
Kong). Other reagents used were: hcptanesulphonic acid (Sigma, St. Louis, M O , 
U.S.A.), acetic acid and acetonitrile ( A R grade, Merck). 
Apparatus and chromatographic conclilions 
The chromatographic system consisted of a Waters M45 pump (Waters As-
soc., Milford, MA，U.S.A.), a Model 7125 injcctor (Rheodyne, CA，U.S.A.) and 
a variable-wavelength Hitachi 220-S UV detector with a built-in chart recorder 
(Hitachi, Tokyo, Japan). Analyses were performed on a //Bondapak reversed-
phase Ci8 column (10 " m , 300 mm x 3.9 I .D. , Waters Assoc.) linked to a Cg 
precolumn (30 //m, 30 mm x 4.6 mm I .D. , Waters Assoc). The mobile phase was 
acetonitrile-water—triethylamine (70:30:0.4, v/v) with 5 mM hcptanesulphonic 
acid at pH 6.0 (adjusted with acetic acid). Other conditions, flow-rate 1 ml/min; 
pressure, 35 bar; ambient temperature, 25 士 r C ; UV detection wavelength, 320 
nm. All glassware was treated as described previously [12], to reduce loss of drugs 
by adsorption on the glass walls. 
Synthesis of reference compounds 
The salicylhydrazones of isoniazid ( I N H - H D Z ) and phenelzine ( P H E N - H D Z ) 
and the salicylazine of hydrazine were synthesized by a modification of the proce-
dure used by Jenner and Ellard [10]. A standard amount of I N H or phenelzine 
sulphate or hydrazine hydrate was shaken with excess salicylaldehyde in cthanol, 
and the mixture was heated in a water-bath at 60。C for 30 min. The products were 
purified by crystallization in ethyl acctalc and were distinguished from the pa rent 
compounds by their UV absorption spectra and by thin-lavcr chromatom-apln 
(TLC: system T1) [13]. Briefly, the compounds, in niclhanolic solutions of 1 
mg/ml, were spotted on a silica plate (coalcd with silica G 60, 0.2 mm thick： 
Sigma) 1.5 cm from the bottom line. The plalc was placcd in a lank containing 
ammonia-mcthanol (1.5:100) lo a depth of 0.5 1 cm, and ihc tank was made 
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、 airtight with a lid. After 30 min the plate was dried in air and ihc compounds were 
located by potassium iodoplatinatc spray (Sigma). 
Sample preparation 
Samples of rabbit plasma and cerebrospinal lluid (CSI:) were obtained as 
described earlier [14]. Plasma or CSF (0.2-0.5 ml) was pippcttcd into a 10-ml 
test-tube, and 50 /] o f phenelzine sulphate (50 //g/ml) were added as internal 
standard. After the addition ofO. 1 ml of aqueous acctic acid (v/v) to adjust pH to 
4, the impurities were extracted by shaking with 5 ml of/z-hexanc for 30 min, and 
then centrifuged for 10 min at 1870 人： T h e organic layer was discarded.. The 
sample was denvatized by addit ion of 0.3 ml of an ethanolic solution of 0 .1% 
(v/v) salicylaldehyde and 0.4 ml of 10% aqueous acetic acid, and heated in a 
water-bath for 30 min at 60。C. After cooling to room temperature (25 土 1。C) the 
sample was shaken for 10 s with 1 ml of 1 M K2HPO4 buffer (pH 6.5) for 
opt imum extraction and removal of the exccss salicylaldehyde. The salicylhydra-
zones and azine were extracted from the cooled aqueous mixture by shakine with 
5 ml of diethyl ether for 10 min and centrifuging for 10 min al 1870.;-. The extract 
was transferred into a tapered test-tube and evaporated dry under a stream of 
nitrogen at 40。C. The residue was dissolved in 50 "1 of mobile phase, and dupli-
cate 25-//1 aliquots were injected into the H P L C system. The extraction and deriv-
atization procedure took cu. 2 h for a batch of ten samples, and the derivatives 
could be stored for three days at 4°C without loss of accuracy. 
RESULTS A N D D I SCUSS ION 
Characterization of the reference compounds 
The derivatives absorbed UV radiation much more than the parent com-
pounds’ making the choicc of detcctor appropriate. They exhibited lai-er reten-
tion factors because they are less polar, viz.: I N H = 0.52 and I N H - H D Z = 0 66. 
PHEr^ r 0.47 and P H E N - H D Z 二 0.73; H Y D = 0.28 and azine 二 0.70. sal-
icylaldehyde 二 0.5. By dissolving appropriate amounts of these compounds in 
the mobile phase，the H P L C separation conditions were developed. 
Derivatizing conditions of the sample 
Heating of the reaction mixture lor 30 min at 60’ 80 and 90。C showed that the 
derivatives are thermolabile. The yield was poor at lower temperatures, and 
variable when the mixture was healed for a shorter lime. The opt imal reaction 
conditions were 6 0 � C for 30 mm. P H E N exhibited many 丨 m c r m L i 丨 a t e produ ts 
wheja heated for a shorter time. Il was used as nUcrnal standard b e c a L o f u； 
similar structural and solubility properties to isoniazid. I N H and P H F N irc 
hydrazides and rcact with sal.cylaldchydc al the hydrazine functional " roup ^ 
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Pcrfornuuicc of the HPLC systci)i 
Representat ive chromalogra i i i s of the c o m p o u n d s in s tandard solut ion, and ol 
the plasma extract from a treated rabbit, arc shown in Fig. 1. The analytical 
peaks are symmetrical, with retention times of 96 s for INH-I i DZ , 1KO s for 
PHEN-HDZ , and 240 s for the azine. The excess salicylaldchydc was resolved al 
126 s. The peak-height ratio was satisfactory for quantitation to be performed. 
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Fig. 1. Representative chromalograms of (a) a standard soluiion wiih conccniralions cquivalcni lo 0.5 
"g/ml for I N H and P H E N and 0.05 /ig/ml lor H Y D , (b) drug-free plasma and (c) a plasma cxiracl from a 
rabbit 5 h after an intravenous dose of INM (5 mg/kg). Peaks: 1 = INH : 2 = P H E N (inlcrnal standard)-
= H Y D . ‘ 
Linearity, sensitivity, precision, rccovcrv and sclccfivitv 
• • 
Concentration ranges of 0.5-10 //g/ml for INH and 76.8-768.0 ng/ml for 
H Y D , in plasma or CSF, were used for standardization and regression analysis. 
The mean correlation coefficients for six standardization curves were 0.993 lor 
I N H and 0.9997 for H Y D . The standard curvcs for plasma and CSF were identi-
cal- The limit of detection was 0.2 "g/ml lor INH and 10 ng/ml for UYD. To 
assess recovery, peak heights of the directly injcctcd INH-I I D Z or a/inc were 
compared with those obtained after applying the cxiraciion procedure to INH-
H D Z or azine, and with INH or H Y D when taken through the whole procaiurc 
SIlOR r COMMIINIC ATIONS 2(, 
、 ofdcrivatization and extraction at concentrations o{'i).5 aiui S //g/ml lor INH ami 
153.6 ng/ml for H Y D (//二 5). 'I he cllicicncy of dcrivali/ation was at 0.5 
//g/ml and 83.6% at 5 //g/ml for INH and 73.7% at 153.6 ng/ml for H Y l ) . 
Extraction of the hydrazones was 59.5% at 0.5 //g/ml and 60.2% at 5 //g/ml l,()r 
INH, and 67.4% at 153.6 ng/ml for HYD; this gave an overall rccovci-y 01,52.4% 
at 0.5 f i g / m \ and 50.3% at 5 //g/ml for INH , and 49.7% at 1 53.6 ng/nil for H Y D . 
Drugs such as rifampicin, pyrazinamide and /^-aminosalicylic acid were tested, 
and did not interfere with the assay. Most of these arc extracted in hexane and 
they do not react with the salicylaldchydc. 
C O N C L U S I O N 
The procedure is economical and convenient with respect to the materials and 
sample volume used. Like other procedures [1,10], this one can only detcct the 
acid-labile I N H and metabolite. Monoacctylhydrazine was not determined under 
the conditions described. 
The assay allows direct determination of total H Y D formed dunng I N H me-
tabolism. We have used the procedure to study the disposition and kinetics of 
I N H and H Y D in rabbits [15] and in elderly tuberculosis patients. The results and 
conclusions were similar to those obtained by other methods for rabbits [16] and 
humans [17]. The assay is a useful research and clinical tool in the study of H Y D 
as a metabolite of INH . 
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